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Abstract 
Lentiviral gene therapy has the potential to target HIV-1 reservoirs, by delivering 
protective gene constructs into resting cells. However, a major obstacle in effectively 
targeting the HIV-1 latent reservoir is the lack of efficient gene delivery that occurs 
within cells. The viral protein Vpx from the SIVSM/HIV-2 lineage is capable of 
increasing lentiviral reverse transcription (RTn); by antagonizing the restriction factor 
SAMHD1. This study aimed to investigate the feasibility of incorporating Vpx into 
lentiviral vectors, to alleviate the obstacle established by SAMHD1. Primary 
macrophages and dendritic cells were utilised as resting cell models.  
Firstly, we determined the short and long-term effects post-Vpx exposure. Results 
revealed Vpx exposure led to increased permissiveness of cells to HIV-1 infection 
over a period that exceeded two weeks and was associated with lower potency of HIV 
antiretrovirals that target HIV RT or integration. 
Secondly, we incorporated Vpx with lentiviral gene therapy approaches that target 
HIV pre- and post-RTn and determined whether the inclusion of Vpx increased their 
effectiveness. When Vpx was incorporated into anti-HIV gene therapy constructs, 
transduction levels were significantly increased. However the increase in gene 
delivery only translated into an increase in HIV protection with constructs that inhibit 
pre-RTn phases of the virus life cycle. 
Thirdly, we utilised proteomics to determine any hidden phenotypes, in macrophages 
and dendritic cells, post-Vpx exposure, which could affect the usage of Vpx in gene 
therapy protocols. Significant protein changes were further investigated by generating 
a panel of THP1 knockdown/overexpression cell lines and examining whether 
individual changes, similar to SAMHD1 depletion, could increase HIV-1 infection. 
 xix 
No detrimental hidden phenotypes were revealed in both macrophages and dendritic 
cells. Importantly, two knockdown cell lines, CALR and FKBP5, were shown to 
enhance HIV-1, in the absence of Vpx. 
In conclusion, this study supports the use of Vpx with gene therapy vectors as a way 
to overcome the major genetic delivery obstacle presented in resting cells. This effect 
was the greatest when incorporating anti-HIV constructs that target HIV-1 prior to 
reverse transcription.  Importantly this approach can target cells of the existing HIV-1 
latent reservoir or in resting cells that require HIV-1 protection. 
 
 xx 
Acknowledgements 
I would firstly like to thank my primary supervisor A/Prof Stuart Turville. My PhD 
has not been a usual one and through his support of my research ideas I am able to 
submit this thesis with a provisional patent being filed and one first authored paper. 
After the expiry of my APA Stuart also generously provided me with financial help, 
which enabled me to focus on the research at hand.  
My co-supervisor, Dr Chantelle Ahlenstiel was appointed during the final stages of 
experiments required for the patent/paper. Chantelle’s expertise has helped the filing 
of my provisional patent and the reading of my first drafts allowed me to send the 
final drafts off to Stuart in a timely manner.  
There are several people who deserve a special mention for helping me substantially 
over the course of this thesis. The collaboration with Calimmune was an integral part 
to Chapter 3 and the provisional patent. I would like to thank in particular Prof Geoff 
Symonds for supporting the collaboration and Dr Scott Ledger for providing me with 
required plasmids for lentiviral production. 
To A/Prof Stuart Cordwell and Dr Nestor Solis who processed my samples for the 
iTRAQ experiments in Chapter 4. The proteins identified from the iTRAQ 
experiments allowed me to investigate, in depth, protein changes occurring during 
Vpx exposure and to generate a protein target list for further analysis in Chapter 5. 
Thank you to Dr Anu Aggarwal for her advice on the generation of THP-1 stable cell 
lines in Chapter 5. A lot of troubleshooting was involved for the overexpression cell 
lines, and Anu provided me with invaluable help. 
 xxi 
To the “Turvites”, past and present, I thank Dr Anu Aggarwal for her continual advice 
on experiments and data interpretation. To Dr Tina Iemma, Alberto Ospina Stella, Ivy 
Shih and Andrew Wong, thanks for the experimental support and constant 
coordination for the weekly blood delivery, ensuring we all had enough cells for our 
experiments. 
Thank you to the people who assisted in proof reading my thesis, A/Prof Stuart 
Turville, Dr Chantelle Ahlenstiel, Dr Anu Aggarwal, Dr John Wilkinson and 
Roderick McAllery.  
Thank you to the people at AMR and IVPP at the Kirby Institute, I am so grateful to 
have conducted my research in a welcoming and sociable environment. A special 
thanks goes to Andrew Wong, Dr Chan Phetsouphanh, Sofia Bartlett, Dr Scott 
Ledger, Ivy Shih, Dr Kristin McBride, Annett Howe, Daniel Murray, Rata Joseph, 
Will Hey-Nguyen (nee Hey-Cunningham), Michelle Bailey, Catalina Mendez, Yin 
Xu, John Zaunders and Kat Marks. 
Finally I would like to thank my family. Their unconditional love and support has 
been the rock in my life through the tough times, and the completion of this PhD 
would truly have been not possible without them. 
 
 
 
 
 xxii 
Publications and Patents 
 
Papers 
McAllery SA, Ahlenstiel CL, Suzuki K, Symonds GP, Kelleher AD and Turville SG 
The feasibility of incorporating Vpx into lentiviral gene therapy vectors. Molecular 
Therapy – Methods and Clinical Development. (2016) 5: 16066. 
Aggarwal A, Iemma TL, Shih I, Newsome TP, McAllery S, Cunningham AL, et al. 
Mobilization of HIV spread by diaphanous 2 dependent filopodia in infected dendritic 
cells. PLoS Pathogens. 2012;8(6):e1002762. 
 
Review 
Aggarwal A, McAllery S, Turville SG. Revising the Role of Myeloid cells in HIV 
Pathogenesis. Current HIV/AIDS reports. 2013;10(1):3-11. 
 
Patents 
“Vector and Method” (Application No. 2016901535). Filed in April 2016. Inventors 
A/Prof Stuart Turville and Ms Samantha McAllery 
 
 
 1 
 
 
CHAPTER ONE: LITERATURE REVIEW 
 
 
 
 
 
 
 
 
 
 2 
1. Literature Review 
 
 
1.1. Introduction 
In the late 1970s a unique disease emerged, where previously healthy patients 
suddenly became immunodeficient, and suffered from a range of opportunistic 
infections (such as cytomegalovirus-associated retinitis, cryptococcal meningitis and 
pneumocystis jiroveci), rare cancers (non-Hodgkin’s lymphoma and Kaposi’s 
sarcoma) and lymphadenopathy (1). A common symptom among all patients was a 
marked depletion of their CD4+ T-lymphocytes (CD4+ T cell) in the peripheral 
blood. The disease was first alerted to the medical community in 1981 (2), with  
several other affected populations subsequently described (3). It was evident an 
unidentified pathogen was causing these symptoms. 
In 1983, the virus was successfully isolated from infected individuals by French 
scientists Barre-Sinoussi and colleagues who named the virus Lympadenopathy 
Associated Virus (LAV) (4). Simultaneously, Gallo and colleagues claimed Human 
T-cell Lymphotropic virus-III (HTLV-III) was the etiological agent of acquired 
immunodeficiency syndrome (AIDS) (5-7). However, upon sequence analysis, it was 
shown that HTLV-III was identical to the previously identified LAV (8). Indeed, it 
was later revealed that the French scientists originally supplied the isolates the Gallo 
team had identified. In 1986, the International Committee on the Nomenclature of 
Viruses renamed the AIDS virus as Human Immunodeficiency Virus (HIV) (9). 
 3 
The first simian immunodeficiency virus (SIV), SIVmac, was isolated from captive 
rhesus macaques (Macaca mulatta) soon after the identification of HIV-1 (10, 11). 
Clinical symptoms similar to AIDS were evident in the infected rhesus macaques, 
which soon generated the hypothesis that HIV-1 had a simian origin. To date at least 
45 different species of SIV have been isolated from African non-human primates (12). 
In their natural hosts, SIV appears to be non-pathogenic, as the primates remain 
healthy (13, 14). A close simian relative of HIV-1 was found in chimpanzees, which 
represented the first evidence AIDS emerged in humans as a result of cross species 
infections (15). Indeed, it is now evident that HIV-1 resulted from multiple cross 
species transmissions (16). 
 
1.2. Clinical HIV-1 Pathogenesis 
The course of HIV-1 disease can be divided into three stages: primary HIV-1 
infection (PHI), chronic (asymptomatic) infection, and advanced disease (AIDS). The 
typical course of HIV-1 infection, including CD4+ T cells counts and plasma viral 
load is illustrated in Figure 1.1. 
 
1.2.1. Transmission and PHI 
The majority of HIV-1 cases worldwide have been attributed to sexual transmission 
across mucosal surfaces (17), with men who have sex with men (MSM) receiving 
anal intercourse with at the highest risk (18). Other important modes of transmission 
include parenteral transmission and transmission from mother to child (19, 20). 
Despite MSM having a higher transmission probability per coital act, nearly 70% of 
HIV-1 infections worldwide are attributed to heterosexual transmission (21). 
 4 
The theory of HIV-1 transmission involves a bottleneck of quasi-species, causing the 
selection of high-fitness virus, which establishes primary HIV-1 infection. Founder 
HIV-1 strains are defined as the viruses that appear at the earliest stages of primary 
infection. Multiple studies have investigated the genetic and biological properties of 
founder strains in an attempt to better define the characteristics responsible for 
enhanced risk of transmission (22). Compared to viruses isolated from chronic 
patients, founder viruses were demonstrated to replicate at higher levels in the 
presence of IFN-α (23). Additionally, founder strains tend to use CCR5 as their 
coreceptor and replicate efficiently in CD4+ T cells. However, significantly lower 
replication was observed in macrophages compared to prototypic macrophage tropic 
viruses (24). 
Regardless of the mode of HIV-1 transmission, within the first couple of days, viral 
replication converges to the gastrointestinal tract, where gut-associated lymphoid 
tissue (GALT) is located (25-27). Within the GALT, HIV-1 rapidly replicates, which 
correlates with a considerable increase in plasma viral load (1 x 106-107 copies/mL). 
PHI is characterised by a sharp decline in peripheral blood CD4+ T cells and occurs 
with a concurrent increase in CD8+ T cells (28-30). Several months after primary 
infection the viral load normally stabilizes at what is termed the viral set point (31, 
32).  
 
1.2.1.1. Symptoms 
In 50-70% of infected individuals, symptoms displayed from PHI are relatively non-
specific and are common among acute viral illnesses. The symptoms usually occur 
two weeks post-exposure and can persist for three to four weeks. Patients commonly 
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display a fever, headache, malaise, pharyngitis, myalgia and lymphadenopathy (3, 33-
36).  
 
1.2.1.2. Diagnosis 
The symptoms of PHI are common among many other viral infections therefore 
differential diagnosis is difficult. Laboratory diagnosis is the preferred way of 
diagnosing HIV-1 infection. In most individuals antibodies to HIV-1 become 
detectable within six to 12 weeks post-infection (37-39).  Improved HIV-1 laboratory 
immunoassays (IAs) can detect acute HIV-1 infection earlier than traditional HIV-1 
tests such as western blots. Fourth generation IAs can simultaneously detect IgM, IgG 
antibodies and p24 antigen in an immunometric antigen sandwich format (40). 
 
1.2.2. Chronic HIV-1 Infection 
A prolonged period of asymptomatic chronic infection occurs following the 
establishment of a baseline plasma viral load after the resolution of PHI (41). The rate 
of disease progression varies widely between patients. While most remain 
asymptomatic during much of this phase, ongoing viral replication and CD4+ T cell 
depletion occurs. Plasma viral load strongly predicts the rate of decrease in CD4+ T 
cells and progression to AIDS (42, 43).  
During this otherwise asymptomatic phase of HIV-1 infection many patients note 
symptoms of fatigue and lymphadenopathy. With advancing disease, the most 
frequently encountered symptoms are HIV-related neurologic complications (44, 45). 
Patients in developing countries have a high prevalence of HIV wasting syndrome 
 6 
(“slim disease”), characterised by persistent fever and diarrhoea lasting for more than 
one month and an involuntary weight loss of greater than 10%.  
 
1.2.3. Advanced Disease 
The development of HIV-1 infection to AIDS varies considerably between 
individuals and is defined when the CD4+ T cell count is below 200 cells/μL (46). 
Increasing complications arising from HIV-1 infection is correlated with the depletion 
of the CD4+ T cells (47) Opportunistic infections such as oral candidiasis, 
pneumococcal infections, reactivation of herpes simplex, and varicella zoster become 
more common with CD4+ counts below 500 cells/μL. Once the CD4+ T cell count 
drops below 200 cells/μL the risk of life-threatening complications increases 
significantly. These complications include Pneumocystis jiroveci pneumonia, Candida 
esophagitis, disseminated histoplasmosis, toxoplasma encephalitis, and cryptococcal 
meningitis (48).  Opportunistic infections, such as disseminated Mycobacterium 
avium complex infection, reactivation of cytomegalovirus (CMV), and 
cryptosporidiosis, microsopridiosis are all indicative of severe immunodeficiency, 
which usually occurs in patients with CD4 counts below 50 cells/μL. Malignancies 
associated with AIDS generally are related to underlying viral infection. For example, 
Kaposi's sarcoma is caused by infection with human herpes virus-8 and lymphomas 
are associated with Epstein-Barr virus infection. Although potent antiretroviral 
therapy has clearly altered the risk of Kaposi's sarcoma and non-Hodgkin's 
lymphoma, the effect on Hodgkin's lymphoma still remains unclear (49, 50). 
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Figure 1.1: Typical course of HIV-1 infection. Adapted from (51) 
 
1.2.4. Antiretroviral Therapy (ART) 
Through the administration of antiretroviral monotherapy in 1985, HIV-1/AIDS, a 
once fatal disease, became a treatable chronic illness. Further improvements resulted 
in five classes of antiretrovirals and the introduction of combination ART (cART), 
which includes the use of several classes of drugs to prevent the emergence of viral 
drug resistance. The introduction of cART resulted in the suppression of viral 
replication to levels below current detection methods (<50 copies RNA/mL). The five 
classes of antiretrovirals are discussed below. 
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1.2.4.1. Nucleoside/nucleotide Analogue Reverse 
Transcriptase inhibitors (NRTI) 
NRTIs inhibit the reverse transcription stage of the viral replication cycle.  They are 
analogues of endogenous 2’-deoxy-nucleoside and nucleotides and require 
phosphorylation by cellular kinases for activation (52-56). Acting as competitive 
inhibitors, they compete with cellular dNTPs for incorporation into viral DNA by 
HIV reverse transcriptase (RT). Since NRTIs lack a 3’-hydroxyl group at the sugar 
moiety, the formation of the phosphodiester bond is prevented, resulting in 
termination of the viral DNA chain (57-59). 
Currently, there are eight FDA-approved NRTIs: abacavir (ABC), didanosine (ddI), 
emtricitabine (FTC), lamivudine (3TC), stavudine (d4T), zalcitabine (ddC), 
zidovudine (AZT), and Tenofovir disoprovil fumarate (TDF). NRTIs are commonly 
administered with antiretrovirals from other drug classes as part of cART. 
 
1.2.4.2. Non-nucleoside Reverse Transcriptase Inhibitors 
(NNRTI) 
NNRTIs inhibit HIV-1 RT by binding to a hydrophobic pocket near the polymerase 
active site. This reduces polymerase activity, inhibiting reverse transcription (60-63). 
Currently, there are four approved NNRTIs: etravirine, rilpivirine, efavirenz, and 
nevirapine, and several in development, including doravirine. 
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1.2.4.3. Protease Inhibitors (PI) 
PIs are usually peptidomimetic inhibitors, which compete for binding in the active site 
of HIV-1 protease (64, 65). Virions produced from drug treated cells are unable to 
mature rendering them non-infectious. The FDA has currently approved ten PIs: 
amprenavir (APV), atazanavir (ATZ), darunavir (TMC114), fosamprenavir, indinavir 
(IDV), lopinavir (LPV), nelfinavir (NFV), ritonavir (RTV), saquinavir (SQV), and 
tipranavir (TPV). 
 
1.2.4.4. Entry Inhibitors 
Currently there are two types of entry inhibitors; fusion inhibitors and CCR5 
antagonists. The fusion inhibitor enfuvirtide (T-20) is a polypeptide, which is 
homologous to a region of gp41. When bound to gp41, it prevents a crucial 
conformational change required for virus fusion (66, 67). Subcutaneously 
administered, T-20 is generally used for patients with limited treatment options from 
multi-class antiretroviral resistance (68). The antiretroviral maraviroc (MVC) binds 
the hydrophobic transmembrane pocket of CCR5, inducing a conformational change 
that prevents interaction of gp120 with CCR5, restricting fusion (69, 70).  
 
1.2.4.5. Integrase Inhibitors 
The most recent drug class of antiretrovirals is integrase inhibitors. Raltegravir (RAL) 
was approved by the FDA in 2007, and recently dolutegravir (DTG) and elvitegravir 
(EVG) have also been approved (71-73). Integrase inhibitors prevent the strand 
transfer step during viral integration (74-77). Integrase inhibitors are commonly used 
as part of a salvage therapy regimen. 
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1.2.4.6. Current guidelines for ART 
Recent clinical trials have identified a significant benefit of initiating ART with a 
CD4+ T cell count around 350-500 cells/μL as opposed to previous guidelines of 
<350 cells/μL (78-80). Immediate initiation of ART is now recommended for all 
HIV-1 patients regardless of their CD4+ T cells counts (73). Currently, recommended 
ART consists of the administration of a dual-NRTI (e.g. abacavir/lamivudine or 
tenofovir/emtricitabine) and either a PI (e.g. darunavir and ritonavir) or an integrase 
inhibitor (e.g. raltegravir or dolutegravir) (73). 
 
1.3. Biological Properties of HIV 
1.3.1. Classification – The Retroviridae Family 
HIV is a member of the Lentivirus genus, a subgroup of the Retroviridae family, 
which is characterised by the ability to reverse transcribe their RNA genome in 
cDNA, allowing for integration into the hosts genome  (81, 82). A literal translation 
of lentivirus from Latin is ‘slow virus’, and was so named due to the slow progression 
of disease. Other members of the Lentivirus genus include the simian-, feline-, and 
bovine- immunodeficiency viruses, all characterised by their deleterious effect on the 
host animals immune system. Lentiviruses are single-stranded positive sense, 
enveloped ribonucleic acid (RNA) viruses. There are two major subtypes of HIV, 
type 1 (HIV-1), and type 2 (HIV-2). HIV-1 evolved from SIV of Chimpanzee 
(SIVcpz) and is divided into Groups M, N and O. The most common virus worldwide 
is Group M, which is further divided into nine clades (A-K). Each clade is prevalent is 
distinct parts of the world, for example clade B is most prevalent in North America 
and Europe. HIV-2 evolved from SIV of sootey mangabey (SIVsm) and is prevalent 
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in West Africa. HIV-2 is less virulent compared to HIV-1, only causing AIDS in a 
minority of patients (83). 
 
1.3.2. HIV-1 
HIV-1 is classified as a lentivirus, encoding a complex genome and is characterised 
by unique virion morphology, with rod or conical cores (84). The HIV-1 genome 
encodes the typical gag, pro, pol, and env genes common to all lentiviruses and in 
addition encodes the accessory genes vif, vpr, vpu, tat, rev, and nef. These accessory 
genes encode proteins that control an array of functions including viral transcription, 
virion assembly and host gene expression (85).  
 
1.3.2.1. HIV-1 Genomic Structure 
The HIV-1 genome is approximately 9.8 kb in length and consists of 9 open reading 
frames, which is illustrated in Figure 1.2 (86) The viral genome is a homodimer of 
linear, positive sense, single-stranded RNA. The dimer is maintained by interactions 
between the two 5′ ends of the RNA in a self-complementary region termed the dimer 
linkage structure (DLS). The RNA genome is generated by normal host 
transcriptional machinery thus, exhibits many of the features of a normal mRNA. The 
RNA is capped at the 5′ end and contains a series of poly(A) sequences, at the 3′ end 
(85). 
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Figure 1.2: HIV-1 genome structure, from HXB2 strain. Adapted from 
http://www.hiv.lanl.gov/content/sequence/HIV/MAP/landmark.html (Sourced 
01/09/2016) 
 
1.3.2.2. Virion Structure 
Mature HIV-1 virions are icosahedral in structure and have an average diameter of 
145 nm, the virion structure is illustrated in Figure 1.3 (87). The virus is enveloped by 
a host cell derived lipid bilayer, and consists of 72 spikes formed by glycoproteins 
gp120 and gp41 (88-91). The HIV-1 lipid bilayer also includes various host proteins 
acquired during virion budding such as class I and class II histocompatibility proteins, 
various tetraspanins and transmembrane receptors (91). Proteolytic cleavage is 
required for the maturation of the virion, involving the condensation of the immature 
core to form a cone/rod shaped that is required for HIV-1 infectivity (92, 93). 
The basic structure of HIV-1 consists of four structural proteins; p24, p17, p7 and p6; 
all of which are derived from the p55 gag precursor protein, which is cleaved by HIV-
1 protease. The p24 capsid (CA) protein is the major component of the inner shelf of 
the nucleocapsid. The p17 matrix (MA) protein is myristylated and associates with the 
inner surface of the lipid bilayer. The p7 nucleocapsid (NC) binds directly to the 
genomic RNA (91, 94). The core contains two RNA strands, reverse transcriptase 
(RT), integrase, Vpr, Vif, Nef and other cellular factors. The protease is located 
outside of the cor (95, 96). 
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Figure 1.3: HIV-1 virion structure. Adapted from 
http://web.archive.org/web/20041119131214/http://www.niaid.nih.gov/factsheets/gr
aphics/howhiv.jpg (Sourced 31/08/2016) 
  
1.4. HIV-1 Life Cycle 
The HIV-1 life cycle is illustrated in Figure 1.4 and detailed below. 
 
1.4.1. Viral Entry 
HIV-1 entry into the host cell involves two main steps; binding of the virion to the 
host cell plasma membrane and fusion. Virus entry is initiated when the HIV-1 
envelope trimer (each subunit consists of gp120 and gp41) binds to the surface 
receptor CD4 (97-99). Subsequent conformational changes are induced to expose the 
co-receptor (CXCR4 or CCR5) binding site, which activates fusion (100-105). 
Further to the co-receptors CXCR4 and CCR5, several viral attachment receptors 
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have been discovered that promote virus attachment to the cell surface and subsequent 
binding to CD4/chemokine receptors for entry. C-type lectin receptors (CLR) are the 
most characterised, which include DC-SIGN, Langerin (CD207), and macrophage 
mannose receptor (MMR) (CD206) (106-109). Siglec-1 (CD169) and syndecans are 
other identified virus attachment receptors (110, 111). Upon fusion, the viral core is 
released into the host cell’s cytoplasm. 
 
1.4.2. Viral Uncoating, Reverse Transcription and Transport to the 
Nucleus 
Upon entry, destabilisation of the viral core occurs in the cytoplasm that initiates 
reverse transcription of the viral single stranded RNA (ssRNA) genome, into double 
stranded DNA (dsDNA). This process is completed in the cytoplasm by the HIV-1 
RT enzyme. The viral protein RT can function as a DNA polymerase and as an 
RNAse H; which digests the RNA templates (112, 113). 
To initiate reverse transcription, HIV-1 uses a specific transfer RNA (tRNA) known 
as tRNALys3 (114). The process of reverse transcription is highly error prone, which is 
mainly due to RT not having a ‘checking system’, leading to a high rate of mutation. 
The frequent switching between templates also contributes to the high mutation rate 
(115, 116). The total HIV-1 in vivo mutation rate has been measured to be 3 x 10-5 per 
base pair per cycle of replication (117). The high rate of mutation contributes to the 
viruses ability to generate significantly genetically diverse viral progeny and in doing 
so can lead to the emergence of HIV variants that are resistant to ART. During 
reverse transcription, long terminal repeats (LTRs) are generated, which flank both 
ends of the genome. This is an important part of the viral genome as transcriptional 
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promoter and regulatory motifs are located at the 5’ LTR (118). The full length linear 
copies of viral DNA are transported into the nucleus through the nuclear pore as a 
pre-integration complex (PIC), containing multiple viral proteins such as gag-matrix, 
RT, integrase and Vpr. However, the mechanism of nuclear import has yet to be 
elucidated (119, 120). 
 
1.4.3. Proviral Integration 
Once transported through the nuclear pore, the viral DNA genome is integrated into 
the host cells genomic DNA (121, 122). The integrated viral genome, known as 
provirus, remains for the lifetime of the infected cell and serves as a template for the 
transcription of viral genes. Integration is catalysed by the IN enzyme and the 
insertion of the viral DNA genome involves three main steps. Firstly, IN removes 
two-three nucleotides from the 3’ ends of the viral linear DNA, resulting in ‘sticky 
ends’. Secondly, IN catalyses a staggered cleavage of the hosts genomic DNA, 
whereby the 3’ ends of the viral linear DNA binds to the 5’ overhanging ends of the 
host genomic DNA. Finally, host cellular repair machinery fills the gap (123-125). 
Site selection for HIV-1 integration does not depend on specific host sequence 
requirements, however the process is not random. Large-scale analyses of HIV-1 
integration site selection demonstrated a biased preference for integration into regions 
of DNA that encode for genes (126-128). Integration of the viral DNA into the host 
genome does not always occur, with viral DNA forming 1-LTR or 2-LTR circles as a 
consequence of incomplete HIV integration reactions. The latter non-integrated viral 
DNA circles cannot produce infectious progeny (129, 130). 
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1.4.4. Viral Transcription 
Transcription of the integrated proviral DNA serves as a single primary 
transcript/template for further processing, generating unspliced, spliced and multiply 
spliced mRNA that encode viral proteins (131). The initiation of viral transcription 
occurs through the 5’ LTR region, which contains the core promoter (132, 133), trans-
acting response element (TAR) (134) and multiple enhancer elements such as NFκβ 
and NFAT (135, 136). During early stages of infection multiple spliced mRNA are 
generated encoding Tat, Rev and Nef, which are exported out of the nucleus to the 
cytoplasm, where translation occurs (137). The transcription rates are increased by the 
binding of the Tat protein to the TAR element in the 5’ LTR. The Tat protein also 
enhances the elongation phase of HIV-1 transcription, allowing full-length transcripts 
to be produced (138-140). 
During late stages of infection the viral protein Rev, is transported back into the 
nucleus and binds to the rev response elements (RRE) in unspliced mRNA (141, 142). 
This facilitates the stabilisation and transport of unspliced mRNA, which encode gag 
and gag-pol (137, 143, 144). Additionally, singly spliced mRNA is also generated 
encoding env, vif, vpu and vpr. The majority of viral genes are translated on free 
cytoplasmic ribosomes. However, the translation of the env precursor protein, gp160, 
occurs in the endoplasmic reticulum, followed by processing in the Golgi complex 
where it is glycosylated and cleaved into the gp120 and gp41 subunits. 
 
1.4.5. Virion Assembly, Budding and Maturation 
During late stages of infection, uncleaved Gag accumulates in the cytoplasm and 
istranslocated to the site of virion assembly at the plasma membrane (145). During 
 17 
trafficking, interaction between Gag and viral RNA occurs and low levels of 
multimerisation is induced (146, 147). Conformational changes induced by Gag 
multimerisation  reveals the once buried myristoylation site of MA (refrrered to as the 
myristoylation switch) (148). The switch is required for the binding of Gag to the 
phospholipid phosphatidylinositol-(4,5)-bisphosphate (PI(4,5)P2) (149, 150). The 
anchorage of Gag in the plasma membrane induces the recruitment of “raft”-
associated proteins and lipids and promotes higher order multmerisation of Gag (151). 
The precursor envelope protein gp160 protein, is translated in the ER and 
subsequently cleaved into gp120 and gp41 by the cellular protease furin (152, 153). 
The protein can be sequestered at the ER through interactions with newly synthesised 
CD4. The viral protein vpu promotes the degradation of CD4, thus allowing the 
transport of gp160 to the plasma membrane (95, 154). Once at the surface, HIV-1 
envelope is incorporated into budding virions through gp41’s association with HIV 
MA (155). 
At the final stages of virion budding, TSG101 binds to the PTAP motif of p6 and 
recruits endosomal sorting complexes required for transport (ESCRT) machinery to 
mediate viral scission (156). Upon or during the process of budding, maturation of the 
virion takes place, involving the cleavage of gag and gag-pol precursors by the viral 
protein protease. This results in the characteristic mature HIV virions bearing the 
electron dense fullerene capsid core (87). Dimerisation of the genomic positive strand 
RNA is also required for full virion maturation and infectivity (157). 
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Figure 1.4: HIV-1 replication cycle. The essential steps are discussed in section 
1.4. Adapted from (150). 
 
1.5. HIV-1 Latent Reservoir 
The success of ART has dramatically reduced the plasma viral load in HIV-1 patients 
leading to a decrease in HIV-1 related morbidity and mortality (158, 159). However, 
despite early ART intervention HIV-1 still persists in patients (160-163). Upon 
cessation of ART, plasma viral loads rebound rapidly (164). It has been estimated to 
take at least 60 years to eradicate the latent reservoir using current ART strategies 
(165, 166). Consequently, patients need to remain on ART for the rest of their lives, 
which is expensive, has multiple side effects and is not available to everyone, making 
the eradication of the HIV-1-reservoir a critical hurdle for curing HIV-1.   
 19 
The HIV-1 latent reservoir consists of replication-competent virus that can persist in 
certain cell types and upon activation produce infectious viral progeny. The memory 
CD4+ T cell represents the major cell type of the latent HIV-1 reservoir (167-169). 
Replication competent HIV-1 provirus has also been proposed to be present in the 
following cellular and anatomical sites; monocytes/macrophages, dendritic cells, 
central nervous system, cells of the gastrointestinal tract and lymph nodes. However, 
their contribution to the viral reservoir has yet to be elucidated. Each viral reservoir is 
discussed in the sections below. 
 
1.5.1. CD4+ T cells 
The HIV-1 latent reservoir persists predominantly in memory CD4+ T cells and is the 
most characterised reservoir of HIV-1 (168-172). Certain memory CD4+ T cells 
subsets have been shown to differ in their contribution to the HIV-1 reservoir. In 
particular, central memory (TCM) and transitional memory (TTM) CD4+ T cells 
were shown to harbour high frequencies of HIV-1 DNA (169). The relative 
contribution of TCM and TTM cells to the HIV-1 reservoir is highly variable from 
one patient to another. Patients with CD4+ TCM cells as their major constituent were 
more likely to have higher CD4 counts compared to patients with CD4+ TTM cells as 
their major contributor (169).  
Naïve CD4+ T cells also contain HIV-1 DNA, albeit at a lower frequency compared 
to other subsets (173-175). Additionally, a newly identified subset of CD4+ T cell 
with stem cell like properties has also been shown to contain relatively high 
frequencies of HIV-1 DNA (176, 177). 
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1.5.2. Monocytes, Macrophages and Dendritic Cells (DCs) 
Monocytes, macrophages, and DCs are early targets for HIV-1 infection, and 
disseminate the virus throughout the body including the brain, gut, lymph nodes, 
spleen, and lung (178). Infection of monocyte/macrophage lineage cells are less 
susceptible to the HIV-1 cytopathic effect compared to that of activated CD4+ T cells 
(179, 180). Indeed, macrophages are able to produce viral progeny for longer periods 
of time with insignificant cell death (181). Macrophages and dendritic cells play an 
important role in viral transmission as they are immune sentinels at the mucosa and 
are one of the first cell types HIV encounters (182-186).  
HIV-1 DNA has been detected in monocytes of infected patients (187-189). The 
detection of HIV-1 DNA has also been reported in tissue macrophages residing in the 
gastrointestinal tract, lungs and brain (190-194). Although recently, it has been 
suggested this DNA may have originated from phagocytosed infected dying CD4+ T 
cells (195). True de novo infection in macrophages is evident in SIV animal models 
where there is irreversible depletion of CD4+ T cells, yet maintenance of high viral 
loads within the macrophage/myeloid compartment (196). Additionally, pre-depletion 
of CD4+ T cells in Rhesus macaques, still proceeds with SIV infection ad 
establishment of high viral loads, with 80% of SIV RNA positive cells in lymph 
nodes being macrophages. 
In HIV-1 models Honeycutt and colleagues established a humanised mouse model 
containing only human myeloid cells, termed myeloid-only mice (MoM). Human 
myeloid cells were present in all tissues, including the brain. After HIV-1 infection, 
productive and sustained replication and replication-competent virus was detected in 
multiple tissues including bone marrow, spleen, liver lung and brain (197).  
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Direct evidence that HIV-1 can originate from a specific macrophage population has 
been observed in a study, which isolated macrophages-derived HIV-1 using 
macrophage specific markers. In patients with untreated pulmonary tuberculosis, virus 
could be isolated and detected by immunocapture using macrophage restricted anti 
CD36 magnetic beads (198). This finding is important as virions can only be derived 
if actively replicating within the cell type. This evidence supports a macrophage 
specific HIV-1 population independent of phagocytosed infected CD4+ T cells. 
Recent studies (especially those on the restriction factor SAMHD1) have down-
played HIV-1 infection of myeloid cells in vivo. However, this support has recently 
waned as it is now appreciated most HIV-1 target cell populations are equipped with 
equivalent or at times more potent levels of viral restriction (199, 200). Furthermore, 
pre-depletion of CD4+ T cells in macaques showed substantial levels of SIV infection 
in myeloid cells detected in lymph nodes and mucosal tissues (201). To conclude, 
there is substantial evidence both in animal and human studies that macrophages and 
cells of the myeloid lineage constitute a real reservoir. 
 
1.5.3. Central Nervous System – Anatomical Site 
During early infection, HIV-1 crosses the blood brain barrier to infect the CNS, 
predominantly targeting perivascular macrophages, microglia and astrocytes (202-
204). CNS infiltration of activated monocytes/macrophages and microglial activation 
has been widely reported to be essential in the development of HIV-associated 
neurological disorders. Indeed, neurocognitive impaired patients were shown to 
contain higher infection frequencies of macrophages, microglia and astrocytes (205). 
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Although vast evidence has been provided to show HIV-1 infects cells of the CNS, 
whether it serves as a latent viral reservoir remains to be elucidated. Replication 
competent virus is required to be present within the reservoir to contribute to 
persistence. Reactivation of integrated provirus has been demonstrated in vitro, 
however not in vivo (206, 207). Experimentally this will be challenging, as live cells 
from infected patients CNS are required for these experiments. 
 
1.5.4. GALT 
The GALT is the largest lymphoid organ infected by HIV-1 and harbours 
approximately 5-20% of the total body lymphocytes (208).  During all stages of HIV-
1 disease CD4+ T cell depletion is the most substantial in the GALT (209). This 
reservoir has shown to contribute to HIV-1 persistence with low levels of replication 
detected despite patients being on ART (210-212). An increase in viral diversity 
within a patient has been shown to accompany disease progression of HIV-1 infection 
(213). In the GALT, replication occurs in a distinct compartment resulting in different 
HIV-1 quasispecies (213). The importance of GALT as a viral reservoir still needs to 
be elucidated. In fact, the majority of HIV-1 DNA present in whole blood is from 
non-gut-homing resting memory CD4+ T cells (172). Furthermore, minimal and 
similar decay rates have been observed in both GALT and whole blood (169, 210, 
212, 214). 
 
1.5.5. Lymph nodes 
Similar to GALT, lymph nodes (LN) could also be an important location for the 
persistence of HIV reservoirs. Germinal centres (GC) within LN may provide a 
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sanctuary site for persistent HIV replication. Fukazawa and colleagues demonstrated 
in an SIV model cytotoxic virus-specific CD8+ T cells were relatively excluded from 
B cell follicles within the GC, preventing the elimination of productively infected 
cells (215). While LN are known to be a major site of replication during early stages 
of disease (216), there is little evidence regarding HIV reservoirs in LN during 
suppressive ART. Two separate studies led by Chomont and Stockenstrom compared 
the frequency of latently infected CD4+ T cells from LN and WB and found no 
statistical difference (169, 217). The role LN may play as a reservoir for HIV during 
still needs to be elucidated. 
 
1.6. HIV-1 Restriction Factors 
Evolution of retroviruses and humans has occurred concurrently for tens of thousands 
of years. As a result, our immune systems have adapted to express multiple restriction 
factors against viruses. Many viruses, including HIV-1 have evolved to express 
proteins that can counteract specific restriction factors. HIV-1 is a small virus 
compared to others such as the herpes simplex virus, however it has devoted a 
considerable amount of its genome to encode accessory proteins that can neutralise 
host restriction factors. Listed and detailed below are the host restriction factors for 
HIV-1, how they restrict infection and how the virus has evolved counter-measures to 
restriction. 
 
1.6.1. APOBEC3 Protein Family 
The apolipoprotein B mRNA–editing enzyme catalytic polypeptide–like 3 
(APOBEC3) protein family is expressed in a diverse range of tissues and has 
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increased expression in hematopoietic cells (218, 219). All proteins with the 
APOBEC3 family exhibit single-stranded DNA deaminase activity, which has the 
ability to restrict HIV-1 infection (220, 221). Multiple proteins of the APOBEC3 
family can restrict HIV-1 infection, namely proteins G, D, F and H (222). The protein 
APOBEC3G (A3G) has been studied the most and will be the protein that is referred 
to hereafter. 
The antiviral effect of A3G is observed in the subsequent cycle of infection, after 
A3G is incorporated into assembling HIV-1 virions through an interaction with the 
NC region of gag (223). Upon infection with an A3G-loaded viral core, A3G is 
released into the cytoplasm and through specific interactions with the RTC, 
deaminates cytidine (C → U) residues in the nascent minus strand viral DNA (224-
227). Depending on the extent of deamination the hypermutated viral cDNA is either 
recognised by the cell as abnormal and degraded, or integration occurs but no 
infectious progeny can be produced due to the extent of mutagenesis (225, 228). 
There is evidence of a secondary approach whereby A3G can restrict HIV-1 infection. 
A study by Bishop and colleagues have shown that A3G can interfere with reverse 
transcription through steric hindrance of the RTC, causing early termination of minus-
strand synthesis (229). 
Studies have shown that the accessory protein Vif is required for production of 
infectious HIV-1 progeny in primary CD4+ T cells and in several common CD4+ T 
cells lines (eg. CEM). However, Vif is not essential in other cell lines such as CEM-
SS (230-232). A phenotypic study between CEM and CEM-SS cell lines led to the 
discovery that A3G is the protein responsible for the differences between the cell lines 
and Vif overcomes its antiviral activity (233). In the presence of Vif, degradation of 
A3G occurs in the producer cell, thus A3G cannot incorporate itself into assembling 
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virions and exert its antiviral effect. For degradation of A3G, Vif interacts with an E3 
ubiquitin ligase complex consisting of Cul5 elongin B and C and Rbx-1 (234, 235). 
The complex ubiquitinates bound A3G, which is then rapidly processed through the 
proteasomal degradation pathway (236, 237). 
 
1.6.2. TRIM5 
The host range of HIV-1 is limited to humans and chimpanzees. As a result, Old 
World monkeys (OWM) such as rhesus (Rh) and cynomolgus (CM), cannot be 
infected by HIV-1. In contrast, SIV macaque (SIVmac) can replicate efficiently in 
OWM (238-241). In 2004, a cDNA library screening of Rh monkeys identified 
TRIM5α as a host factor that plays a crucial role in the restricted host range of HIV-1 
(242). TRIM5 is part of the tripartite motif (TRIM) protein family and contains a 
RING, B-box2, coiled coil and SPRY domains (243, 244). The human TRIM5α 
protein does not target HIV-1, but restricts infections by other strains such as murine 
leukemia virus (MLV) and equine infectious anemia virus (EIAV) (245). 
TRIM5α restricts lentiviral infection post-entry, before the generation of viral reverse 
transcription products. However, the underlying restriction mechanism remains 
unclear. It is known that TRIM5α-mediated restriction occurs through the interaction 
of intact lentiviral capsid cores with the SPRY domain of TRIM5α (242, 246-248). 
This interaction promotes the premature uncoating of viral capsid, which in turn can 
significantly impact reverse transcription (249, 250). TRIM5α has also been shown to 
act as a pattern recognition receptor (PRR). It recognises HIV-1 CA and activates NF-
κβ and activator protein -1 (AP-1) and enhances transcription of IFN-β (251). Whilst 
accessory proteins of HIV and SIV are equipped to evade restriction factors, 
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countering the TRIM family of proteins is an exception to the rule and typically 
involves changes in CA to enable evasion of this innate response (252). 
 
1.6.3. Tetherin 
Tetherin is a type II single pass transmembrane protein, which has a transmembrane 
domain at the N-terminus and a glycophosphatidylinositol (GPI) at the C-terminus 
(253, 254). Both of these regions are essential for the antiviral activity of tetherin 
(255). Induced by interferon-α, tetherin causes budding virions to remain trapped at 
the plasma membrane of the infected cell (256, 257). Consequently, the accumulated 
virions are trafficked into early and late endosome compartments for degradation 
(258). Tetherin can also act as a sensor for viral infection. Upon accumulation of 
tetherin at the plasma membrane, it becomes unlinked to the cortical actin 
cytoskeleton and is phosphorylated. A signaling cascade is initiated, which activates 
NFκβ and induces the expression of pro-inflammatory cytokines CXCL10, IL-6 and 
type I IFN (259-261). 
The expression of HIV-1 Vpu can inhibit both the effect tetherin has on viral release 
and viral sensing (262). Tetherin’s sensitivity to the antagonism of Vpu is species 
specific (263, 264). Multiple studies have demonstrated Vpu co-immunoprecitates 
with tetherin, which reduces the level of tetherin present on the cells surface by either 
retarding its process through the secretory pathway or by causing its internalization 
(265-269). Curiously, a recent study on HIV O subtypes has observed HIV Nef to 
also function in tetherin evasion (270). 
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1.6.4. SAMHD1 
Sterile alpha motif and histidine-aspartate-domain-containing protein 1 (SAMHD1) 
was originally identified as the cDNA orthologue to mouse IFNγ-induced gene Mg11 
(271). Mutations in the SAMHD1 gene are associated with Aicardi-Goutieres 
Syndrome (AGS), a disease characterised by over expression of interferon alpha 
(IFN-α) and upregulation of IFN-stimulated genes (272, 273). SAMHD1 is 
upregulated in response to viral infection and subsequent interferon production (271, 
274-276). 
In the absence of nucleotides, SAMHD1 exists in its inactive monomer and dimer 
form (277, 278). Activation of SAMHD1 occurs through two activator sites, both of 
which require nucleotides to catalyse tetramerisation. The observed dNTPase activity 
is conducted through the SAMHD1 tetramer (279-281). Structurally, SAMHD1 
contains a SAM domain in the N terminus, a nuclear localisation signal (NLS) and a 
catalytic HD domain. Two HIV-1 restriction activities have been identified, both 
linked to the HD domain (282). Initially, SAMHD1 was discovered to exhibit 
triphosphohydrolase activity, which hydrolyses dNTPs into deoxynucleosides and 
triphosphates (279, 283-285). This activity restricts HIV-1 infection, as cells 
expressing SAMHD1 (ie. macrophages, dendritic cells and resting CD4+ T cells) 
have cellular dNTPs levels below the threshold required for efficient HIV-1 reverse 
transcription (286, 287).  
In contrast to the proposed SAMHD1 mechanism of HIV-1 restriction (dNTPase 
activity), SAMHD1 has also been shown to be a nucleic acid binding protein. It has 
been reported SAMHD1 possesses 3’-5’ exonuclease activity against single stranded 
RNA (ssRNA) such as the HIV-1 genome (282, 288-290). Furthermore, key 
mutagenesis experiments, which generated mutant SAMHD1 proteins possessing 
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either dNTPase or nuclease activity, demonstrated SAMHD1 nuclease activity is 
required for HIV-1 restriction (291, 292). However, other studies have reported no 
nuclease activity of SAMHD1 (282, 284, 290, 293). One particular study hypothesises 
that the reported SAMHD1 nuclease activity could be due to unknown nucleases 
contaminating the purified SAMHD1 samples (290). (274). However, new evidence 
has shown that SAMHD1 has phosphorolytic RNase activity. The previous studies 
reported no RNase activity were based in Tris buffers and lacked inorganic 
phosphates to enable RNase activity (294). 
Vpx is encoded by SIV of sootey mangabey (SIVSM) and other related viruses such 
as SIV of macaque (SIVmac) and HIV-2. Although not essential for infection, it has 
been established Vpx contributes to disease progression in non-human primates and is 
critical for efficient reverse transcription in myeloid cells, a well-known restricted cell 
type (295-298). The biological activity of Vpx is mediated through an interaction with 
DCAF and its assemblage with the CUL4A-DDB1 E3 ubiquitin ligase complex (299-
301). It has been hypothesised that Vpx overcomes the restriction observed in 
myeloid cells by targeting a specific restriction factor to the E3 ubiquitin ligase 
complex for proteasome-dependent degradation (300). 
HIV-1 restriction is also observed in resting lymphoid and myeloid cells, at a post-
entry level (238, 239, 302, 303). Although HIV-1 does not encode Vpx, multiple 
studies have reported the virus is highly susceptible to its effects (295, 299, 301, 304). 
Multiple investigations have been conducted to identify the restriction factor targeted 
by Vpx. Through pull down assays it was discovered SAMHD1 is the cellular 
restriction factor counteracted by Vpx (305, 306). 
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1.6.5. SERINC5 
For over 20 years it has been known Nef increases the infectivity of HIV-1 virions 
(307-309). Recently, it has been discovered that HIV main group subtype Nef 
counteracts a SERINC5 and to a lesser extent SERINC3, which are potent inhibitors 
of HIV-1 virion infectivity (310, 311). Localising to the plasma membrane, SERINC5 
is efficiently incorporated into virions, decreasing subsequent infectivity (310, 311). 
Nef excludes SERINC5 and SERINC3 from the HIV-1 virion by redirecting the 
proteins to a Rab7-positive endosomal compartment (310). Constitutively expressed 
in cells, SERINC5 is part of a unique protein family that contains 11 transmembrane 
domains and is highly conserved among eukaryotes’ all members (312). The exact 
role of SERINC proteins is unknown, but evidence suggests they play a role in the 
regulation of lipid biosynthesis (312). 
 
1.7. Cure Strategies 
Two types of cure strategies, ‘sterilising’ and ‘functional’, have been pursued during 
the course of HIV-1 research. A ‘sterilising’ cure completely eradicates replication-
competent HIV-1 from all reservoirs, while a ‘functional’ cure permanently controls 
viral reservoirs in the absence of ART. Clinical evidence has been observed for both 
strategies. The case study of a HIV-1 infected patient with acute myeloid lymphoma, 
known as the ‘Berlin patient’, had two bone marrow irradiations and received a stem 
cell transplant from a homozygous CCR5Δ32 donor. This rare genetic mutation 
rendered cells resistant to HIV-1 infection, as the expression of CCR5 on the cells 
surface is prevented. To date, the Berlin patient has remained without viral rebound 
after the transplantation and discontinuation of ART (313, 314). This case study has 
been viewed as a sterilising cure, however, certain viral reservoirs such as the CNS 
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can only be examined for viral DNA post-mortem. It is presently unclear if the cure 
was established by the transplantation procedure itself, the subsequent bone marrow 
transplant with the CCR5 mutation or a combination of both. 
Several published case studies have claimed to achieve a functional cure, including 
the Visconti cohort, which initiated ART to patients during primary infection. Off 
therapy, long term virological remission was observed for several years after 
interruption, with some patients showing a further reduction to their already low viral 
reservoir (315). Other ‘functional’ cures have been reported which include the 
‘Mississippi Baby’ (316) and the two ‘Boston patients’ (317). Unfortunately, both of 
these case studies eventually rebounded after the cessation of treatment (318, 319). A 
‘sterlising’ cure for HIV-1 is difficult to achieve due to the presence of viral 
reservoirs. Therefore, priority has been given to finding a ‘functional’ cure. 
Current ART (detailed in section 1.2.4) for HIV-1 has successfully depleted plasma 
viral load to almost undetectable levels (<50 copies/mL) (320-322). However, if 
treatment is interrupted HIV-1 rebounds rapidly (323, 324). Consequently, patients 
are required to continue ART for the rest of their lives. Despite constant 
improvements of HIV-1 antiretrovirals, ART a ‘sterilising’ or ‘functional’ cure has 
not been achieved 
Currently, three core strategies are being pursued; ‘shock and kill’, therapeutic 
vaccines and gene therapy. ‘Shock and kill’ strategies involve the reactivation ‘shock’ 
of the viral reservoir, which could make them more susceptible to be eradicated 
‘killed’ by immune mediated cytolysis. Latency reactivation agents (LRAs) such as 
the histone deacetylase inhibitor (HDACi), vorinostat, have been shown to increase 
HIV-1 RNA levels, however the effect has been modest (325-327). Other LRAs have 
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been evaluated, such as romidepsin, however no definite effect on the viral reservoir 
has been reported (328). Additional strategies are required to eliminate the reactivated 
cells, with on strategy being a therapeutic vaccine used in conjunction with LRAs. 
Multiple clinical trials including therapeutic vaccines are in the pipeline, with their 
aim to eliminate patient’s existing infection by enhancing the immune response to 
HIV-1 (328). 
Vaccines, to date, have shown very little to nil efficacy. The prophylactic RV144 
vaccine has been the most successful, with an estimated vaccine efficacy of 31.2% at 
42 months (329). Lessons from the RV144 trial have shown the importance of IgG 
antibodies directed against a scaffolded V1V2 region of gp120. As a result, improved 
Env immunogens have been generated with pre-clinical data currently being 
generated (330). Gene therapy is a cell-based therapy involving the genetic 
modification of cells. Both ‘functional’ and ‘sterilising’ cures are being pursued with 
this approach. Gene therapy is fundamental to this thesis and a detailed outline of 
gene therapy is described below. 
 
1.7.1. Gene Therapy 
Several types of gene modifications have been investigated in search for a ‘sterilising’ 
or ‘functional’ cure. The excision of the entire or sections of the HIV-1 integrated 
genome could potentially eradicate the viral reservoirs, leading to a sterilising cure. 
Multiple nuclease-based approaches have been investigated. These include the 
established methods of zinc finger nucleases and Transcription Activator – Like 
Effector Nucleases (TALENS) (331, 332). All these technologies are guided systems 
which induce double stranded breaks in the genome. 
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A new and exciting approach which has received immense attention of late is the 
CRISPR/Cas9 system. A naturally existing adaptive immune system present in 
prokaryotes, CRISPR/Cas9 has recently been developed into a novel genome editing 
system in mammalian cells (333). Multiple studies have demonstrated success in 
excising the HIV-1 integrated genome using guided RNAs (gRNA) against conserved 
regions of Rev, Gag, LTR, Pol and Env (334-338). However, key challenges include 
targeting all viral quasispecies within a given patient sample as well as viral escape 
variants. Furthermore the selection of viral escape variants is also a concern and has 
been documented in a study by Wang and colleagues (338). 
The most common approach for a gene therapy ‘functional’ cure is protecting cells 
against HIV-1 infection through the full or partial replacement of the immune system 
with genetically modified cells.  The replacement of the immune takes place in either 
CD34+ progenitor cells or CD4+ T cells. The down regulation of the co-receptor 
CCR5 is a popular therapeutic target to render the cell resistant to HIV-1 infection. 
This has been accomplished using nuclease method employing ZFN (339), TALEN 
(340) or CRISPR/Cas9 utilising either single or dual gRNAs (341, 342). Another 
nuclease strategy to protect cells against infection is the utilisation of a unique ACA-
specific endoribonuclease, which cleaves mRNA, term MazF. Encoded by 
Escherichia coli it has been shown to restrict viral integration and replication without 
generating cellular toxicity (343, 344). 
The method of RNA interference (RNAi) in the form of short hairpin (shRNA) has 
also successfully down regulated CCR5 expression (345-348). RNAi has been well 
described in mammalian cells as the binding of complementary double stranded RNA 
(dsRNA) to an endogenous mRNA target for degradation (349). Many cellular 
processes are regulated by miRNAs and scientists have utilised this process to 
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specifically degrade dsRNA resulting in knockdown of a specific protein. Targeting 
the tat/rev transcript through shRNA has also been successful (267, 350-353) 
Another novel approach, which has shown some promise targeting HIV-1 infected 
cells is utilising chimeric antigen receptor (CAR) CD8+ T cells. Genetically modified 
CD8+ T cells are generated by linking viral or tumour antigen binding domains with 
the activating signaling domain of a receptor such as CD3ζ. A few studies have 
reported CD4-based CAR which, when genetically engineered into CD8+ T cells, 
gave them the capability for specific direct cytotoxic activity against Env expressing 
cells (354, 355). 
Replacing all or part of the immune system though genetic modifications can only 
protect uninfected cells from HIV-1 infection, the infected cells are still present and 
may proliferate. Permanently silencing the HIV-1 provirus is an approach, which has 
investigated preventing reactivation of HIV-1 provirus by initiating DNA epigenetic 
modification to the HIV-1 integrated genome. Transcriptional gene silencing (TGS)-
inducing shRNA which targets the NF-κβ binding domains in the HIV-1 5’ LTR have 
shown successful silencing of HIV-1 for up to one year. The shRNA, termed PromA 
induced CpG methylation within the 5’ LTR region (356-358). Another group has 
also shown suppression of HIV-1 using small non-coding RNA targeting HIV-1 LTR. 
However this suppression was only demonstrated for one month (359). While, 
specificity has been demonstrated with the PromA shRNA, future studies need to be 
conducted primary cell models / animal models to determine efficiency and safety. 
A multipronged antiviral approach to gene therapy is likely to be the most effective 
HIV-1 gene therapy. Clinical trials using a combination approach are currently 
underway. This includes the investigation of a triple combination vector coexpressing 
 34 
a TAR decoy, anti-tat/rev shRNA and an anti-CCR5 ribozyme (360 and 
NCT01961063). Another clinical trial utilises a dual anti-HIV gene vector called Cal-
1, which encodes a short hairpin RNA (shRNA) for the down-regulation of CCR5 in 
combination with the HIV-1 fusion inhibitor, C46 (348). 
 
1.7.1.1. Lentiviral vectors 
For more than two decades, genetically modified lentiviruses have been used to 
deliver genes into mammalian cells. Continuous improvements of packaging systems 
have increased the biosafety and infectivity of lentiviral vectors. These packaging 
systems can be categorised into three generations and are shown in. 
First generation lentiviral vectors are produced from three separate plasmids: (i) a 
transfer vector; (ii) an Env plasmid encoding a viral glycoprotein; and (iii) a 
packaging plasmid. The packaging plasmid expressed HIV Gag, Pol and 
regulatory/accessory proteins from a strong mammalian promoter (361). 
The second generation vectors are also produced from three separate plasmids. The 
key difference between first and second generation was the deletion of accessory 
genes in the packaging plasmid. This was due to a discovery that accessory genes 
were not essential for efficient gene delivery (Zufferey, Nagy et al. 1997). Therefore, 
decreasing the likelihood of the generation of replication-competent lentiviruses 
(RCLs). 
Third generation vectors have two extra modifications to increase biosafety. Firstly, 
the 5’LTR from the transfer vector is replaced by a strong tat-independent constitutive 
promoter. Secondly, the rev gene is expressed in a separate plasmid (362, 363).  
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Additional elements are routinely included in lentiviral vectors to enhance gene 
transduction efficiency. This includes the cis-acting cPPT and woodchuck hepatitis 
virus post-transcriptional regulatory element (WPRE), which improve nuclear import 
and gene expression, respectively (364),(365) 
 
1.8. Overview and Aims 
This literature review has provided a summary of HIV-1 pathogenesis, HIV-1 
restriction factors and current cure strategies, and specifically gene therapy. Current 
HIV-1 gene therapy protocols target CD4+ T cells and/or CD34+ progenitors. Since 
resting CD4+ T cells contain the restriction factor SAMHD1, ex vivo gene therapy 
protocols activate CD4+ T cells prior to transduction to increase efficiency.  
For successful gene delivery into the latent HIV reservoir, efficient RTn needs to 
occur for integration and subsequent gene expression. Since Vpx can overcome the 
restriction factor SAMHD1 the future use of Vpx in the context of lentiviral gene 
therapy vectors and DC-based vaccines has been supported (306, 366-369). Whilst 
Vpx has immense potential in gene therapy strategies for an HIV-1 cure, the effects of 
introducing Vpx into an HIV positive individual in vivo/ex vivo are not known. This 
needs to be carefully considered since the positive effect Vpx has on RTn for 
lentiviral gene therapy vectors would also affect existing HIV-1 infected cells.  
The overall aim of this thesis was to determine the feasibility of Vpx being 
incorporated into lentiviral gene therapy vectors. Specifically each chapter examined 
the following: 
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Chapter 3 sought to characterise three unknowns in utilising Vpx:  
o If cells were exposed to Vpx ex vivo, do the effects of Vpx rapidly 
decay? 
o Does Vpx affect the efficacy of antiretroviral therapy, and if so, how 
long post-Vpx exposure does this persist?  
o Since Vpx increases viral RTn would there be differences in HIV 
protection if Vpx was incorporated with anti-HIV genes that inhibited 
HIV infection pre- or post-RTn? 
Chapter 4 conducted proteomic studies to: 
o Determine any hidden phenotypes, which could affect the usage of 
Vpx in gene therapy protocols  
o Investigate whether any SAMHD1 independent changes are occurring 
which also enhance HIV infection/gene delivery 
Chapter 5 generated knockdown and knockin THP-1 cell lines to: 
o Determine whether any of the protein targets generated in Chapter 4 
were capable of enhancing HIV-1 infection. 
o If any protein targets do enhance HIV-1 infection similar to SAMHD1 
knockdown, the protein levels for each target will be examined short 
and long-term post-Vpx stimulation. The protein levels of primary 
macrophages, dendritic cells and resting CD4+ T cells will be 
investigated. 
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CHAPTER TWO: MATERIALS AND 
METHODS 
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2. Material and Methods 
2.1. Solutions and Buffers 
The following is a list of solutions and buffers used in the experiments of this thesis. 
Reagents with no suppliers provided were made in house. 
Annealing Buffer 
1X TE buffer supplemented with 50 mM of sodium chloride (NaCl) Sigma-Aldrich, 
St Louis, MO, USA). 
Luria Broth (LB) Agar 
1% (w/v) bacto tryptone, 0.5% (w/v) yeast extract, 0.5% (w/v) NaCl, 0.08% (v/v), 5 
M sodium hydroxide and 1.5% (w/v) agar in distilled water. Stored at room 
temperature (RT).  
LB medium 
1% (w/v) bacto tryptone, 0.5% (w/v) yeast extract, 0.5% (w/v) sodium chloride, 
0.08% (v/v) and 5 M sodium hydroxide in distilled water. The solution was sterilised 
by autoclaving. 
MACS Buffer (1x) 
1x phosphate buffered saline (PBS) (Thermo Fisher, Waltham, MA, USA)  (pH 7.2), 
2 mM EDTA (Sigma-Aldrich) and 1% (v/v) human serum (Sigma-Aldrich). 
MOPS running buffer 
Immediately before use, 20X NuPAGE MOPS SDS running buffer (Life 
Technologies, Carlsbad, CA, USA) was diluted 1 in 20 with distilled water. The 1X 
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buffer consisted of 50 mM MOPS (3-morpholinopropane-1-sulfonic acid), 50 mM 
Tris base, 0.1% (w/v) SDS and 1 mM EDTA at pH 7.7. 
4% Paraformaldehyde 
An aqueous solution of 16% paraformaldehyde (ProSciTech, Queensland, Australia) 
was diluted 1 in 4 in PBS to obtain 4% paraformaldehyde working stocks, which were 
stored in the dark. 
10X PBS/Saponin/Gelatin (PSG) Buffer 
A 10X stock was generated by dissolving 27.5 mL of fish skin gelatin (50%) (0.5 g of 
saponin (Sigma-Aldrich) and 0.2 g of sodium azide (Sigma-Aldrich) in 500 mL of 
PBS and was stored at 4 °C. A 1X working stock was made by diluting the 10X stock 
1 in 10 with PBS and was stored at RT. 
RIPA buffer  
150 mM NaCl, 1.0% (v/v) IGEPAL® CA-630 (Sigma-Aldrich), 0.5% (w/v) sodium 
deoxycholate (Sigma-Aldrich), 0.1% (w/v) SDS, 50 mM Tris, pH 8.0 (Sigma-
Aldrich). 
10X Transfer Buffer 
10X buffer contained 250 mM Tris and 1.92 M glycine (Sigma-Aldrich), pH 8.3. 
1X Tris-EDTA (TE) Buffer 
TE buffer comprised of DNAse/RNAse free distilled water (Thermo Fisher) 
supplemented with 10 mM Tris (Sigma-Aldrich) and 1 mM EDTA (Sigma-Aldrich), 
pH 8.3. 
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Tris Buffered Saline (TBS) 
1X TBS contained 10 mM Tris and 150 mM NaCl  in distilled water. 
TBS with 2.5% skim milk 
1.25 g of skim milk powder was dissolved in 50 mL of TBS buffer. The solution was 
stored at 4°C. 
Tris Buffered Saline with Triton X (TBS-T) 
1X TBS contained 10 mM Tris pH 7.5 and 150 mM NaCl and 0.05% (v/v) Triton X-
100 (Sigma-Aldrich) in distilled water. 
TZM.bl Developing Solution 
4.2 μM potassium ferrocyanide (Sigma-Aldrich), 4.2 μM potassium ferricyanide 
(Sigma-Aldrich) and 420 μg/mL X-gal in PBS. Solution was prepared immediately 
before use. 
X-gal 
5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal) powder (Thermo Fisher 
Scientific, Massachusetts, USA) was dissolved in dimethylformamide (DMF) (Sigma-
Aldrich- Aldrich) to 50 mg/mL and stored in the dark at -20°C. 
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2.2. Antibodies 
The following primary antibodies in Table 2.1 were used for western blot (WB) or 
immunofluorescent staining (IF). 
 
Table 2.1: Primary antibodies used in this study 
 
 
 
 
 
 
 
 
 
 
Antibody Species Clone Supplier
Application 
and Dilution
SAMHD1
Rabbit 
polyclonal
- Sigma WB 1:1000
HIV-1 p17 Mouse IgG1 κ
MH-
SVM33C9
ATCC1 IF 1:10
HIV-1 p24 Mouse IgG1 κ 183-H12-5C NIH2 IF 1:20
β-actin Mouse IgG1 AC-15 Sigma WB 1:3000
GAPDH Mouse IgM
GAPDH-
71.1
Sigma WB 1:1000
Calreticulin
Rabbit 
Polyclonal
- NovusBio WB 1:1000
FKBP51
Rabbit 
Polyclonal
- Origene WB 1:500
1 American Type Culture Collection
2 National Institutes of Health, AIDS Reagent Program
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The following secondary antibodies in Table 2.2 were used for WB or IF. 
Table 2.2: Secondary antibodies used in this study 
 
 
2.3. Antiretrovirals 
The antiretrovirals used for this study are listed below in Table 2.3. 
Table 2.3: Antiretrovirals used in this study 
 
 
2.4. Primers 
Two types of primers were used in this study. Firstly, primers used for either 
amplification of GeneBlocks (IDT) or sequencing. Secondly, primer/probe sets used 
Antibody Species Supplier
Application and 
Dilution
Anti-mouse IgG HRP Sheep
GE 
Healthcare
WB 1:3000
Anti-rabbit IgG HRP Donkey
GE 
Healthcare
WB 1:3000
Anti-mouse AlexaFluor-555 Goat
Life 
Technologies
IF 1:200
Compound Mode of action Solvent Source
AZT 
(Zidovudine)
Nucleoside reverse transcription inhibitor Water
NIH AIDS 
Reagent 
Program 
(Cat#3485)
Efavirenz
Non-nucleoside reverse transcription 
inhibitor
DMSO
NIH AIDS 
Reagent 
Program 
(Cat#4624)
Raltegravir Integrase Inhibitor Water
NIH AIDS 
Reagent 
Program 
(Cat#11680)
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for gene expression PCR assays. The details for both types of primers are detailed 
below in Table 2.4 and Table 2.5, respectively. 
Table 2.4: Primers used in this study 
 
 
Table 2.5: Primer/probe sets used in this study 
 
 
Primer Name Sequence (5' - 3') Length (bp) TM (°C) 
1
GC (%) 2
U6 5' primer TAC GAT ACA AGG CTG TTA GAG AG 23 53.5 43
LVX 5' primer ATC CAC GCT GTT TTG ACC TC 20 51.8 50
PTAP 5' primer CCA AAT GAA AGA TTG TAC TGA GAG A 25 52.8 36
Adapter 5' primer AAA ATT GCG TGG AGC GGC ACC 21 56.3 57
Adapter 3' primer GTT GCG CTG GCA AAT GTT CAC 21 54.4 52
1 TM: melting temperature
2 GC: guanine-cytosine content
Gene 
Symbol
Assay ID RefSeq
Amplicon 
Length
Fluorophore 
ACSL3 Hs00244853_m1 NM_004457.3 100 FAM
ATP13A1 Hs00220755_m1 NM_020410.2 73 FAM
CALR Hs00189032_m1 NM_004343.3 95 FAM
CCT6 Hs00798979_s1 NM_001762.3 74 FAM
CD63 Hs01041237_g1 NM_001257400.1 84 FAM
CYP27A1 Hs01026016_m1 NM_000784.3 80 FAM
EPB41L2 Hs00154988_m1 NM_001252660.1 97 FAM
ERO1L Hs00205880_m1 NM_014584.1 63 FAM
FKBP5 Hs01561006_m1 NM_001145775.1 75 FAM
GLOD4 Hs00933148_m1 NM_016080.3 100 FAM
PARK7 Hs00994896_g1 NM_007262.4 157 FAM
SAMHD1 Hs00210019_m1 NM_015474.3 70 FAM
SH3BGRL3 Hs00606773_g1 NM_031286.3 66 FAM
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2.5. Media and Supplements 
Foetal Bovine Serum (FCS) 
Foetal Calf Serum (CSL, Australia), heat inactivated for 30 min in a 55°C water bath 
and stored at -20°C. 
Human AB serum  
Human serum (Sigma-Aldrich) was collected from human male AB plasma and 
sterile filtered. Each bottle was thawed, centrifuged at 3000 x g for 5 mins, aliquoted 
and stored at -20°C. 
Dulbecco’s phosphate-buffered saline (PBS) 
DPBS minus calcium and magnesium (Thermo Fisher) was stored at 4°C. 
Dulbecco’s Modified Eagle Medium (DMEM) 
DMEM contained high glucose, pyruvate and L-glutamine (Thermo Fisher). 
Catalogue number: 11995073 
DMEM with 10% FCS (DMEM-10) 
DMEM was supplemented with 50 mL of heat-inactivated FCS to create DMEM with 
10% v/v FCS (DMEM-10). 
L-glutamine 
L-glutamine (200 mM) (Thermo Fisher) was aliquoted and stored at -20°C. 
Roswell Park Memorial Institute 1640 Medium (RPMI) 
RPMI (Thermo Fisher) was supplemented with L-glutamine to a final concentration 
of 2 mM. 
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RPMI with 10% FCS (RPMI-10) 
RPMI was supplemented with 50 mL of heat-inactivated FCS to create RPMI with 
10% (v/v) FCS. 
RPMI with 10% human AB serum (RPMI-AB) 
RPMI was supplemented with human AB serum (Sigma-Aldrich) to create RPMI 
with 10% v/v human serum. 
RPMI with 10% FCS and 2 μg/mL of puromycin (RPMI-puro) 
RPMI with 10% (v/v) FCS was supplemented with 2 μg/mL of puromycin. 
 
2.6. Culture of Cell Lines 
Cell lines used throughout this study are outlined in Table 2.6. All cells were 
maintained at 37°C with 5% CO2 in a humidified incubator. Adherent cell lines (i.e. 
293T or TZM.bl) were passaged when a maximum 90% confluency was reached, in 
either a T75 or a T175 flask (Thermo Fisher Scientific, MA, US). For passaging, the 
media was first removed from the flask before the cells were gently washed with PBS. 
The cell monolayer was dissociated by incubating with 1X Trypsin-EDTA (Life 
technologies) at 37°C for approximately one to five mins. Following dissociation, 
approximately one tenth of the original cells were re-seeded into an identical sized 
flask using DMEM-10. 
For suspension cells (i.e. THP-1 or U937), cells were passaged when a maximum of 1 
x 106 cells/mL was reached. For passaging, the cells were removed from their culture 
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flask and reseeded in fresh RPMI-10 to a cell density of approximately 1 x 105 
cells/mL. 
For cell lines, frozen seed stocks were generated for long-term storage. To generate 
frozen seed stocks, cells were resuspended at 5 x 106 cells/mL in freezing media (90% 
FCS and 10% dimethyl sulfoxide (DMSO) (Sigma Aldrich)). For cryopreservation, 
the Cool Cell alcohol free controlled freezing rate container was used (Biocision, CA, 
US). Cells were transported to liquid nitrogen vapour phase for long-term storage. 
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2.7. Culture of Primary Cells 
2.7.1. Isolating Peripheral Blood Mononuclear Cells (PBMCs) from 
Human Whole Blood 
Whole blood (Red Blood Cross, Australia) was diluted 1:1.6 with RToC PBS, and 
transferred (40 mL/tube) into 50 mL conical centrifuge tubes (BD Falcon, USA). 
Using the underlay method, Ficoll-Paque (GE Healthcare, Sweden) (10mL/tube) was 
carefully added to the 50 mL conical tubes. 
PBMCs were separated using Ficoll gradient centrifugation at 600 x g in a swing 
bucket rotor for 23 min at RToC with slow acceleration and no brakes (Beckman 
Coulter, CA, US). The PBMCs were collected at the plasma/Ficoll interface using a 
10 mL serological pipette. PBMCs were then pooled and washed twice with RToC 
PBS with centrifugation at 400 x g for 5 min at RT. 
 
2.7.1.1. Isolation of CD14+ Monocytes from PBMCs 
PBMCs were centrifuged at 400 x g for 5 min at RT. Supernatant was discarded and 
the pellet resuspended in 10 mL of ice-cold MACS buffer and centrifuged again using 
the same conditions. The supernatant was discarded and the cells were counted to 
determine the quantity of CD14 microbeads required. For CD14 magnetic labelling 
the PBMCs were resuspended in 10 μL human CD14 microbeads per 107 cells 
(Miltenyi Biotec, Germany). Next, 20 μL of MACS buffer per 107 cells was added. 
The cells were mixed well and then left to incubate at 4°C for 30 min, with occasional 
agitation. 
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The cells were washed twice in 10 mL MACS buffer by centrifuging at 400 x g for 5 
min at RT. The quadro MACS magnetic stand was set-up and the LS column beads 
pre-wet with 1 mL ice-cold MACS buffer. The PBMCs were run through the column, 
and washed thrice with 3 mL ice-cold MACS buffer. The resulting CD14 monocytes 
were collected by pipetting 5 mL of ice-cold MACS buffer into the column and firmly 
pushing the plunger into the column, thereby flushing out the magnetically labelled 
CD14 monocytes. This step was repeated once more to ensure all the monocytes were 
collected. Monocyte purity using this procedure is greater than 97% CD14 positive 
monocytes. 
 
2.7.1.2. Isolation of CD4+ T cells from PBMCs 
CD4+ T cells were purified either directly from freshly isolated PBMC or from the 
negative fraction of CD14 sort of PBMC. If required, prior to sorting, red blood cells 
were lysed by resuspending the cell pellet in 5 mL of red blood cell lysis solution 
(Sigma-Aldrich) and incubating at RToC for 10 min, followed by centrifugation at 
400 x g for 5 min.  
Isolation was performed using a human CD4 negative isolation kit (CD4+ T cell 
isolation kit II; Miltenyi Biotech) with a few minor changes to the quantity of 
reagents added. Briefly, cells were centrifuged to a pellet at 400 x g and the medium 
was aspirated. The cell pellet was resuspended in 20 μL of FACS buffer and 5 μL of 
biotin-antibody cocktail per 107 cells. The cell suspension was incubated at 4°C for 6 
min, followed by the addition of 15 μL of MACS buffer and 10 μL of anti-biotin 
microbeads per 107 cells. The suspension was incubated at 4 °C for 15 min, followed 
by the addition of MACS buffer at 10-fold original volume and cells were washed 
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with centrifugation at 400 x g for 5 min. The labeled cells were washed once more 
before being resuspended in 500 μL of FACS buffer per 108 cells.  
The suspension was added to a LS separation column held within a quadro MACS 
separator magnet (Miltenyi Biotech), which had been pre-wet with 1 mL of ice-cold 
MACS buffer. Once the labeled cells had run through, the column was washed thrice 
with 3 mL of ice-cold MACS buffer. The eluent, containing the isolated CD4+ T cells 
was pelleted at 400 x g and resuspended in RPMI supplemented with 2% human 
serum at a final density of 5 x 106/mL. Cells were either used immediately or 
activated with a cocktail of human anti-CD2 / anti-CD3 / anti-CD28 microbead 
conjugated particles (Human T cell activation kit II; Miltenyi Biotech) as per the 
manufacturer’s instructions. Activated CD4+ T cells were used for experiments after 
48 hrs post activation. CD4 T cell purity using this procedure is greater than 95% 
CD3/CD4 positive T cells. 
 
2.7.2. Generation of Monocyte Derived Dendritic Cells (MDDCs) 
Monocyte derived dendritic cells (MDDCs) were generated from freshly purified 
CD14+ monocytes by resuspending the cells at 1 x 106/mL in RPMI-10, IL-4 (1000 
U/mL) and GM-CSF (1000 U/mL) (Bio-source, Life technologies). The seeded cells 
were incubated at 37°C, 5% (carbon dioxide) CO2 in a humidified incubator for 24 
hrs allowing for differentiation prior to use. 
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2.7.3. Generation of Monocyte Derived Macrophages (MDMs) 
Monocyte derived macrophages (MDM) were generated from freshly isolated CD14+ 
monocytes by plastic adherence in serum free media. Briefly, CD14+ monocytes were 
resuspended in serum free RPMI and seeded in plastic tissue culture treated plates. 
Cell were seeded at 6 x 105 per well for a 24 well plate, 2.3 x 105 per well for a 48 
well plate, 1 x 105 per well for a 96 well plate and 3.2 x 104 per well for a 384 well 
plate. The seeded monocytes were incubated for 1 hr at 37°C, 5% CO2 in a 
humidified incubator to allow for adherence of the monocytes to the plastic thereby 
differentiating monocytes into macrophages. Equal volume of RPMI media 
containing 20% (v/v) human serum (Sigma-Aldrich, USA) was added to each well, 
making the final concentration of human serum in the well 10% (v/v). MDMs were 
used 6-8 days post-differentiation for experiments. Every 4-5 days, half the medium 
was replaced with fresh RPMI-AB. 
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2.8. Generation of Plasmid Stocks 
Plasmids stocks used for this study are outlined in Table 2.7. 
Table 2.7: Plasmids used in this study 
 
 
2.8.1. Ligations 
In molecular cloning of original expression plasmids, DNA ligation is the last step to 
occur, where cohesive-ended DNA inserts are ligated into plasmid vectors. The 
Plasmid Name Description
Antibiotic 
Resistance
Source
pLVX-mCherry-N1
Lentiviral expression vector encoding the mCherry 
fluorescent protein
Ampicillin Clontech
pLKO.1
The plasmid contains a 1.9kb stuffer which can be 
released with AgeI and EcoRI and replaced with 
your shRNA sequence of choice
Ampicillin Addgene
psPAX2
2nd generation lentiviral packaging construct 
(contains HIV-1 Gag/Pol/Pro) 
Ampicillin
AIDS Reagent 
Program 
psPvpxD
2nd generation lentiviral packaging vector 
containing the Vpx docking site for SIVmac239 in 
the p6 region of gag between the restriction sites 
SphI-to-SbfI 
Ampicillin
Samantha McAllery 
(Section 3.2.1.)
pVpx
CMV-based vector containing codon optimized 
SIVmac239 Vpx fused to a myc-his tag
Ampicillin
Prof. Nathaniel 
Landau - NYU
VSVg (pMD2.G)  VSV-G envelope expressing plasmid Ampicillin Addgene
Cal-1
Lentiviral expression vector encoding CCR5 
shRNA, the fusion inhibitor C46 and GFP
Ampicillin Calimmune Pty Ltd
Cal-1_empty
Lentiviral control expression vector to Cal-1. Only 
encodes GFP
Ampicillin Calimmune Pty Ltd
shPromA
Lentiviral expression vector encoding shRNA 
PromA and GFP
Ampicillin Dr Kaz Suzuki
shPromA_empty
Lentiviral control expression vector to shPromA. 
Only encodes GFP
Ampicillin
Dr Chantelle 
Ahlenstiel
NL43 Δenv iGFP 
(deltaigag)
HIV-1 provirus, with two early stop codons in 
envelope. GFP is sublconed between matrix and 
capsid domains of gag and flanked by protease 
cleavage sites
Ampicillin
A/Prof Stuart 
Turville
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LigaFast Rapid DNA Ligation System (Promega, WI, USA) was used for all 
reactions. The protocol was carried out per manufacturers instructions. Briefly, a 
maximum of 200 ng of vector DNA and insert DNA, combined, was resuspended in a 
final volume of 10 μL containing 1X Rapid Ligation Buffer and 3U of T4 DNA 
Ligase. The molar ratio of vector : insert was 1 : 5. Reaction was incubated at RToC 
for 30 min before being stored at -20°C, ready for transformation. A no-ligase control 
was included for each reaction to control for re-ligation events. 
 
2.8.2. Transformation of Stbl2 competent E.coli 
Transformation of either DNA plasmids (10 ng) or ligation reactions (1 μL) (section 
2.8.1) was performed using 20 μL of MAX Efficiency Stbl2 Competent E. coli (Life 
Technologies) per condition according to the manufacturer’s instructions. 
Transformed bacteria were streaked onto LB agar plates containing antibiotic 
selection (100 μg/mL Ampicillin) and incubated overnight at 30°C in the absence of 
CO2. All incubation steps were at 30°C to limit the recombination events of plasmids 
containing retroviral sequences. 
Individual colonies were selected for screening by ‘picking’ a colony from a LB agar 
plate and incubated overnight at 30°C in polypropylene tubes containing 5 mL of LB 
medium (section 2.1) with the appropriate antibiotic selection. A master stock was 
made by freezing an aliquot of bacteria with 10% (v/v) glycerol at -80°C. The bacteria 
culture was centrifuged at 4000 x g for 10 mins to pellet the bacteria. The resulting 
pellet was lysed and the DNA extracted using a Wizard Plus SV Miniprep DNA 
Purification System (Promega) as per the manufacturer’s instructions. Isolated DNA 
was eluted into 50 μL of DNAse/RNAse free distilled water.  
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Appropriate DNA restriction digests were first performed to determine whether the 
cloning experiment was successful. The digests were run on a 1% agarose gel and 
colonies with correct band digest were sent for sequencing to confirm correct DNA 
sequence. The Australian Genome Research Facility (AGRF, Westmead, Australia) 
performed the sequencing using the Sanger sequencing method. For sequencing of 
shRNA clones, plasmids were digested with XhoI prior to sequencing. 
 
2.8.3. Purification of Plasmid DNA from Bacterial Cultures 
For the generation of large plasmid DNA stocks used for transfection experiments 
large bacteria cultures were grown and the DNA extracted using a HiSpeed Plasmid 
Maxi Kit (QIAGEN, Limburg, Netherlands). Briefly, starter cultures were made by 
scratching a frozen master glycerol stock of transformed Stbl2 bacteria to inoculate 5 
mL of LB medium with 100 μg/mL of ampicillin, and incubated overnight at 30°C 
with shaking. From this starter culture, 1 mL was added to 500 mL LB medium 
containing antibiotics and further cultured overnight at 30°C with shaking. 
Bacteria were centrifuged to a pellet at 7000 x g and DNA extracted using the 
HiSpeed Plasmid Maxi Kit according to manufacturer’s instructions with the 
following modifications. Resuspension of the bacterial pellet occurred in 10 mL of P1 
buffer for every 2 g of bacteria. Following addition of equivalent volumes of P2 and 
P3 buffers with adequate mixing, instead of filtering the mixture through the provided 
QIAfilter the bacterial suspensions were centrifuged at 2500 x g. Following 
centrifugation, the cleared lysate (supernatant) was loaded onto the HiSpeed Maxi Tip 
and the manufacturer’s protocol followed for the rest of the procedure. The isolated 
DNA was eluted in 1 mL of sterile TE buffer, aliquoted and stored at -80°C. 
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New isolation technologies led to a different maxi prep technique that was used later 
on during this thesis. DNA yield results were comparable when comparing the new 
Plasmid Plus Maxi Kit (QIAGEN) with the old Maxi prep kit. The kit was used per 
manufacturers instructions. For low copy-plasmids 200 mL of inoculated media was 
required for DNA extraction whereas for high-copy plasmids 130 mL was required. 
The resulting extracted and purified DNA was eluted with 400 μL TE for all 
plasmids.  
 
2.9. Generation of Viral Stocks 
2.9.1. Transfection of HEK-293T Cells 
The generation of viral stocks was generated through plasmid DNA transfection of 
HEK293T cells using the modified polyethylenimine (PEI) method (370). Briefly, 
stocks of PEI were made by dissolving PEI ‘Max’ (Polysciences Inc., Pennsylvania, 
USA) in DNAse/RNAse free distilled water (Life Technologies) to 10 mg/mL to 
create at 10x master stock, which was stored at -80°C until required. A 1x working 
stock (1 mg/mL) at neutral pH (pH 7.0) was made by aliquoting 1 mL of the 10x 
master stock, adding 35 µL of 1 M sodium hydroxide and making up the volume to 
10 mL with DNAse/RNAse free distilled water. Aliquots of this neutralised 1x 
working stock were stored at -80°C. The appropriate amount plasmids were diluted in 
tissue culture grade 0.9% (w/v) NaCl (Sigma-Aldrich) into a final volume of 500 μL.  
A total of 10 μg of DNA was used for each transfection, the ratios of plasmids used is 
outlined in Table 2.8. To the diluted plasmid DNA, 60 μL of PEI Max was added 
drop wise and vortexed for 10 sec. The plasmid-DNA mix was incubated at RToC for 
30 min, whereby 7 x 106 trypsinised HEK293T cells was added drop wise to the 
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mixture and incubated for 5 min at RT. This mixture was added drop wise to a 10 cm 
petri dish and the final volume was brought to 7 mL with DMEM-10. The media was 
carefully changed 18 hrs after transfection with fresh media. At 72 hrs post 
transfection the supernatant was harvested by centrifugal pre-clearing of viral 
supernatant at 3000 x g for 20 min at 4°C, aliquoted and frozen at -80°C. 
 
2.9.2. Propagation of Viral Stocks in SupT1 Cells 
Large quantities of high-titre HIV-1 BaL stocks were propagated in the SupT1-CCR5-
CL.30 cell line by Dr. Stuart Turville (371). Briefly, HEK-293T transfection was 
performed to generate HIV-1 BaL stocks pseudotyped with VSV-g using a ratio of 12 
μg provirus and 8 μg envelope. At 18 hrs post-transfection the culture medium was 
changed to DMEM-10 supplemented with 100 μg/mL of DNAse I (Roche, Basel, 
Switzerland). The cells were cultured for a further 36 hrs, and viral supernatant 
harvested and cleared of debris by centrifugation at 2000 x g for 20 min at 4°C.  
This viral supernatant was used to infect SupT1-CCR5-CL.30 cells at an approximate 
multiplicity of infection (MOI) of 0.2. The infected cell line was fed every 4 days by 
splitting the volume and cells 1 in 3 and refreshing with uninfected SupT1-CCR5- 
CL.30 cells. Propagation of the infected cell line continued until 3 L of viral 
supernatant was generated. After pre-clearing of debris, this supernatant was 
concentrated via tangential filter concentration using the Millipore Lab scale system 
(Millipore, Massachusetts, USA), using a 300 kDa cut-off Pellicon filter (Millipore) 
to a volume of 30 mL. The virus was further concentrated via ultracentrifugation over 
a 20% (v/v) sucrose cushion at 120000 x g for 90 min at 4°C. The concentrated virus 
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was resuspended in sterile PBS. Titers of this viral stock was measured at 3.02 x 108 
TCID50/mL. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 59 
Table 2.8: Transfection combinations used in this study 
 
 
Name
Proviral 
Vector and 
Quantity
Envelope 
Vector and 
Quantity
Other 
Vector and 
Quantity
Other 
Vector and 
Quantity
BaL 12ug BaL VSVg 8ug - -
VLP (-Vpx) - VSVg 2.72ug
psPvpxD 
5.44ug
Salmon sperm 
DNA 1.84ug
VLP (+Vpx) - VSVg 2.72ug
psPvpxD 
5.44ug
Vpx 1.84ug
HIV-1 GFP deltaigag 5ug VSVg 2.5ug psPAX2 2.5ug -
HIV-1 GFP (-Vpx)
deltaigag 
3.52ug
VSVg 1.76ug
psPvpxD 
3.52ug
Salmon Sperm 
DNA 1.19ug
HIV-1 GFP (+Vpx)
deltaigag 
3.52ug
VSVg 1.76ug
psPvpxD 
3.52ug
Vpx 1.19ug
promA (-Vpx) promA 4ug VSVg 2ug psPvpxD 4ug
Salmon sperm 
DNA 1.35ug
promA (+Vpx) promA 4ug VSVg 2ug psPvpxD 4ug Vpx 1.35ug
promA-empty (-Vpx)
promA empty 
4ug
VSVg 2ug psPvpxD 4ug
Salmon sperm 
DNA 1.35ug
promA-empty (+Vpx)
promA empty 
4ug
VSVg 2ug psPvpxD 4ug Vpx 1.35ug
Cal-1 (-Vpx) Cal-1 4ug VSVg 2ug psPvpxD 4ug
Salmon sperm 
DNA 1.35ug
Cal-1 (+Vpx) Cal-1 4ug VSVg 2ug psPvpxD 4ug Vpx 1.35ug
GFP control (-Vpx)
Cal GFP 
control 4ug
VSVg 2ug psPvpxD 4ug
Salmon sperm 
DNA 1.35ug
GFP control (+Vpx)
Cal GFP 
control 4ug
VSVg 2ug psPvpxD 4ug Vpx 1.35ug
pLKO shRNA VLPs shRNA 4ug VSVg 2ug psPAX2 4ug -
pLVX VLPs pLVX 4ug VSVg 2ug psPAX2 4ug -
Spln7 VLPs (-Vpx) -
psPvpxD-
Spln7 7.5ug
Salmon Sperm 
DNA 2.5ug
Spln7 VLPs (+Vpx) -
psPvpxD-
Spln7 7.5ug
Vpx 2.5ug
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2.9.3. Concentration of Viral Supernatant 
For transfections requiring further concentration the pre-cleared supernatant was 
carefully aliquoted into polyallomer tubes (Beckman Coulter) and centrifuged at 
27000 x g for 90 mins, with slow acceleration and no brake. The pelleted 
virus/pseudovirus/VLPs was gently resuspended in 100 μL of RPMI supplemented 
with 20% FCS per petri dish of transfection supernatant harvested. 
 
2.9.4. Determination of Viral TCID50 
To determine the TCID50 a titration on the indicator cell line TZM.bl was performed 
for lentiviruses containing either HIV-1 or VSVg envelopes. The indicator cell line 
TZM.bl is routinely used to titrate lentiviruses, as they have been engineered to stably 
express large amounts of CD4 and CCR5 (372). Additionally they have integrated 
copies of luciferase and β-galactosidase (β-gal) gene under the control of the HIV-1 
promoter. Thus, HIV-1 infection can be detected by using either β-gal or luciferase as 
a reporter. For our assays, we have utilised the β-gal reporter for lentivirus infection. 
TZM.bls were seeded in an opaque 96 well plate at 5 x 103/well in a total volume of 
100 μL and left to adhere overnight at 37°C, 5% CO2. Viral supernatant (11 μL) was 
added to the top row of the plate generating a 1 in 10 dilution (11 μL in 111 μL). 
After thorough mixing, 20 μL of this volume was transferred into the next row, 
creating a 1 in 6 dilution (20 μL in 120 μL). The 1 in 6 dilution series was continued 
vertically down the plate until the last row; where 20 μL was discarded. The plate was 
incubated at 37°C, 5% CO2 for 4 days. Infected cells were detected by adding the 
TZM.bl developing solution (section 2.1) to the wells and incubating for 1 hr at 37°C, 
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5% CO2. The developing solution contains X-gal, which is cleaved by β-gal 
producing a blue dye, thus staining cells blue. The wells were counted and scored by 
manual inspection using a light microscope for the presence or absence of blue 
infected cells. Each well was marked as positive or negative for infected cells and the 
Reed Muench method used to determine TCID50 (Reed and Muench, 1938).  
A titre for VLPs could not be determined using the indicator cell line TZM.bl, 
therefore a RTn assay was used to determine the amount of pg of RT was present in 
the sample (373-375). Equivalent RT amounts were used for subsequent experiments. 
 
2.10. SDS-PAGE and Western Blot 
Whole cell lysates were generated using RIPA buffer supplemented with 1X complete 
mini protease inhibitor (Roche), which was added before use. The cells were 
incubated for 30 mins at 4°C with rotation. The insoluble material was removed by 
centrifugation at 14000 x g, 4°C for 10 min. Supernatants were stored at -80°C before 
use. 
Cell lysates were separated on 4-12% Bis-Tris SDS-PAGE (Invitrogen) and 
transferred to a polyvinylidene fluoride (PVDF) membrane (Millipore, MA, USA). 
The membrane was blocked at RToC with 2.5% (w/v) skim milk in TBS for 1 hr. The 
membrane was probed with the antibodies described in Table 2.1, which also outlines 
the conditions for probing. All dilutions were made in 2.5% skim milk in TBS.  
The membrane was washed (3 times for 5 mins with TBS-T) and probed with a 
secondary antibody outlined in Table 2.2 for 2 hrs at RToC. The membrane was 
washed (3 times for 5 mins with TBS-T) and developed using Clarity HRP 
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Chemiluminescent Kit (BioRad, CA, USA). Images of the developed membranes 
were taken using the GBox Chemi XX6 (Syngene, Cambridge, UK). 
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3. Chapter Three: Feasibility of Incorporating Vpx into Lentiviral 
Gene Therapy Vectors 
 
3.1. Introduction 
Current drug therapy has greatly improved prognosis for HIV infected patients, 
reducing HIV-1 RNA in the blood to almost undetectable levels (<50 copies/ml) 
(320-322). However HIV-1 persists in cellular reservoirs of certain long-lived 
immune cells, including quiescent CD4+ T cells (qCD4+ T cells), dendritic cells and 
monocytes/macrophages (165, 170, 376, 377). Consequently, upon cessation of 
treatment, HIV-1 levels rapidly rebound (323, 324). It has been estimated that the half 
life of qCD4+ T cells is 44 months and has been projected to take up to 60 years of 
continuous drug therapy to clear HIV-1 from this one latent reservoir (165, 166, 378, 
379). Alternative approaches are needed, resulting in a HIV-1 functional cure outside 
of recurrent ART. 
Targeting the HIV-1 latent reservoir and/or protection of future HIV-1 target cells is a 
crucial step towards a HIV-1 cure. One method of achieving this is through gene 
therapy. Multiple approaches have been used to inhibit HIV-1 infection, which 
include inhibiting CCR5 expression through zinc finger nucleases, (380, 381) 
hammerhead ribozymes (382, 383) and RNA interference (345-347, 384). 
Additionally, the potential for permanently silencing the latent HIV-1 reservoir has 
been demonstrated through transcriptional gene silencing in the HIV-1 promoter 
region (358, 385, 386). Whilst there are diverse approaches in tackling the latent 
reservoir, efficient delivery with current lentiviral (LV) gene therapy vectors is 
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limited. This lack of delivery is due to inefficient RTn of genetic constructs, resulting 
in poor integration and gene expression (387). 
A cellular protein, SAMHD1, has been established as the HIV-1 restriction factor 
responsible for inefficient gene delivery in resting cells (305, 306). SAMHD1 was 
first discovered to hydrolyse the cellular dNTP pool to a point below the threshold 
required for efficient RTn (279, 286). Recently, it has also been discovered to exhibit 
RNAse activity that degrades HIV-1 RNA (288, 291, 292). Nonetheless, both of these 
effects are relevant to HIV-1 and LV gene therapy vectors, as both carry RNA genetic 
information and utilise HIV-1 reverse transcriptase before genetic integration within 
the host genome. 
For successful gene delivery into the latent HIV-1 reservoir, efficient RTn needs to 
occur for integration and subsequent gene expression. A viral protein called Vpx, 
encoded by the Sooty Mangabey SIV (SIVSM) and HIV-2 lineages has been shown to 
alleviate SAMHD1 mediated HIV-1 restriction (305, 306). Experiments have revealed 
that Vpx degrades SAMHD1 through the proteasomal dependent degradation pathway 
(298, 300, 388). In the absence of SAMHD1, the cellular dNTP levels can increase 
above the threshold needed for efficient LV RTn (389). This phenotype supports the 
future use of Vpx in the context of LV gene therapy vectors and DC-based vaccines 
(306, 366-369).  
Whilst this has immense potential in gene therapy strategies for an HIV-1 cure, the 
effects of introducing Vpx into an HIV-1 positive individual in vivo/ex vivo are not 
known. This needs to be carefully considered since the positive effect Vpx has on 
RTn for LV gene therapy vectors would also affect existing HIV-1 infected cells. To 
determine the feasibility of Vpx being incorporated into LV gene therapy vectors, this 
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study sought to characterise three unknowns in utilising Vpx. Firstly, if cells were 
exposed to Vpx ex vivo, do the effects of Vpx rapidly decay? Secondly, does Vpx 
affect the efficacy of antiretroviral therapy, and if so, how long post-Vpx exposure 
does this persist? Finally, since Vpx increases viral RTn would there be differences in 
HIV-1 protection if Vpx was incorporated with anti-HIV-1 genes that inhibited HIV-1 
infection pre- or post-RTn? To investigate these key questions an important resting 
cell type model of monocyte derived macrophages (MDMs) generated from primary 
cells was used.  
 
3.2. Methodology 
3.2.1. Cloning of psPvpxD 
A second generation LV vector capable of packaging Vpx was generated by 
subcloning the SphI-to-SbfI region containing the Vpx packaging motif from pNL4.3-
luc3-E-R- SIV p6 17-26 (kind gift from N. Landau) into psPAX2 (Obtained from 
Didier Trono through NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: 
psPAX2 (Catalogue # 11348)) (see Figure 3.1). The modified plasmid was termed 
psPvpxD. 
 
 
 
Figure 3.1: Schematic of cloning strategy to clone Vpx docking site into the 2nd 
generation lentiviral packaging vector psPAX2 
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3.2.2. Time of Addition Assay (ToA) 
Macrophages seeded at 1 x 105/well in a 96-well plate were spinoculated with either 
HIV-GFP -/+ Vpx (MOI 0.1) or -/+Vpx VLPs (670 pg RT) at 1200 x g for 30 mins at 
4°C. At the indicated time-point post infection (hpi) either 10 μM of azidothymidine 
(AZT) (Obtained from the NIH AIDS Reagent Program, Division of AIDS, NIAID, 
NIH (Cat# 3485)), or 1 μM of raltegravir (RAL) (Obtained through the NIH AIDS 
Reagent Program, Division of AIDS, NIAID, NIH: Raltegravir (Cat # 11680) from 
Merck & Company, Inc) or -/+ Vpx VLPs (670 pg RT) were added to macrophage 
cultures. At five days post infection (dpi) the plate was fixed with 4% PFA and GFP 
positive cells were counted on a fluorescent Elispot plate reader (AID Diagnostika, 
Strasburg, Germany). Results were either presented as total GFP positive cells or as a 
percentage of HIV-1 infection using the infected no drug control as the denominator. 
 
3.2.3. IC50 of AZT, RAL and EFV 
Macrophages seeded at 3.2 x 104/well in a 384 well plate were stimulated with  -
/+Vpx VLPs (670 pg RT) for 1 or 7 days. At the stated time points, macrophages 
were treated with a 4-fold dilution series of either AZT (starting concentration 10 
μM), EFV (starting concentration 1 μM) or RAL (starting concentration 1 μM) for 30 
mins before being spinoculated with HIV-1 GFP –Vpx (MOI 0.1) at 1200 x g for 30 
mins at 4°C. At five dpi GFP positive cells were enumerated on the Deltavision 
(Applied Precision). The results were represented as percent suppression compared to 
the no drug control. 
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3.2.4. High Throughput Microscopy 
Macrophages were seeded at 3.2 x 104/well in a 384 well plate and transduced at MOI 
0.2 with anti-HIV-1 gene therapy vectors packaged with or without Vpx through 
spinoculation at 1200 x g for 30 mins at 4°C. At 7 or 14 days post transduction the 
macrophages were infected with R5 BaL virus at three MOIs; 0.02, 0.1 and 0.2. At 7 
dpi macrophages were fixed with 4% paraformaldehyde for 20 mins at RToC and 
then neutralized with 50 mM NH4Cl (Sigma-Aldrich) for 3 mins. Cells were 
permeabilised with 0.05% Triton-X for 1 minute at RToC and blocked for 20 mins in 
10% goat serum. Macrophages were stained with the monoclonal antibodies p17 
(ATCC; clone MH-SVM33C9) and p24 (Obtained from Dr. Bryan R. Cullen through 
NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: pWT/BaL (Catalogue 
# 11414) (390)). The secondary antibody used was goat anti-mouse Alexa Fluor 647 
(IgG H + L; Highly cross-absorbed; (Invitrogen)) All washes were performed in 1X 
PSG (section 2.1). The macrophages were counterstained with DAPI (ThermoFisher, 
MA, USA) before being visualized on the Cytell Cell Imaging System (GE 
Healthcare, Little Chalfont, UK). The resulting images were transformed into an 
XDCE file before being analysed by IN Cell Investigator software (GE Healthcare). 
The total number of cells, transduced cells and infected cells were enumerated. A 
linkage protocol was used to determine the number of transduced cells that were also 
infected. The non-parametric ANOVA (Friedman test) was performed for all data sets 
along with a Dunn’s multiple comparisons test. 
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3.3. Results 
3.3.1. Generating a Vpx Delivery System 
The accessory protein Vpx is packaged into virions through a specific interaction with 
the amino-terminus of the Gag-derived protein, p6. A dileucine motif D-X-A-X-X-L-
L was discovered by Accola and colleagues to be required for the incorporation of 
SIVmac Vpx (391). As such, current HIV-1 based lentiviral packaging vectors such 
as the second-generation vector psPAX2, are incapable of packaging Vpx into 
assembling virions.  
HIV-1 can be modified to package Vpx by inserting the binding motif into the p6 
domain of Gag. Sunseri and colleagues successfully demonstrated this by identifying 
the minimal Vpx packaging motif of SIVmac239,17DPAVDLLKNY26, and subcloned 
this into HIV-1. The chimeric virus was able to package Vpx and substantially 
increase HIV-1 infection in monocyte derived dendritic cells (MDDCs) and monocyte 
derived macrophages (MDMs) compared to wild-type virus. (392). We hypothesised 
the same minimal packaging motif could be subcloned into the psPAX2 to enable the 
vector to successfully package Vpx. The subcloning strategy is outlined in section 
3.2.1 and the vector generated was termed psPvpxD. To verify whether psPvpxD was 
able to package Vpx, a proof of principle experiment was performed. Briefly, virus 
like particles (VLPs) were generated using either the parent plasmid psPAX2 or 
psPvpxD. Each transfection condition contained equimolar amounts of packaging 
vector, VSVg plasmid and SIVmac239 Vpx plasmid. The resulting VLPs were added 
to MDDCs and then infected with HIV-1 GFP. After 5 dpi, the cells were fixed and 
analysed using flow cytometry and the percentage of infected cells was quantified on 
the live cell population. The VLPs generated with psPvpxD showed 15% infection 
compared to 0.54% infection from VLPs generated with psPAX2, representing a 27.8 
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fold increase compared to the parent plasmid (Figure 3.2). This substantial increase 
demonstrated the Vpx minimal binding motif reported by Sunseri and colleagues can 
be used effectively to generate a lentiviral Vpx delivery system. 
 
 
 
Figure 3.2: psPvpxD can effectively package Vpx into virions 
Virus like particles (VLPs) were generated using either psPAX2 or psPvpxD, and 
equimolar amounts of VSVg and SIVmac239 Vpx plasmids. VLPs were added to 
MDDCs and infected HIV-1 GFP. At 5 dpi cells were fixed and analysed using flow 
cytometry. Gated on the live cell population, the percentage of infected cells were 
quantified and shown in the lower right quadrant. 
 
3.3.2. Characterisation of Vpx Short Term Effects 
To address whether Vpx would make a suitable candidate to incorporate into gene 
therapy vectors, we first performed a time of addition (ToA) assay. The kinetics of 
short-term Vpx exposure can be mapped by assessing the effect Vpx has on RTn and 
integration. We used macrophages as the resting cell model in the following 
experiments. Macrophages express high levels of SAMHD1 and contain a depleted 
cellular dNTP pool, common among all cells of the latent HIV-1 reservoir (306). 
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3.3.2.1. Vpx Effects Lentiviral Reverse Transcription and 
Integration Kinetics 
Macrophages were infected by spinoculating HIV-1 GFP packaged with or without 
Vpx (HIV-1 GFP ±Vpx). At different time points spanning 0-72 hpi the antiretrovirals 
AZT or RAL were added. The length of time taken for the antiretrovirals to lose their 
antiviral activity was interpreted as the completion of the part in the HIV replication 
cycle that the drug inhibits. Therefore, AZT and RAL were used to determine the RTn 
and integration kinetics, respectively. A schematic of the above method is shown in 
(Figure 3.3A)  
Analysis of the AZT/RAL ToA in Figure 3.3B demonstrated that the control virus 
(HIV-1 GFP -Vpx) had comparable kinetics for both RTn and integration with their 
50% completion of HIV infection occurring within 1 h from each other (AZT –Vpx = 
26.78 hpi and RAL –Vpx = 25.74 hpi). Whereas, upon Vpx stimulation the RTn and 
integration kinetics increased and separated with the 50% completion of HIV 
infection from AZT and RAL treated cells occurring 17.63 hrs and 9.47 hrs earlier, 
respectively (AZT +Vpx = 9.15 hpi and RAL –Vpx = 16.37 hpi). Interestingly, the 
separation of RTn and integration kinetics observed upon Vpx stimulation is also 
observed in other cell types with abundant cellular dNTP pools (393), such as the 
HeLa cell line TZMbl (Figure 3.4) 
 
3.3.2.2. Vpx Effects Overall Gene Delivery 
The increase in kinetics does not take into account the magnitude of completed RTn 
and integration events. Since GFP expression is indicative of successful integration 
and gene expression we compared the total number of GFP positive cells between 
 72 
HIV-1 GFP packaged with and without Vpx to evaluate the effect on successful gene 
delivery. In the presence of Vpx a significantly higher number of GFP expressing 
macrophages were observed from 6 hpi and 18 hpi in the AZT and RAL treated cells, 
respectively (p>0.0001) (Figure 3.3C). Therefore, Vpx not only increases RTn and 
integration kinetics, but also increased the overall magnitude of HIV-1 infection. 
 
3.3.2.3. Vpx can ‘Rescue’ HIV-1 Infection up to 48 hpi 
To assess the action kinetics of Vpx, a further ToA assay involving the addition of 
VLPs packaged with Vpx (Vpx VLPs) at multiple time points post HIV-1 infection 
was performed. This was important for two reasons, firstly, it would determine the 
optimal time to add Vpx in the context of gene therapy strategies. Secondly, the half-
life of RT can be indirectly measured by determining how long post HIV-1 infection 
the addition of Vpx can enhance infection. The Vpx ToA revealed RTn was ‘rescued’ 
up to 48 hpi, where 1.68 fold more RTn complexes proceeded to integration 
compared to the control (Figure 3.3D)  
Vpx induced enhancement was the greatest at 0 hpi, indicating Vpx addition for gene 
therapy strategies would be most advantageous occurring simultaneously with gene 
delivery. It was also demonstrated that the effect of Vpx addition was largely 
refractory after 72 hr. Interestingly, a trend towards biphasic decay was observed in 
the ability of Vpx to ‘rescue’ RTn. While a proportion of HIV-1 reverse transcription 
complexes (RTC) decay early, within 24 hr, components of this can persist for greater 
than 48 hr.  
The increase observed in RTn and integration kinetics after Vpx exposure and the 
increase in total magnitude of transduction could potentially facilitate gene therapy 
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transduction ex vivo, supporting the cause of incorporating Vpx into gene therapy 
vectors. However, if clinical protocols were designed to isolate, transduce cells with 
Vpx packaged vectors and re-introduce in vivo within 48 hr, this could provide 
several complications in the context of HIV-1 replication. Firstly, a large pool of cells 
could be primed for HIV-1 infection. Secondly, any otherwise abortive infections 
could be saved and proceed to either full productive infection and/or latency. We 
therefore focused on longer term ex vivo protocols, as significant culturing of 
transduced cells may allow SAMHD1 to return to protective levels against HIV-1 
infection. 
 
3.3.3. Characterisation of Vpx Long Term Effects 
To further evaluate the possibility of incorporating Vpx into gene therapy vectors we 
investigated how long cells retained enhancement to HIV-1 infection after Vpx 
stimulation. The experimental design was modeled to a typical ex vivo gene therapy 
protocol (394). 
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Figure 3.3: The short term effect Vpx has on HIV infected macrophages in the 
context of reverse transcription and integration.  
 
 
(A) Protocol outline of AZT/RAL Time-of-addition (ToA) assay. (B) Reverse 
transcription (RT) and integration kinetics of HIV-1 GFP packaged with or without 
Vpx, protocol outlined in (A). Macrophages were spinoculated with HIV-1 GFP 
packaged with or without Vpx. At indicated time points, spanning from 0-72 hours 
post infection (hpi), antiretrovirals were added. AZT (10 μM) was used as a 
surrogate for RTn and RAL (1 μM) was for use for integration. Virus infected cells 
were enumerated by GFP fluorescence at 120 hpi. Relative infection (%) compared 
to the non-inhibited replication control is plotted. Each data set was fitted with a 
sigmoidal curve. (C) Total number of GFP positive cells for each data point in (B). 
(D) The extent of Vpx rescue post-HIV-1 infection. Primary macrophages were 
spinoculated with HIV-1 GFP, Vpx VLPs were added at the indicated time points, 
spanning from 0-72 hpi. Virus infected cells were enumerated by GFP fluorescence 
at 120 hpi. Fold change enhancement was determined by comparing Vpx stimulated 
cells with the negative control. 
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Figure 3.4: Reverse transcription and integration kinetics of the TZMbl cell line 
 
3.3.3.1. Vpx Long Term Effects in Macrophages 
Briefly, macrophages were spinoculated with VLPs packaged with or without Vpx 
(VLPs ±Vpx). At multiple time points post-stimulation, the cells were challenged 
with a replication incompetent HIV-1 GFP. The infection time points represented the 
time at which the ex vivo transduced cells were transferred back into an HIV-1 
positive patient (See Figure 3.5A for schematic). The level of enhanced H-1IV 
infection and SAMHD1 protein levels were determined for each time point.  
When macrophages were stimulated with Vpx containing VLPs, enhancement of 
HIV-1 infection was observed across all donors to at least 14 days post stimulation 
(dps)  (Figure 3.5B and C). The protein level of SAMHD1 in macrophages remained 
low during the time course, with levels only starting to increase at 14 dps (Figure 
3.5D). The observed long-term enhancement of HIV-1 infection upon Vpx 
stimulation raises questions of the suitability of Vpx to be incorporated into gene 
therapy vectors. However, this data is only from one resting cell type. We sought to 
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gather more evidence using other cell types to determine whether this was just a 
macrophage specific effect. 
 
3.3.3.2. Vpx Long Term Effects in Dendritic Cells 
We turned our attention to another cell type, monocyte derived dendritic cells 
(MDDCs). These cells are also sensitive to Vpx, making them suitable to further 
investigate our above observations. The same experimental protocol outlined for 
macrophages was also used for MDDCs. A comparable trend was observed from 1 
dps onwards (Figure 3.5E and F), and across all donors enhancement of HIV-1 
infection to at least 14 dps was shown. The SAMHD1 protein expression pattern for 
MDDCs showed complete degradation by 5 dps. This level remained stable for the 
length of the experimental time course, which was contrast to macrophages, which 
had partially depleted levels of SAMHD1 (Figure 3.5G) 
Our collective observations reveal that while Vpx can significantly enhance gene 
delivery, it also ‘primes’ cells long term to be more permissive to HIV-1 infection. In 
addition to its potential to expand the HIV-1 reservoir in an individual, the increased 
levels of RTn may influence HIV-1 drug therapy. Indeed, a recent study demonstrated 
Vpx stimulation of macrophages caused a significant decrease in HIV-1 sensitivity to 
various NRTI’s (395, 396). To further these recent observations we examined the 
short, and more importantly, long term effects of Vpx exposure on the efficacy of 
both RTn and IN drugs.  
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Figure 3.5: The long term effect Vpx has on HIV-1 infection.  
(A) Protocol outline to determine the long term Vpx effect on HIV-1 infection. (B, C 
and D) Fold change enhancement of HIV-1 infection and SAMHD1 protein 
expression of Vpx stimulated macrophages up to 14 dps. Macrophages were 
spinoculated with Vpx VLPs and challenged with HIV-1 at the indicated time points. 
Fold change enhancement was determined by enumerating GFP positive cells and 
normalizing the numbers to unstimulated cells. Two representative donors are shown. 
Protein expression of SAMHD1 was determined by western blot. Data was 
normalised to actin and represented as portion of the negative control. One 
representative MDM donor of three is displayed. (E, F and G) Fold change 
enhancement of HIV-1 and SAMHD1 protein expression of Vpx stimulated MDDCs 
up to 14 dps. Two representative donors are shown. The fold change enhancement 
and protein expression of SAMHD1 was analysed as previously described. 
 
3.3.4. Vpx Effects the Efficiency of AZT, EFV and RAL both Short and 
Long Term 
Previous studies have shown Vpx stimulation causes a significant decrease in HIV-1 
sensitivity to various NRTI’s (395, 396). We examined whether Vpx could alter the 
efficiency of AZT, EFV and RAL, for both short and long-term post Vpx exposure. 
Briefly, macrophages were stimulated with VLPs ±Vpx, at 1 and 7 dps, the 
macrophages were treated for 30 min with a varying doses of AZT, EFV and RAL 
before being infected with HIV-1 GFP. The amount of HIV-1 infection was 
determined for each AZT and RAL concentration by enumerating the GFP positive 
cells via high throughput microscopy at 5 dpi. 
Log dose-response curves were generated to compare relative drug efficiencies at 1 
and 7 dps. Upon Vpx stimulation macrophages showed a considerable reduction in 
sensitivity to AZT at both 1 and 7 dps (Figure 3.6A). Sensitivity to EFV and RAL 
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was also reduced, but to a lesser extent (Figure 3.6B and C). From the log dose-
response curves the IC50 were calculated. The AZT IC50 values from both time 
points were significantly different between -Vpx and +Vpx stimulated samples 
(p<0.05; n=4) (Figure 3.6D), with the difference median values of 1 dps and 7 dps 
being -3.11 μM and -0.36 μM, respectively. The EFV IC50 values were not 
significantly different between -Vpx and +Vpx stimulated samples (Figure 3.6E). The 
RAL IC50 values for 1 dps was significantly different between -Vpx and +Vpx 
stimulated samples (p<0.05; n=4) (Figure 3.6F), with the difference median values of 
1 dps being -0.02 μM. The results clearly demonstrate that the decreased efficacy of 
the nucleoside reverse transcription inhibitor (NRTI), AZT and integrase inhibitor, 
RAL persists long-term. 
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Figure 3.6: The long term effect Vpx has on the efficiency of AZT, EFV and 
RAL.  
Macrophages were stimulated with VLP packaged with or without Vpx for either 1 or 
7 days before being treated with decreasing concentrations of AZT (A), EFV (B) or 
RAL (C) and infected with HIV-1 GFP. To determine the % of suppression, GFP 
positive cells were counted 5 days post infection and normalized to non-treated cells 
stimulated with VLP ± Vpx. The IC50 values of AZT (D) were calculated using (A), 
a non-parametric Kruskal-Wallis was used to determine the significance. The IC50 
values of EFV (E) and RAL (F) were calculated using (B) and (C), respectively.  The 
same statistical test was used as in (D). Mean + SD were plotted; n=3. One 
representative donor of three is displayed. 
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3.3.5. Anti-HIV-1 Genes Packaged with Vpx Show a Greater Anti-Viral 
when Targeting pre-RT, but not post-RT 
To evaluate the therapeutic potential of incorporating Vpx with anti-HIV genes we 
used two gene therapy strategies that inhibit HIV-1 replication at stages pre and post-
RT. This was primarily motivated by the influence Vpx has on RTn in the short and 
long-term. The pre-RT approach inhibits viral entry, while the post-RTn approach 
prevents post-transcriptional activity after viral integration occurs. The first approach 
utilises a vector called Cal-1, which encodes a short hairpin RNA (shRNA) for the 
down-regulation of CCR5 in combination with the HIV-1 fusion inhibitor, C46 (348). 
This construct has been used in non-human primates, a humanised mouse model and 
is currently undergoing Phase I/II trials in Australia and the United States of America 
(397, 398). The second approach uses a vector encoding an shRNA called shPromA, 
which targets the HIV-1 5’LTR promoter and induces profound silencing of 
integrated HIV-1. Studies have shown that shPromA suppresses viral replication long-
term by epigenetic modifications through an RNAi pathway called transcriptional 
gene silencing (TGS) (356-358). 
Despite dendritic cells showing a greater effect with Vpx, macrophages were selected 
to determine the effectiveness of these strategies in the presence of Vpx. The focus of 
our study was targeting the HIV-1 latent reservoir and macrophages have a more 
accepted role in contributing to the viral reservoir than dendritic cells (197, 399-402). 
The anti-HIV genes therapy vectors were generated and packaged in trans with or 
without Vpx. Appropriate controls encoding GFP were also generated for both gene 
therapy approaches. All expression constructs encoded GFP, which acted as a reporter 
for successful transduction. A high content microscopy approach was used for the 
HIV-1 challenge experiments enabling individual cell analysis. Briefly, macrophages 
 82 
were transduced and at time points 7 and 14 days post-transduction (dpt) and were 
challenged with infectious R5 BaL virus at increasing MOI’s. High throughput image 
acquisition was performed using the Cytell Cell Imaging System. Using Cell 
Investigator the total number of cells, transduced cells and infected cells were 
enumerated. A linkage protocol was used to determine the number of transduced cells 
that were also infected. Distinguishing between transduced/uninfected cells and 
transduced/infected cells allowed us to determine the effectiveness of incorporating 
Vpx into gene therapy vectors. 
At 14 dpt the transduction efficiencies for both Cal-1 and shPromA gene therapy 
approaches were significantly increased in the presence of Vpx, with fold changes of 
85.4 (p≤ 0.001, n=3) and 10.7 (p≤ 0.01, n=3) observed for Cal-1 and Cal-1-eGFP and 
9.0 (p≤ 0.05, n=3) and 9.7 (p≤ 0.05, n=3) for shPromA and shPromA-eGFP, 
respectively (Figure 3.7A, B). The gene transduction efficiencies observed at 7 dpt 
were also comparable (Supplementary Figure 3.1). 
HIV-1 infection was analysed in two measures, firstly, overall HIV-1 infection, which 
was independent of eGFP transduction. Secondly, HIV-1 infection was specifically 
investigated in eGFP transduced cells. At the highest MOI of 0.2, Cal-1 transduced 
cells showed the greatest inhibition in the presence of Vpx, with over a log reduction 
in HIV-1 infection compared to the –Vpx control (Figure 3.7C; Cal-1 (-Vpx) 2.64%, 
Cal-1 (+Vpx) 0.24%, n=3). Only a small percentage of transduced cells were also 
infected, with 0.03% and 0.07% (Figure 3.7D n=3) observed for Cal-1 (-Vpx) and 
Cal-1 (+Vpx) conditions, respectively. Indicating, in either the presence or absence of 
Vpx, Cal-1 transduced macrophages were protected against HIV-1 infection. No 
inhibition of HIV-1 infection was observed in the eGFP transduced cells, in the 
presence of Vpx, a 3.5 fold-increase in HIV-1 infection was observed (Figure 3.7C; 
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eGFP (-Vpx) 1.19%, eGFP (+Vpx) 4.15%; n=3). Furthermore, HIV-1 infection of 
eGFP transduced cells increased by 40.3 fold in the presence of Vpx (Figure 3.7D; 
eGFP (-Vpx) 0.09%, eGFP (+Vpx) 3.63% n=3). The above observations for eGFP-
transduced cells were expected for two reasons; firstly, no anti-HIV gene was 
encoded in the control plasmid. Secondly, in the presence of Vpx, successfully 
transduced cells would be primed for HIV-1 infection, therefore having a greater 
capacity for RTn completion post-Vpx exposure. This was observed in both 7 and 14 
dpt and across all MOI’s 0.02, 0.1 and 0.2 Supplementary Figure 3.2A-E). 
Additionally, there is no evidence of bystander cells demonstrating enhanced HIV-1 
infection. 
In the shPromA post-RTn gene therapy condition, at the highest MOI of 0.2, we 
observed no inhibition of HIV-1 infection in the absence or presence of Vpx (Figure 
3.7E; PromA (-Vpx) 1.14%, PromA (+Vpx) 2.72%, vs untransduced 0.61%; n=3). In 
contrast, in the absence of Vpx at lower MOI’s, protection against HIV-1 infection 
was observed (Supplementary Figure 3.3A-E). However, in the presence of Vpx, we 
also observed a 2.4 and 5.6 fold-increase in HIV-1 infection for PromA and eGFP 
conditions, respectively (Figure 3.7E; n=3). This trend was observed across all MOI’s 
(Supplementary Figure 3.3A-E). HIV-1 infection in transduced cells also increased in 
the presence of Vpx by 20.1 and 36.2 fold for PromA and eGFP transduced 
conditions, respectively (Figure 3.7F). These observations were also present in time 
points 7 and 14 dpt and across HIV-1 challenges at increasing MOIs (Supplementary 
Figure 3.3A-E) 
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Figure 3.7: The effectiveness of Vpx incorporation into anti-HIV gene therapy 
vectors is case dependent.  
Macrophages were transduced with either Cal-1, PromA or their respective controls 
packaged with or without Vpx. At 14dpt, the macrophages were infected with R5 BaL 
at MOI 0.2. After 7 days of infection, the cells were fixed and stained for p17/p24 and 
counterstained with DAPI. The cells were imaged on the Cytell and analysed using IN 
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Cell Investigator software. Using DAPI as the denominator the percentage of 
transduced cells was calculated for Cal-1 (A) and PromA (D), the percentage of 
infected cells for Cal-1 (B) and PromA (E), and the percentage of transduced and 
infected cells for Cal-1 (C) and PromA (F). The non-parametric Friedman test was 
used for statistical analyses.  p ≤ 0.05 (*), p ≤ 0.01 (**) and p ≤ 0.001 (***) 
 
3.4. Discussion 
In this study we have demonstrated that Vpx increases lentiviral RTn and integration 
kinetics, which in turns increases levels of LV gene delivery and transduction. The 
increased permissiveness persisted over a period of at least two weeks and 
consequently showed lowered potency to HIV-1 antiretrovirals that target HIV-1 RTn 
or integration. Furthermore, Vpx has the ability to ‘rescue’ HIV-1 infection 48 hrs 
after infection. This poses the possibility of detrimental complications if incorporating 
Vpx into LV gene therapy vectors for in vivo/ex vivo treatment of HIV-1 infected 
individuals. Re-introducing transduced cells into the patient, which are more 
permissive to HIV-1 infection, could increase the HIV-1 reservoir. The observed 
increase in IC50 values associated with Vpx treatment was of similar magnitude to 
prototypical resistant HIV-1 reverse transcriptase clones, such as HIV-1 4755-5 and 
6463-13.(403) The decrease in AZT efficacy short term post Vpx exposure is 
consistent with a previous study conducted by Amie and colleagues.(395, 396) The 
increased IC50 observed post-Vpx treatment both short- and long-term in RAL 
treated cells was not equivalent to any prototypical resistant mutant strains.(404) 
Nonetheless, the decrease of AZT and RAL efficacy implies antiretroviral therapy 
may be influenced by Vpx exposure and thus either lead to reduced protection by 
therapy and/or promote subsequent viral replication and antiviral resistance. 
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Whilst some of the previous observations are suggestive of the negative potential Vpx 
could have on the HIV-1 reservoir, the crucial test was investigating the effectiveness 
of anti-HIV genes delivered with or without Vpx. To address this, two gene therapy 
approaches were used that inhibited HIV-1 infection either pre-RTn (Cal-1) or post-
RTn (shPromA). Vpx enhances the RTn step of HIV-1 replication. Utilising pre- or 
post-RTn approaches addressed whether Vpx requires complementation with a 
specific category of anti-HIV genes to effectively restrict HIV-1 infection. When Vpx 
was incorporated with the anti-HIV genes, transduction efficiencies were significantly 
increased in both pre- and post-RTn approaches. In the absence of Vpx, both of the 
anti-HIV gene approaches restricted HIV-1 infection. Furthermore, when examining 
on a single cell level, all transduced macrophages were protected against HIV-1 
infection. However, in the presence of Vpx, the step at which the anti-HIV gene 
restricted replication was critical in determining whether inhibition of HIV-1 
replication occurred. Macrophages transduced with Cal-1, which restricts HIV-1 
replication before RTn at the step of entry/fusion, showed complete protection against 
HIV-1 infection in the presence of Vpx. However, macrophages transduced with 
shPromA, which restricts HIV-1 replication after RT, post-integration, failed to 
protect all of the macrophages with the majority of transduced cells also being 
infected with HIV-1. This effect observed for the post-RTn approach was amplified 
when the MOI for HIV-1 infection increased. The lowered protective capacity could 
be due to an increase in viral RTn-activity as a result of pre-Vpx exposure.  An 
increase in viral RTn and subsequent integration, could render shPromA unable to 
target all the HIV-1 genomes beyond a certain threshold level. Hence, an increase in 
HIV-1 infection is observed when the MOI is increased. These results clearly 
demonstrate incorporating the Vpx protein with a pre-RTn gene therapy approach 
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significantly increases the number of successfully transduced resting cells, which in 
turn enhances HIV-1 protection levels. Furthermore, the use of Vpx does not have any 
deleterious bystander target effects as there is no evidence of non-transduced cells 
with an HIV-1 enhanced Vpx phenotype. Ex vivo gene delivery protocols need to wait 
till the protective anti-HIV construct is active for re-infusion, as immediate 
transduction and then re-infusion into patients would render them highly permissive 
to HIV-1 infection.  
The incorporation of Vpx protein into gene therapy vectors could also be beneficial in 
facilitating gene therapy protocols targeting resting cells. An increase in both RTn and 
integration kinetics upon Vpx stimulation alongside a significant increase in overall 
gene delivery, could help in two key ways. Firstly, scaling up to generate Good 
Manufacturing Practice (GMP)-compliant lentivirus batches for clinical trials would 
be economically more feasible. Since substantially less lentivirus would be required 
to achieve equivalent transduction rates a reduced number of batches for high-titer 
vector preparations would be needed. Typically, an MOI of at least 1 is used in 
clinical protocols, which is at least 5 times more than used in our protocols (348, 398, 
405). Therefore the number of time consuming and rigorous tests required for each 
batch can be reduced.  Additionally, using less lentivirus to achieve equivalent 
transduction rates would decrease the likelihood of toxicity, inflammation or immune 
responses observed in vivo (406, 407). Secondly, the time required to generate 
transduced cells for re-infusion could be decreased, since it takes significantly less 
amount of time to achieve successful gene expression due to the increase in RTn and 
integration kinetics.  
The long-term enhancement after Vpx stimulation observed in resting cells effectively 
restricts the use of this accessory protein to only pre-RTn gene therapy approaches. 
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To expand the use of Vpx, decreasing the window of opportunity to enhance lentiviral 
reverse transcription and integration kinetics needs to occur. One study has observed 
that Vpx is rapidly degraded in the cell through the proteasomal pathway (392). 
Therefore, it could be hypothesised that the long-term phenotype is due to an 
interaction with a host protein. Indeed, our MDDC long term data showed the greatest 
enhancement of HIV-1 infection when SAMHD1 levels were at their highest. This 
interaction may not necessarily be SAMHD1, as a study by Hollenbaugh and 
colleagues has shown that post-Vpx treatment the rate of SAMHD1 recovery and 
dNTP depletion does not correlate (408). Mutagenesis studies could reveal a novel 
mutant, which is unable to interact with the host protein responsible for the long-term 
phenotype, but retain the RTn enhancing capacity of a short term phenotype.  
This study demonstrates a way to overcome the major delivery obstacle presented 
when delivering anti-HIV genes into cells of the HIV-1 latent reservoir. Vpx 
significantly increased delivery with all gene therapy conditions. However, it was 
case-dependent whether the increase in gene delivery also translated into an enhanced 
antiviral effect, with pre-RTn inhibition of HIV-1 replication with Cal-1 showing the 
greatest effect. This result is of great importance, as Cal-1 is currently undergoing 
Phase I/II trials in the United States of America. Additionally, oncology studies have 
started to incorporate Vpx in their gene therapy protocols (409, 410). For Vpx 
containing LV vectors, the dual utilisation of Cal-1 (pre-RT), to protect against HIV-1 
infection, and shPromA (post-RT), to stabilize the latent reservoir, would have the 
greatest effect on HIV-1 infected patients. For uninfected cells, the dual approach 
would prevent HIV-1 entry. For infected cells, the shPromA would restrict HIV-1 
reactivation and Cal-1 would prevent any potential superinfection and enhancement 
of HIV-1 replication because of the presence of Vpx. The potential inclusion of Vpx 
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in the future LV preparations may help further expand the delivery of this construct to 
unstimulated cells in clinical protocols, such as the resting CD4+ T cell population, as 
cells would not need to be stimulated/activated. 
 
3.5. Supplementary Figures 
 
 
 
 
 
 
 
Supplementary Figure 3.1: Transduction efficiencies of transduced 
macrophages infected at 7dpt.  
Macrophages were transduced with either Cal-1, shPromA or their respective controls 
packaged with or without Vpx. At 7dpt, the macrophages were infected with R5 BaL 
at MOI 0.2. After 7 days of infection, the cells were fixed and stained for p17/p24 and 
counterstained with DAPI. The cells were imaged on the Cytell and analysed using IN 
Cell Investigator software. Using the DAPI as a denominator the percentage of 
transduced cells was calculated for Cal-1 (a) and shPromA (b). All statistical analysis 
used the non-parametric Friedman test.  p ≤ 0.05 (*), p ≤ 0.01 (**) and p ≤ 0.001 
(***). Mean + SD were plotted; n=4 
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CHAPTER FOUR: A PROTEOMIC STUDY 
OF MDM AND MDDCs, POST VPX 
EXPOSURE 
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4. Chapter 4: A Proteomic study of MDMs and MDDCs, Post Vpx 
Exposure 
 
4.1. Introduction 
Drugs and biotherapeutics can have hidden phenotypes caused by unexpected 
modulation of proteins (411). Two consequences could arise from unexpected 
interactions. Firstly, the effect could be detrimental, leading to cell toxicity, or 
secondly the effect could be beneficial, leading to new therapies. Hidden phenotypes 
are usually discovered by coincidence, but identification can be accelerated by the use 
of gene microarrays, proteomics or high-content protein-fragment complementation 
assays (PCAs) (411).  
The potential use of Vpx in clinical protocols, requires further investigation into how 
Vpx modulates a cell for gene delivery enhancement. The protein Vpx has many 
binding partners (412), which could affect various cellular pathways, attributing to 
hidden phenotypes. The proteomic method isobaric tags for relative and absolute 
quantitation (iTRAQ) was utilised to quantify the protein changes occurring post-Vpx 
stimulation within resting cell models. The iTRAQ proteomic method is a quantitative 
technique that uses isobaric tags to chemically modify the primary amine groups of 
peptides. Currently, up to eight distinct isobaric tags are available, enabling 
multiplexing of up to eight samples is one mass spectrometry (MS) experiment. Upon 
fragmentation in the mass spectrometer, the reporter groups from the isobaric tags are 
detected, with each having a different mass in the fragmentation spectra. The intensity 
of the distinct reporter groups was used to calculate the relative abundance of the 
corresponding peptide and proteins. 
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Aims for this chapter were to identify and quantify protein changes occurring post-
Vpx stimulation within resting cell models to: 
1. Determine any hidden phenotypes, which could affect the use of Vpx in 
gene therapy protocols 
2. Investigate whether SAMHD1 independent protein changes are occurring 
which also enhance HIV-1 infection/gene delivery 
 
4.2. Methodology 
4.2.1. Generation of Samples 
For the proteomic studies, two iTRAQ experiments were performed. The first 
experiment included two MDDCs biological replicates harvested at 1 and 4 dps. The 
second experiment included two biological replicates of MDDCs and MDMs, 
harvested at 1 dps. For the generation of samples, monocytes were seeded into a 24 
well plate at 1 x 106/well/mL for MDDCs and 6 x 105/well/500 μL for MDMs and 
were differentiated according to methods above section 2.7.2 and 2.7.3, respectively. 
Once fully differentiated, an RT equivalent of 6700 pg or 4020 pg of Vpx containing 
VLPs or their control was added onto MDDCs or MDMs, respectively. At either 1 or 
4 day/s post stimulation (dps), the cells were harvested for iTRAQ labeling, by 
washing the cells twice in PBS and stored as a dry cell pellet at -80°C. 
 
4.2.2. Extraction of Protein and iTRAQ Labeling 
Proteins pellets were suspended in 850 μL phenylmethylsulfonyl fluoride (PMSF) 
(1µM) dissolved in PBS per condition. Samples were bath sonicated for 5 min. SDS 
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was added to a final concentration of 1% (w/v) before cell lysates were tip probed 
sonicated 2 times for 20 secs, with breaks on ice (tip probe setting 3; Branson sonifier 
250). 
2 μL of Benzonase (500U) was added to each sample and left to incubate at RToC for 
15 min. Samples were centrifuged at 15 000 x g for 15 min at 4°C. Supernatant was 
subjected to a chloroform/methanol clean up. Briefly, in a LoBind tube (Eppendorf, 
Hamburg, Germany), for every 200 μL of sample, 800 μL of -20°C methanol 
(100%v/v) was added and vortexed. Subsequently, 200 μL of 4°C chloroform was 
added and vortexed. Lastly, 600 μL of 4 °C milliQ H2O was added and vortexed 
before being centrifuged at 9000 x g, 2 min at 4°C. The upper phase was subsequently 
removed without disturbing the interphase, which contained the protein. Samples 
were washed with 600 μL of -20°C methanol and centrifuged at 9000 x g, 2 min at 
4°C. Without disturbing the pellet, the supernatant was carefully removed.  The 
sample was washed twice more with 1000 μL of -20°C methanol and then centrifuged 
at 9000 x g, 2 min at 4°C. The supernatant was carefully removed and the pellet 
slightly dried before being resuspended in 200 μL of PBS and 200 μL of 6 M urea, 2 
M thiourea, 500 mM tetraethylammonium bromide (TEAB) and bath sonicated for 10 
min. 
The samples were reduced for 1 hr with 10 mM dithiothreitol (DTT) followed by 
alkylation with 20 mM iodoacetamide for 30 min under exclusion of light. Alkylation 
was quenched with 10 mM DTT. 
Samples were diluted 1:2 with 0.5 M TEAB and digested with 20 μg porcine 
sequencing grade trypsin (Promega, Madison, WI) for 16 hr at 25°C. Peptides were 
concentrated and desalted by solid-phase extraction using tC18 Sep-Pak columns 
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(Waters, Milford, MA). Columns were washed with 1 mL of 100% methanol, 1 mL of 
100% acetonitrile (AcN), and 2 mL of 0.1% (v/v) trifluoroacetic acid (TFA), 
consecutively. Peptides were acidified to a concentration of 0.1% TFA and passed 
through a column two times. Peptides were washed with 5 mL of 0.1% TFA and 
eluted with 1 mL of 80% (v/v) AcN, 0.1% TFA.  
Samples were dried and stored at −20 °C. Peptides were resuspended in 0.5 M TEAB, 
and 100 μg of each peptide mix was labeled using 4-plex iTRAQ (ABSciex, Foster 
City, CA) according to the manufacturer’s instructions. Peptides were labeled for 1 hr 
at 25°C, the reaction was terminated by the addition of ultrapure water. Purification of 
the peptides from the excess iTRAQ reagent was accomplished by strong cation 
exchange (SCX) using a handheld cartridge. 
 
4.2.3. 2D-LC-MS/MS 
Peptides were resuspended in buffer A (5 mM phosphate, 25% (v/v) AcN, pH 2.7) 
and loaded onto a PolyLC PolySulfethyl A 200 mm × 2.1 mm 5 μm column (PolyLC 
Inc., Columbia MD) using an Agilent 1100 (Agilent Technologies, Santa Clara, CA) 
liquid chromatography (LC) system. Peptide fractionation was achieved by altering 
the concentration of buffer B (5 mM phosphate, 350 mM KCl, 25% AcN, pH 2.7). 
Initially, the column was washed with 10% buffer B for 6 min and then increased 
from 10 to 45% over 70 min. Buffer B concentration was then adjusted to 100% for 
10 min. The system was run with a constant flow rate of 200 μL/min, and fractions 
were collected every 2 min. 
Peptides were analysed by LC-MS/MS utilising an AB SCIEX TripleTof 5600 system 
(AB SCIEX, Framingham, MA, U.S.A.) connected directly online to an Eksigent 
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nanoLC Ultra (Eksigent, Redwood City, CA, U.S.A.). Initially, peptides were 
resuspended in buffer A (0.1% (v/v) formic acid (FA)) and once injected were loaded 
onto a C18 trap column (C18AQ Reprosil, 3 cm x 150 µm x 3 µm particle size) for 5 
min at a flowrate of 5 µL/min with 2% buffer B (100% MeCN, 0.1% FA). Following 
which, peptides were resolved with a C18 analytical column (C18AQ Reprosil, 20 cm 
x 75 µm x 3 µm particule size) for 90 min at a flowrate of 200 nL/min using a linear 
gradient of 2-95% (32% @ prior to rampup) buffer B directly online to a quadrupole-
time-of-flight AB SCIEX TripleTof 5600 tandem mass spectrometer. Electrospray 
was conducted at 150°C and 2.25 kV needle voltage to desolvate and ionise peptides 
which were then accelerated into the mass spectrometer. A top 20 method was setup 
where precursor ions were measured in full scan mode (370-1300 m/z) for 250 msec 
at 60,000 resolution and the twenty most intense ions (charge states above 2) were 
selected for fragmentation using collision induced dissociation (CID) with a 20 sec 
dynamic exclusion. Precursor ions were isolated for 150 msec and MS/MS spectra 
acquired at 40,000 resolution for a mass range of 110-2000 m/z. 
Data files (.wiff format) were then searched against the entire Swiss-Prot database 
with ProteinPilot version 4.5 using the Paragon algorithm with settings as follows; 
Sample type as iTRAQ 4-plex (peptide labelled), digestion set to Trypsin, Cysteine 
alkylation set as iodoacetic acid, Homo sapiens set as species and using the 5600 
instrument settings. Furthermore, the search was conducted using the thorough ID 
setting with a detected protein threshold of 0.05 (10.0%). 
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4.3. Results 
4.3.1. iTRAQ Experiment from MDDCs Harvested 1 and 4 dps Failed to 
Generate an Extensive List of Protein Targets 
For this iTRAQ experiment, MDDCs were selected, as they are more sensitive to Vpx 
mediated HIV-1 enhancement of infection compared to MDMs. The first iTRAQ 
experiment included MDDCs exposed to Vpx-containing or empty VLPs and 
harvested at 1 and 4 dps. These time points were selected because degradation of 
SAMHD1 occurred from 1 dps and remained Vpx sensitive to at least 14 dps. The 
time point 4 dps was included compared to a later time point because we hypothesised 
too much ‘background’ protein changes could accumulate from DC differentiation, 
masking Vpx specific protein changes. A common problem with proteomics is 
identifying lower abundance proteins as they tend to be masked by higher abundance 
proteins during MS analysis. Two biological replicates, which consumed one 4-plex 
iTRAQ kit, were processed for analysis by LC-MS/MS utilising an AB SCIEX Triple 
TOF 5600 system with methodology outlined in Figure 4.1. 
Two rounds of separation was utilised for iTRAQ methodology. Firstly, mixed 
labelled peptides were separated using strong cationic exchange (SCX) (separates 
based on charge of peptide) where on average 20-30 fractions are generated (413). 
Each fraction was further separated using an octadecyl carbon chain (C18)-bonded 
silica analytical column, which separated based on hydrophobicity (most hydrophilic 
peptides eluted first). Two rounds of separation need to occur as whole cell lysate is 
complex and a greater level of peptide separation is needed for fewer co-eluting 
peptides, translating into an increase in identification and quantification of proteins. 
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Figure 4.1: iTRAQ sample preparation summary 
Proteins were extracted from MDDCs stimulated with Vpx-containing or empty VLPs 
harvested at 1 and 4 dps and labelled using iTRAQ tags 114-117. Equal amounts of 
peptide from each condition were mixed prior to Strong Cationic Exchange (SCX) 
fractionation. The first biological replicate was labelled as above and the second was 
labelled in reverse order. 
 
The RAW files generated in the iTRAQ experiments, were imported into ProteinPilot 
version 4.5 and searched against the entire Swiss-Prot database. Peptide spectral 
matches were filtered to a minimum of 2 peptides per protein in each biological 
replicate and protein false discovery rate (FDR) was set to a maximum of 5%. The 
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peptide matches were combined to generate final peptide log ratios and used to 
determine protein log ratios. The first and second biological replicate quantified a 
total of 560 and 625 proteins, respectively. Frequency plots depicting protein log 
ratios displayed a normal distribution around zero for both 1 and 4 dps (Figure 4.2A 
and B). However, larger scatter was observed between biological replicates in the 4 
dps frequency plot compared to 1 dps. 
Rank-based z-score thresholds determined biologically significant protein changes. 
The loss of linearity when z-scores were plotted against log ratios infers the data no 
longer follows normal distribution and therefore of biological significance. This 
described change occurs at approximately z-score ± 2 (Figure 4.2C and D). However 
to be more inclusive, the threshold was set at ±1.5. A total of 84 proteins for each 
time point for the first biological replicate were considered significantly different in 
abundance (42 more abundant and 42 less abundant in Vpx stimulated cells compared 
to unstimulated cells) (Appendix Table 1 and 2). For the second biological replicate a 
total of 76 proteins for each time point were considered significantly different in 
abundance (38 more abundant and 38 less abundant in Vpx stimulated cells compared 
to unstimulated cells) (Appendix Table 3 and 4). For the selection of protein targets, 
the following criteria were applied; z-score ±1.5, present in both biological replicates 
and have the same change in abundance. However, when applied, only a total of 2 and 
6 protein targets were generated for 1 dps and 4 dps, respectively (data not shown). 
The low number of quantified proteins could be the reason for the smaller than 
expected number of protein targets. When total quantified proteins were compared 
between biological replicates, only 376 were common amongst both (Figure 4.2E) 
representing only 67% and 60% of total proteins quantified for the first and second 
biological replicate respectively.  
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Figure 4.2: iTRAQ analysis of DCs at 1 and 4 dps showed normally distributed 
quantitation ratios.  
(A and B) Histogram of number of identified proteins and their log2 ratio (+Vpx/-
Vpx) for 1 dps (A) and 4 dps (B). In each graph both biological replicates were 
represented with SD plotted. (C and D) Rank based z-scores plotted against log2 
ratios allowed for determination of thresholds for downstream analysis where non-
linear regression was observed; 1 dps (C) and 4 dps (D). Protein changes were 
deemed significant if lying outside the -/+ 1.5 z-score threshold. (E) Venn diagram 
showing overlap of quantified proteins across both biological replicates. 
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4.3.2. iTRAQ Experiment from MDDCs and MDMs Harvested 1 1dps 
Generated an Extensive Protein Target List 
For the second iTRAQ experiment, MDMs were included and the 4 dps time point 
excluded, with both cell types harvested at 1 dps. The reasoning behind this is the 
iTRAQ kit that was used could only incorporate 4 samples in each experiment. Since 
Vpx effects have been observed at early time points such as 1 dps, the later time point 
was excluded in order for the same biological donor to be included in one experiment. 
Two iTRAQ experiments were conducted, involving two biological replicates. The 
same methodology was used for the iTRAQ experiment and LC-MS/MS was acquired 
on the same mass spectrometry machine (Figure 4.3). Frequency plots depicting 
protein log ratios displayed a normal distribution around zero for both MDDCs and 
MDMs (Figure 4.4A and B). The first and second biological replicates identified 1596 
and 1530 proteins and quantified 947 and 919 proteins, respectively. Common 
proteins between the two biological replicates totaled 722 proteins, equating to 76% 
and 79% total protein quantified (Figure 4.4E). In comparison to the previous iTRAQ 
experiment the common proteins increased by almost double. The same method 
utilised in the previous iTRAQ experiment was used to determine the log ratio 
thresholds for biologically significant protein changes. The rank based z-scores were 
plotted against log ratios and the threshold was set at ±1.5 (Figure 4.4C and D). A 
total of 126 proteins for each cell type of the first biological replicate were considered 
significantly different in abundance (63 more abundant and 63 less abundant in Vpx 
stimulated cells compared to unstimulated cells) (Appendix Table 5 and 6). For the 
second biological replicate a total of 122 proteins for each cell type were considered 
significantly different in abundance (61 more abundant and 61 less abundant in Vpx 
stimulated cells compared to unstimulated cells) (Appendix Table 7 and 8). 
 103 
 
 
 
Figure 4.3: iTRAQ sample preparation summary. 
Proteins extracted from MDMs and MDDCs after 1 d stimulation with Vpx-
containing or empty VLPs, were labelled using iTRAQ tags 114-117. Equal amounts 
of peptide from each condition were mixed prior to Strong Cation Exchange (SCX) 
fractionation. The first biological replicate was labelled as above and the second was 
labelled. 
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Figure 4.4: iTRAQ analysis of macrophages and DCs at 1 dps showed normally 
distributed quantitation ratios. 
(A and B) Histogram of number of identified proteins and their log2 ratio (+Vpx/-
Vpx) for MDDCs (A) and MDMs (B). In each graph both biological replicates were 
represented with SD plotted. (C and D) Rank based z-scores plotted against log2 ratios 
allowed for determination of thresholds for downstream analysis where non-linear 
regression was observed; MDDCs (C) and MDMs (D). Protein changes were deemed 
significant if lying outside the -/+ 1.5 z-score threshold. (E) Venn diagram showing 
overlap of quantified proteins across both biological replicates. 
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4.3.3. Vpx Stimulation Significantly Altered Proteins Abundances 
Predominantly in the Nucleus and Function Protein Analysis 
Showed Extensive RNA Binding Potential 
Gene Ontology Annotations with Support Vector Machines (GOASVM) was used to 
determine the subcellular location of biologically significant proteins. This software 
searches gene ontology of proteins using accession numbers through the aid of vector 
support machines (414). The majority of protein changes occurred in the nucleus for 
all replicates and cell types (iTRAQ3 MDDCs 82.5% iTRAQ3 MDMs 77.8%, 
iTRAQ4 MDDCs 82.0% and iTRAQ4 MDMs 80.3%) (Figure 4.5). This is 
unsurprising as Vpx contains a nuclear localisation signal (415). The remaining 
proteins were primarily located in the cytoplasm and mitochondria. 
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Figure 4.5: Significant protein changes from Vpx stimulation predominantly 
occur in the nucleus 
The subcellular location of significantly changed proteins was determined by entering 
the UniProt accession numbers into GOASVM, a subcellular location database. 
Significantly changed proteins from MDMs and MDDCs are shown for both 
biological replicates 
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Biologically significant proteins were also analysed using Search Tool for the 
Retrieval of Interacting Genes/protein (STRING) v10 (416) to establish interactions 
and functional associations. Protein networks for each cell type were generated 
separately for up-regulated and down-regulated proteins. Three functional networks 
were observed for Vpx stimulated MDDCs (Figure 4.6).  These were: 
1. RNA binding (including SAMHD1, eukaryotic translation initiation 
factor proteins, ubiquitin c and heterogeneous nuclear ribonucleoproteins)  
2. Protein processing in the ER (including calreticulin and s-phase 
kinase-associated protein 1)  
3. Ribosome (including ribosomal family proteins).  
For Vpx stimulated MDMs four functional networks were observed (Figure 4.7). 
These were: 
1. RNA binding (including ribosomal proteins, eukaryotic translation 
initiation factor proteins, exportin-1 and proteasome subunit α type1)  
2. Translation initiation activity (including eukaryotic translation 
initiation factor proteins)  
3. Fatty acidic metabolism (including acyl-CoA synthetase long-chain 
protein family)  
4. Proton transport (including ATP synthase complex proteins). 
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Figure 4.6: Functional protein association network maps (STRING) in Vpx 
stimulated dendritic cells 
Protein interaction networks were generated for significantly different proteins in Vpx 
stimulated dendritic cells (DCs), Vpx stimulated DCs compared control stimulated (-
Vpx) DCs. (A) Significantly up-regulated proteins. (B) Significantly down-regulated 
proteins. K means clustering of 4 was implemented to both up- and down-regulated 
network maps. 3 groups of functional proteins were observed (1) RNA binding (2) 
protein processing in the endoplasmic reticulum (3) Ribosome 
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Figure 4.7: Functional protein association network maps (STRING) in Vpx 
stimulated MDMs 
Protein interaction networks were generated for significantly different proteins in 
Vpx stimulated monocyte derived macrophages (MDMs), Vpx stimulated MDMs 
compared to control stimulated (-Vpx) MDMs. (A) Significantly up-regulated 
proteins. (B) Significantly down-regulated proteins. K means clustering of 4 was 
implemented to both up- and down-regulated network maps. 4 groups of 
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functional proteins were observed (1) RNA binding (2) translation factor activity 
(3) Fatty acid metabolism (4) proton transport. 
 
4.3.4. Vpx Changes the Metabolic Profile of MDMs 
Proteins associated with proton transport (cellular respiration) were observed in the 
functional network for MDM down-regulated proteins. To determine whether this 
affected proton transport, the metabolic profile of Vpx-stimulated and unstimulated 
MDMs was investigated through a mitochondrial stress test. The Seahorse XF Cell 
Mito Stress Test was utilised for this purpose, which measures key parameters in 
mitochondrial function, outlined in Figure 4.8A. Briefly, MDMs were seeded in a 
XF24 cell culture plate and stimulated with Vpx-containing or empty VLPs for 24 hr. 
Media was replaced with serum free RPMI and placed in a non-CO2 incubator for 1 hr 
prior to measurement on the analyser. The oxygen consumption rate (OCR) was 
measured by solid-state sensor probes located 200 m above the cell monolayer. 
Firstly, the basal respiration is measured. Through the addition of oligomycin, which 
inhibits ATP synthesis, ATP production and proton leak can be calculated. Maximal 
oxygen consumption is induced by the addition of carbonyl cyanide-p-
trifluoromethoxyphenylhydrazone (FCCP), which is an uncoupling agent. The 
addition of rotenone, a Complex I inhibitor, shuts down mitochondrial respiration and 
enables the differentiation of non-mitochondrial and mitochondrial respiration (417).  
A subtle but consistent trend was observed for the basal and non-mitochondrial 
respiration, where respiration capacity decreased approximately 10% in Vpx 
stimulated MDMs. The maximal oxygen consumption rate (OCR) demonstrated a 
considerable decrease of approximately 25% for Vpx stimulated MDMs. The initial 
concentration of 1 μM FCCP used was within parameters of previously used 
 111 
concentrations of FCCP on MDMs (418, 419). However, to ensure absolute 
maximum oxygen consumption, additional FCCP was added to a final concentration 
of 5 μM. After the addition of higher concentration of FCCP, the oxygen consumption 
of the control MDMs marginally increased by 5%, whereas the Vpx stimulated 
MDMs remained at a consistent level (Figure 4.8B). The total OCR, which was 
calculated by determining the area under the curve (AUC), showed Vpx stimulated 
MDMs consumed oxygen significantly less than the control MDMs, representing a 
36.7% decrease (n =12, p ≤0.01) (Figure 4.8C).  
 
4.3.5. Application of Filtering Criteria to Significant Protein Changes 
Generated an Extensive Protein Target List for Further Validation 
One major advantage of proteomics is the large amount of proteins identified 
compared to other methods (413). For example, each iTRAQ replicate identified over 
100 proteins as biologically significant. However, is not feasible to follow up all of 
these proteins for downstream analysis. Filtering measures were applied to generate 
protein targets that could be followed up independently. The following criteria were 
applied for the selection of protein targets; z-score ±1.5, identified in both biological 
replicates and had the same trend (ie. both increased or decreased in abundance). For 
downstream analysis we decided to apply the above criteria to the macrophage data 
only. This was for two reasons, firstly, the THP-1 cell line can be utilised for follow 
up experiments such as knock-downs, since they can be differentiated into 
macrophage like cells with phorbol myristate acetate (PMA) (420). 
Secondly, we hypothesised any potential SAMHD1 independent effects that enhance 
HIV-1 infection/gene delivery would occur in both MDDCs and MDMs, as observed 
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with SAMHD1 degradation. If one of the protein targets displayed any potential in 
enhancing HIV-1 infection/gene delivery, they would be confirmed in MDDCs as 
well. 
 
Figure 4.8: Macrophages have an altered metabolic profile after Vpx 
stimulation 
(A) Outline of metabolic processes measured by the Seahorse metabolic stress test. 
(B) Macrophages were stimulated with Vpx-containing or empty VLPs for 24 hr 
before using the Seahorse XF24 extracellular analyser. The oxygen consumption rate 
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(OCR) was measured in real time under basal cell conditions and in response to the 
following inhibitors: Oligomycin, FCCP and Rotenone. SD were plotted for 11 
replicates. (D) Total oxygen consumption was calculated by determining the area 
under the curve (AUC). ** Significantly different from –Vpx (P<0.05), determined 
from an unpaired t-test. 
 
A total of 13 protein targets were identified following application of the above criteria 
from biologically significant macrophage proteins listed in Appendix Table 5 and 7. 
Out of the total, 5 of the proteins were up-regulated and 8 were down-regulated upon 
Vpx stimulation. A heat map was generated with the software GENE-E using log2 
ratios, MDDCs were also included in the heat map to determine whether the protein 
change also had the same trend (Figure 4.9).  
 
4.3.6. Vpx does not Modulate Protein Targets Transcriptionally 
Four major cellular processes have the ability to alter protein abundance; these 
include transcription, mRNA degradation, translation and protein degradation (421-
423). To investigate whether Vpx has transcriptional or mRNA degradation effects on 
the 13 protein targets, qPCR was performed using pre-optimised primer-probe sets 
ordered from Applied Biosystems. MDDCs and MDMs were stimulated with Vpx-
containing or empty VLPs for 24 h, before being harvested for RNA extraction. 
Isolated RNA was converted into cDNA prior to qPCR to measure the gene 
expression levels of the 13 protein targets (see section 5.2.2.). Data was analysed 
using the ΔΔCt method (424), with each sample being standardised to GAPDH. For 
both cell types, no significant change in gene expression was observed when 
compared to the empty-VLP control (Figure 4.10). 
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Figure 4.9: Heat map of proteins identified as macrophage targets for 
downstream analysis. 
Significantly changed proteins had the following criteria applied: z-score 1.5, 
identified in both biological replicates and with same trend. Displayed is the log2 ratio 
of proteins that passed the filtering criteria. MDM and MDDC log2 ratios are shown 
for both biological replicates. The protein targets were organised in descending order 
of log2 ratios. 
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Figure 4.10: Gene expression of protein targets is not significantly altered after 
Vpx stimulation. 
qPCR was performed on cDNA from Dendritic cells (A) and Macrophages (B) 
harvested 24 hr after stimulation with Vpx-containing or empty VLPs. Fold change in 
cycle threshold (Ct) values between Vpx stimulated and unstimulated is plotted for 
each gene assayed. All values were normalised to GAPDH. SD is plotted based on 6 
replicates, from two biological samples. 
 
4.4. Discussion 
Proteomics has allowed the investigation of whether any hidden phenotypes occur 
during Vpx stimulation. These phenotypes could either be detrimental or beneficial 
for the utilisation of Vpx in HIV-1 gene therapy approaches. Through the application 
of functional protein networks, key pathway/function nodes were identified. 
Additionally, a list of protein targets were generated, enabling further investigation 
into Vpx’s ability to enhance gene delivery/HIV-1 infection independently of 
SAMHD1. 
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The first iTRAQ experiment, which included Vpx stimulated MDDCs at 1 and 4 dps 
did not yield a protein target list. This could be due to the low amount of proteins 
quantified compared to the second iTRAQ experiment. Methodologically, the first 
and second iTRAQ experiments were carried out in the same manner, but iTRAQ 
labelling efficiency could explain the variability observed between experiments. 
Similar numbers of proteins were identified between the first and second iTRAQ 
experiments but fewer proteins were quantified in the first experiment. Maintaining a 
high ratio of iTRAQ reagent to peptides and reducing water competition is crucial for 
optimum labelling conditions (425). Even though the same amount (μg) of peptides 
were labelled for each sample across both experiments, the volume for each sample 
would be different contributing to water competition and thus effecting labelling 
efficiency. Nonetheless, labelling in the first experiment was efficient enough to 
accurately identify and quantify SAMHD1, only the amount of quantified proteins 
was affected. 
The second iTRAQ experiment successfully determined protein targets for 
downstream analysis. The majority of the proteins deemed biologically significant 
after z-score thresholds were applied showed nuclear localisation for both MDMs and 
MDDCs. Unsurprisingly, RNA-binding activity nodes were observed following 
functional protein network analysis for MDDCs and MDMs in both up- and down-
regulated proteins. Functional protein network analysis did not reveal any usual 
stress-activated signaling pathways such as nuclear factor-κβ, mitochondrial 
controlled apoptosis and mitogen-activated protein kinases (MAPK) (426). 
The proton transport network observed in down-regulated proteins from MDMs could 
affect their metabolic profile. A metabolic stress test was undertaken to investigate 
what happens to the mitochondria after 24 hr post-Vpx stimulation. Multiple drugs 
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were added to enable the calculation of basal respiration, ATP production, proton 
leak, non-mitochondrial respiration and maximal respiration. Total oxygen 
consumption rate showed that Vpx stimulated MDMs consume significantly less 
oxygen compared to unstimulated MDMs. This could indicate MDMs are being 
activated during Vpx stimulation to a M1 phenotype (classically activated 
macrophages). A study conducted by Hard showed that activated murine peritoneal 
MDMs had lower levels of oxygen consumption compared to resting ones as well as 
higher levels of glycolysis (427).  
However, no other proteomic evidence was observed to indicate classical activation 
of macrophages, such as the up-regulation of fructose-2,6-bisphosphatase or the 
down-regulation carbohydrate kinase-like protein (CARKL) (428). The second 
biological replicate showed a consistent but insignificant trend of lower oxygen levels 
after Vpx stimulation.   
From the list of biologically significant protein changes that occurred in macrophages, 
a list of protein targets were generated after application of certain criterion. This list 
formed the basis for further investigation into potential SAMHD1 independent Vpx 
effects. For the targets generated, we firstly wanted to explore whether the change in 
protein abundance was due to transcriptional or post-transcriptional regulation. 
Quantitative PCR for each protein target showed there no significant change in 
transcript levels after Vpx stimulation. Indicating Vpx stimulation causes the change 
in protein abundance either by translation or protein degradation regulation. 
To determine whether any of these protein targets can independently enhance gene 
delivery/HIV-1 infection, knock-down and knock-in cell lines were generated to 
perform lentiviral challenge experiments. 
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5. Chapter 5: Investigating Vpx Protein Targets 
 
5.1. Introduction 
Chapter 3 of this thesis demonstrated successful genetic manipulation of primary 
macrophages, which required the incorporation of Vpx. It is known that Vpx 
facilitates the degradation of SAMHD1 (305, 306), however, Vpx modulation of other 
cellular factors have not been determined. Hidden phenotypes could be occurring 
post-Vpx exposure, having detrimental effects. Proteomic experiments were 
conducted to identify the host cell proteins changes post-Vpx exposure. Functional 
protein network analysis did not reveal any usual stress-activated signaling pathways, 
which could be detrimental to the cell. Specific selection criteria (z-score ±1.5, 
identified in both biological replicates and same trend observed), was applied to the 
proteomic data to generate a set of proteins that commonly occur in concurrence with 
SAMHD1 across two biological replicates. The approach of genetic modification to 
up/down-regulate a target protein is a mechanistically powerful tool to examine single 
protein changes and their role in HIV-1 infection. Performing these analyses in 
primary macrophages is not feasible as Vpx is required for efficient genetic 
manipulation of the cells. The protein changes investigated in Chapter 4 result from 
Vpx exposure. We utilised the monocytic cell line, THP-1, as model for genetic 
manipulation. The THP-1 cell line is suitable alternate for genetic manipulation for a 
few of reasons. Firstly, it is derived from an acute monocytic leukaemia and shares 
many phenotypic attributes with peripheral blood monocytes (429). Secondly, genetic 
manipulation can be facilitated by encoding drug resistance vectors transduced cells 
can subsequently be enriched. Finally and importantly, PMA differentiated 
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macrophages derived from the THP-1 cell lines express SAMHD1 (providing a 
positive control target) and also have a Vpx sensitive phenotype, similar to that 
observed in primary macrophages (304). 
A panel of stable THP-1 cell lines were generated either deficient or abundant in a 
protein of interest identified in Chapter 4. Post-Vpx exposure, five of the proteins 
were up-regulated and eight of the proteins were down-regulated. For up-regulated 
proteins, respective genes were expressed in THP-1 cells using a pLVX lentiviral 
expression vector. This plasmid encodes human cytomegalovirus immediate early 
(pCMV) driven expression of the gene of interest. In parallel, the murine 
phosphoglycerate kinase promoter (pPGK) drives the expression of the puromycin 
resistance gene, for latter drug selection of transduced cells (430). For down-regulated 
proteins, respective genes were silenced in THP-1 cells utilising the pLKO.1 
expression vector that encodes U6 driven expression of shRNA in addition to pPGK 
driven expression of puromycin (431). Gene silencing has become an important tool 
in investigating phenotypes from protein-coding genes. We utilised shRNAs, which 
induced stable gene-silencing, by transducing cells with exogenously synthesised 
hairpins subcloned into an expression vector (432).  
The panel of stable THP-1 cells lines will be used in HIV-1 challenge experiments. 
Aims to be addressed in this chapter include: 
To determine whether any of the protein targets are capable of enhancing HIV-1 
infection, in the absence of Vpx. 
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If any protein targets do enhance HIV-1 infection similar to the SAMHD1 
knockdown, the protein levels for each target will be examined short and long 
term post-Vpx stimulation. The protein levels of primary macrophages and 
dendritic cells and will be investigated. 
 
5.2. Methodology 
5.2.1. Generation of Novel Immortalised THP-1 Cell Lines 
Lentiviral transduction was used to deliver shRNA or expression constructs into THP-
1 cells to generate a stable knockdown/over expression for each gene of interest. 
Lentiviral particles packing either pLVX vectors or shRNA pLKO.1 vectors were 
produced by HEK239T transfections and concentrated as previously described in 
section 2.9.1. Two types of immortalised THP-1 cell lines were generated for this 
study; gene knockdowns (pLKO.1 transduction) and gene over expressions (pLVX 
transduction). The details for both methodologies are outlined below. 
 
5.2.2. Generation of LVX-expression Vectors 
The corresponding genes for the up-regulated protein targets identified in Chapter 4 
are listed in Table 5.1. For expression in THP-1 cells, each gene of interest was 
subcloned into the LVX-mCherry-N1 vector for expression 
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Table 5.1: List of genes of interest for expression in THP-1 cells 
 
 
Unfortunately, due to the large protein size and thus large DNA sequence (>3kb) for 
protein EPB41L2, it was not viable to express this gene of interest. The vector pLVX-
mCherry-N1 was selected for gene expression. Each gene of interest was subcloned 
into the expression vector utilising the BamHI and XbaI restriction enzyme sites, 
which replaced the mCherry open reading frame with the codon DNA sequence 
(CDS) of interest. 
The CDS for each gene was designed in silico with the corresponding restriction 
enzyme sites, BamHI and XbaI, placed at the 5’ and 3’ end of the CDS, respectively. 
Furthermore, specific adapter sequences flanked the 5’ and 3’ end to enable PCR 
amplification of the CDS. The final in silico gene of interest followed the outline 
shown below (presented in 5’-3’ format): 
 
AAAATTGCGTGGAGCGGCACC-GGATCC-[gene]-TCTAGAGTTGCGCTGGCAAATGTTCAC 
                                                            (BamHI)                 (XbaI) 
 
The designed genes were ordered as gBlock gene fragments (Integrated DNA 
Technologies, Coralville, IA, United States), flanked by common 5’ and 3’ adapters 
to facilitate latter PCR amplification and cloning. Despite multiple synthesis attempts, 
Uniprot 
Accession 
Number
Entrez 
Gene 
Number
Gene 
Name
Protein 
Size (kDa)
Protein Name
P40227 908 CCT6 58 T-complex protein 1 subunit zeta (CCT6)
O43491 2037 EPB41L2 112.6 Band 4.1-like protein 2
Q9HC38 51031 GLOD4 34.8 Glyoxalase domain-containing protein 4 
Q99497 11315 PARK7 19.9 Parkinson Protein 7
Q5T123 83442 SH3BGRL3 9.4 SH3 domain-binding glutamic acid-rich-like protein 3
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GLOD4 could not be synthesised to the required quality control specifications, hence 
was not pursued further. The sequence of each expression gBlock is detailed in the 
Supplementary Figure 5.1. 
The gene blocks were 250 ng of purified DNA and subsequently resuspended in 20 
μL of sterile TE buffer to give a final concentration of 12.5 μg/mL. Each gene of 
interest was amplified using PCR, to increase the DNA quantity required for cloning. 
Primers specific to the adapters, which flank each gene of interest, were used to 
amplify the DNA fragment. Reactions were made up to a final volume of 50 μL that 
contained 10 μL of (5X) Q5 Buffer (New England BioLabs (NEB), Ipswich, MA, 
United States), 500 nM each of forward and reverse primers, 200 μM dNTPs, 1 U of 
Q5 Hot Start High-Fidelity DNA Polymerase (NEB) and 25 ng of template (gBlock 
gene of interest fragment). Amplification was performed in a thermocycler (BioRad, 
Hercules, CA, Unites States) with the following cycling conditions; 1 cycle at 98°C 
for 30 sec; 24 cycles of 98°C for 10 sec, 69°C for 20 sec and 72°C for 17 sec (PARK7 
and SH3BGRL3 gene fragment) or 35 sec (CCT6 gene fragment); followed by 1 
cycle at 72°C for 2 min. The amplified product was either used immediately or stored 
at 4°C for up to 24 hrs. A small volume of 5 μL for each post-PCR product was used 
to run on a 1% agarose gel, to confirm the expected band size. Upon size verification, 
the amplified DNA within the remaining 45 μL of PCR product was purified using 
the PCR/gel clean up kit (Promega, Madison, WI, United States). 
To subclone the gene of interest into the mCherry region of LVX-mCherry-N1, the 
amplicon and the LVX-mCherry-N1 vector were digested with BamHI High Fidelity 
(HF) (NEB) and XbaI (Roche, Basel, Switzerland). Each digest was made up to a 
final volume of 30 μL and contained 3 μL of CutSmart buffer (NEB), 20 U each of 
BamHI HF and XbaI and 2 μg of DNA.  The reaction was performed at 37°C for 1.5 
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hrs. After digestion, the reaction mixture was run on a 1% agarose gel (pre-stained 
with 1X SYBR Safe DNA gel stain (ThermoFisher)) and appropriate band sizes for 
each gene of interest and LVX-mCherry-N1 backbone were gel excised under the UV 
transilluminator (Clinx, Shanghai, China), utilising the longer 365 nm excitation 
wavelength to minimize DNA damage. DNA was subsequently gel extracted using 
the PCR/gel clean up kit (Promega) prior to ligation. Ligations were carried out for 
each gene of interest at a DNA ratio, of vector to insert, 1 : 5, as per the protocol 
outlined in section 2.8.1 Transformations for each ligation were performed in Stbl2 
chemically competent bacteria (Invitrogen), according to the protocol outlined in 
section 2.8.2. Five bacteria colonies (clones) were picked, miniprepped and verified 
using a BamHI and XbaI restriction digest. Two appropriate clones for each gene of 
interest were selected for DNA sequencing, using a forward primer specific for the 
LVX backbone upstream of mCherry (termed LVX forward, details listed in Table 
2.4).  
Plasmid stocks for the verified clones were generated in preparation for lentiviral 
particle transfections. Lentiviral particles were produced by transfection of the 
vectors; pLVX-gene of interest (4 μg), psPAX2 (4 μg) and VSVg (2 μg) into HEK-
293T cells. At 3 days post transfection the viral supernatant was concentrated by 
ultracentrifugation. A detailed HEK-293T cell transfection protocol is outlined in 
section 2.9.1. 
 
5.2.3. Generation of LKO-knockdown Vectors 
The corresponding genes for the down-regulated protein targets identified in Chapter 
4 are listed in Table 5.2. For gene knockdowns in THP-1 cells, each shRNA hairpin 
 126 
that targeted the gene of interest was sub-cloned into the pLKO.1 vector using Age1 
and EcoR1 restriction sites. 
 
Table 5.2: Outline of genes of interested for LKO-knockdown in THP-1 cells 
 
 
For each gene of interest, two different regions (eg. CDS and 3’UTR) were targeted to 
ensure effective gene knockdown. Therefore, two target sequences were selected for 
each gene of interest. The majority of shRNA target sequences were selected through 
the Genetic Perturbation Platform (http://www.broadinstitute.org/rnai/public/). Two 
assessments of the shRNA target sequence were taken into consideration before 
selection. Firstly, the specificity defining region (SDR) score, which calculates the 
percent match of the hairpin target sequence to the transcript RNA sequence. 
Secondly, the specificity score, which calculates the predicted knockdown 
performance.  
Forward and reverse oligomers were ordered for the selected target sequences, which 
upon annealing, would generate the shRNA hairpin, with Age1 and EcoR1 overhangs 
for directional cloning into pLKO.1. The oligomer details for each knockdown gene 
Uniprot 
Accession 
Number
Entrez 
Gene 
Number
Gene 
Name
Protein 
Size (kDa)
Protein Name
O95573 2181 ACSL3 80.4 Long-chain-fatty-acid--CoA ligase 3
Q9HD20-2 57130 ATP13A1 121.1 Isoform B of Manganese-transporting ATPase 13A1
P27797 811 CALR 48.1 Calreticulin 
P08962 967 CD63 25.6 CD63 antigen
Q02318 1593 CYP27A1 60.2
Cytochrome P450, family 27, subfamily A, 
polypeptide 1
Q96HE7 30001 ERO1L 54.4 ERO1-like protein alpha
Q13451 2289 FKBP5 51.2 Peptidyl-prolyl cis-trans isomerase (FKBP51)
Q9Y3Z3 25939 SAMHD1 72.2
Deoxynucleoside triphosphate triphosphohydrolase 
(SAMHD1)
 127 
of interest are listed below (Table 5.3) with two target regions cited for each gene of 
interest. For scrambled shRNA, lentiviral plasmids were obtained from Santa Cruz 
(catalog # sc-108060). Each oligomer was resuspended in annealing buffer (section 
2.1) to a final concentration of 100 μM. For each complimentary pair of oligomers, 25 
μL was added to a 0.2 mL PCR tube. The oligomers were annealed using a 
thermocycler (BioRad) with the following cycling conditions; 1 cycle at 95°C for 2 
min; 1 cycle at 25°C for 45 min; followed by an indefinite cycle at 4°C.  
The resulting shRNA hairpins were subcloned into the pLKO.1 (Addgene, 
Cambridge, MA, United States) vector. This vector contains a 1.9 kb stuffer fragment 
between AgeI and EcoRI restriction sites, allowing the shRNA hairpin to be 
subcloned into this region. A restriction digest with AgeI and EcoRI for the pLKO.1 
vector is required to release the stuffer DNA, allowing subcloning of the shRNA 
hairpin. The pLKO.1 digest was made up to a final volume of 20 μL and contained 2 
μL of CutSmart buffer (NEB), 30 U each of AgeI and EcoRI and 3 μg of DNA.  The 
reaction was performed at 37°C for 1.5 hrs. After digestion, the reaction mixture was 
run on a 1% agarose gel (pre-stained with 1X SYBR® Safe DNA gel stain) and the 
appropriate band was excised and DNA purified as for the pLVX vector (section 
5.2.1). Ligations were carried out for each gene of interest at a DNA ratio, of vector to 
insert, 1 : 3, as per the protocol outlined in section 2.8.1. Transformations for each 
ligation were conducted in Stbl2 chemically competent bacteria, according to the 
protocol outlined in section 2.8.2. Five bacteria colonies (clones) were picked, 
miniprepped and verified with an AgeI and EcoRI restriction digest. Two appropriate 
clones for each gene of interest were selected for DNA sequencing. Briefly, to enable 
sequencing of the shRNA, the pLKO.1 vector was digested with Xho1 to cleave the 
head of the hairpin and then sequenced using the forward primer specific for the U6 
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promoter region upstream of the shRNA sequence (termed U6 forward, details listed 
in Table 2.4). 
Plasmid stocks for the verified clones were generated in preparation for lentiviral 
particle transfections. For each gene of interest both target shRNA vectors were used 
in the transfection. Lentiviral particles were generated by transfection of the following 
vectors; pLKO.1-target-1 (2 μg), pLKO.1-target-2 (2 μg), psPAX2 (4 μg) and VSVg 
(2 μg) into HEK-293T cells. At 3 days post transfection the viral supernatant was 
concentrated by ultracentrifugation. Full details of the HEK-293T cell transfection 
protocol is outlined in section 2.9.1. 
 
5.2.4. Lentiviral Transduction for the Generation of Stable Knockdown 
and Expression THP-1 Cells 
Pelleted lentivirus was used to transduce THP-1 cells seeded in a flat-bottom 96-well 
plate (5 x 103 cells/well) using a 1 in 2 serial dilution of virus (1, 1:2, 1:4, 1:8, 1:16, 
1:32, 1:64, 1:128, 1:256, 1:512, 1:1024 and 1:2048). Two wells of non-transduced 
THP-1 cells were included as controls. Cells were incubated for 72 hrs at 37°C, 5% 
CO2 to allow efficient transduction of THP-1 cells before the culture medium was 
replaced with RPMI-10 supplemented with puromycin (2 μg/mL). Puromycin 
medium was also added to one of the non-transduced THP-1 control wells, as a 
positive control of the effect of puromycin on non-resistant cells. Both lentiviral 
constructs pLVX-mCherry-N1 and pLKO.1 contain a puromycin resistance gene, 
allowing transduced cells to be resistant to puromycin. Two or three puromycin 
resistant dilutions were transferred to a 24 well plate for further cell expansion. The 
dilution ratios selected for expansion are outlined in Table 5.4. The cell numbers were 
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gradually expanded by transferring transduced THP-1 cells to a 6-well plate and then 
to a T25 flask, with THP-1 cells cultured in puromycin supplemented RF-10 
throughout the expansion. Once the transduced THP-1 cells were expanded to a T25 
flask, further passages were performed in the absence of puromycin. Frozen seed 
stocks were generated for each transduced THP-1 cell line outlined in Table 5.4, 
according to the protocol detailed in section 2.6. 
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Table 5.4: List of transduced THP-1 cells selected for expansion. The rows 
highlighted in bold were the dilution ratios selected for HIV-1 challenge experiments
 
 
5.2.5. Verification of Knockdown and Expression THP-1 Cell Lines 
To determine the extent of knockdown or expression for each gene of interest, qPCR 
was used. Briefly, RNA was extracted from THP-1 cell pellets using the RNA 
extraction kit (Qiagen, Hilden, Germany) according to the manufactures’ instructions 
and RNA was eluted in 50 μL of RNAse free dH2O. The yield and purity of the 
isolated RNA was determined on the Nanospec 2000 (Thermoscientific, Waltham, 
MA, United States). Isolated RNA was typically measured at >150 ng/μL, with a 
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260/280 absorbance of ~2.0, which indicates pure RNA. For cDNA synthesis 100 ng 
of RNA was used for the reaction using the VILO DNA synthesis kit (Life 
technologies). The cDNA synthesis reaction was carried out in a thermocycler 
(BioRad) using the following conditions: 1 cycle at 25°C for 10 min; 1 cycle 42°C for 
60 min; 1 cycle at 85°C for 5 min; indefinite cycle at 4°C. The resulting cDNA was 
diluted 1 in 50 for qPCR. A pre-optimised primer-probe set (Applied Biosystems, CA, 
US) and GAPDH primer-probe was used for each gene of interest for their 
corresponding THP-1 knockdown/expression cDNA (see Table 2.5). Reactions were 
made up to a final volume of 20 μL, which contained 10 μL of IQ5 Supermix 
(BioRad), 0.5 μL (900 nM for each primer and 250 nM of FAM probe) of primer-
probe mix and 2 μL of cDNA template. For measurement of GAPDH, reactions were 
also made up to a final volume of 20 μL, which contained 10 μL of IQ5 Supermix 
(BioRad), 0.25 μL each of forward and reverse primer, 0.3 μL of FAM-probe and 2 
μL of cDNA template. PCR reactions were performed on the LightCycler 480 
Instrument II  (Roche) with the following conditions: 1 cycle at 95°C for 3 min, 
followed by 45 cycles of 95°C for 15 sec and 60°C for 1 min. The relative changes in 
gene of interest expression for each knockdown/expression cell line was determined 
using the ΔΔCt method. This comparative method involved comparing the gene of 
interest Ct values of knockdown/over-expression samples with their respective 
control. These values are then normalised to the GAPDH endogenous house keeping 
gene (424). Statistical analyses was performed using one-way ANOVA 
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5.2.6. HIV-1 Challenge Experiments 
5.2.6.1. Undifferentiated THP-1 Cells 
Undifferentiated wild type and knockdown THP-1 cells (6 x 104/well/500 μL) were 
plated into a 96 well-plate (Falcon). The cells were infected with replication defective 
HIV-1-GFP at an MOI of 0.1. Undifferentiated wild-type THP-1 cells stimulated with 
Vpx containing VLPs (equivalent to 100 pg of RT) was used a Vpx control. The cells 
were cultured for 3 days at 37°C, 5% CO2. The THP-1 cells were fixed for 15 mins 
with 4% (v/v) PFA and then washed twice with FACS wash at a centrifuge speed of 
1200 g, 5 mins, RT. Cells were analysed using the LSRII. Live cells were gated 
according to side and forward scatter and further gated on the GFP positive 
population was interpreted as percent of infection. 
 
5.2.6.2. Differentiated THP-1 Cells 
Undifferentiated wild type, over expression or knockdown THP-1 cells (6 x 
104/well/500 μL) were plated into a 96 well-plate (Falcon). To differentiate the cells a 
10X stock of PMA was added to wells to a final concentration of either 80 ng/mL, 
120 ng/mL or 160 ng/mL. The cells were cultured at 37°C, 5% CO2 for 24 hrs before 
the medium was replaced with fresh RF-10 and infected with replication defective 
HIV-1-GFP at an MOI of 0.1. Differentiated wild-type THP-1 cells were stimulated 
with Vpx containing VLPs (equivalent to 100 pg of RT), as a Vpx stimulated control. 
The cells were cultured for 3 days at 37°C, 5% CO2. The nuclei of live cells was 
stained with NucBlue Live (Life technologies, Carlsbad, CA, United States) (6 
μL/well), for 1 hr at 37°C, 5% CO2 before being imaged on the Cytell using the 4X 
objective (GE Healthcare, Little Chalfont, UK). A total of four fields of view from the 
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GFP, DAPI and white light channels were acquired using the Cytell and converted 
into .XDCE file format for analysis using the IN Cell Investigator software v1.6 (GE 
Healthcare). The number of GFP and DAPI positive cells were enumerated and 
percentage of infection was calculated by normalising cells to the DAPI count and 
expressed as a percentage. The non-parametric Kruskal-Wallis test was performed on 
each experiment. 
 
5.3. Results 
5.3.1. Verification of THP-1 Expression Cell Lines 
To verify the over expression of CCT6, PARK7 and SH3BGRL3 transduced THP-1 
cells, transcript levels of each gene of interest were measured. Pre-optimised primer-
probe sets were used for each gene of interest and a standard primer-probe set from 
our laboratory was used for GAPDH. Briefly, RNA was extracted from wild type 
THP-1 cells (termed THP-1 WT), THP-1 cells transduced with the parent plasmid 
LVX-mCherry-N1 (termed THP-1 mCherry) and each transduced expression THP-1 
cell line. Isolated RNA was converted into cDNA prior to qPCR to measure the gene 
expression levels of CCT6, PARK7 or SH3BGRL3. Each sample was normalised to 
GAPDH Ct values and analysed using the ΔΔCt method (424). Analysis compared 
the normalised gene of interest Ct values of over-expression samples with their 
respective normalised control. For each gene of interest, no significant increase in 
expression of CCT6, PARK7 or SH3BGRL3 was observed in any of the transduced 
THP-1 cells lines, compared to THP-1 mCherry gene expression (Figure 5.1). On 
average a 23.3% (Figure 5.1(A); p=ns; n=3) decrease in CCT6 transcript was 
observed in transduced THP-1 cell lines, compared to THP-1 mCherry CCT6. 
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PARK7 transduced cell lines on average showed 16.3% decrease, compared to THP-1 
mCherry levels. A 19.3% decrease in PARK7 transcript was observed in THP-1 WT 
cells, compared to THP-1 mCherry (Figure 5.1(B); p≤0.01; n=3). The SH3BGRL3 
transduced cell lines, on average, showed a significant 45.1% decrease, compared to 
the THP-1 mCherry control (Figure 5.1(C); SH3BGRL3 1:16; 49.8%; p≤0.0001; n=3 
and SH3BGRL3 1:32; 60.1%; p≤0.0001; n=3). A 29.4% decrease in SH3BGRL3 
transcript was observed in THP-1 WT cells, compared to THP-1 mCherry (Figure 
5.1(C); p≤0.01; n=3). 
 
 
Figure 5.1: Expression confirmation of CCT6, PARK7 and SH3BGRL3 in 
undifferentiated THP-1 cells 
RNA from THP-1 cell lines was extracted and cDNA generated. qPCR was 
performed for the following genes; CCT6 (A), PARK7 (B) and SH3BGRL3 (C) Data 
was normalised to GAPDH transcript levels (n=3). Values were represented as % of 
THP-1 mCherry expression. SD were plotted based on triplicate values. One way 
ANOVA’s were performed for statistical analyses. **p≤ 0.01  **** p≤ 0.0001  
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The absence of any significant expression for CCT6, PARK7 or SH3BGRL3 
transduced THP-1 cell lines was perplexing for two reasons. Firstly, only verified 
LVX-expression plasmids were used to generate the lentiviral particles.  For each 
plasmid, the sequence was confirmed to have 100% identity with the CDS 
corresponding with their Entrez gene number. Secondly, the transduced THP-1 cells 
lines were puromycin resistant, therefore the transduced plasmid is actively 
expressed. In the pLVX-mCherry-N1 plasmid, expression for the gene of interest and 
puromycin are under the control of different promoters. Expression for the gene of 
interest is driven by the pCMV, while puromycin resistance is driven by pPGK. The 
lack of gene expression occurring concurrently with puromycin resistance could be 
due to reduced activity levels of pCMV compared to pPGK in non-PMA stimulated 
THP-1 cells. Indeed, a study conducted by Ramesh and colleagues showed the 
activity of adenosine deaminase (ADA), controlled under PCMV IE, increased 2.7 
fold when THP-1 cells were differentiated with PMA (433). 
To confirm whether the gene of interest expression does increase after differentiation 
with PMA, varying concentrations of PMA was examined. THP-1 WT and THP-1 
mCherry cells were stimulated with differing concentrations of PMA (80, 120 and 
160 ng/mL). After 24 hrs of differentiation, the THP-1 cells were fixed and analysed 
using flow cytometry to determine the level of mCherry expression, and the median 
fluorescent intensity (MFI) of each condition was measured (Figure 5.2). The 
mCherry expression from THP-1 WT was used as a negative control. The MFI for the 
THP-1 mCherry cell line without PMA stimulation was only 3.1 fold more intense 
compared to the THP-1 WT cells. However, once stimulated with PMA, a mean 24 
fold-increase mCherry expression was observed. The increase was dose-dependent, 
with a 6.8% increase occurring with each increase in PMA concentration. 
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Figure 5.2: Comparison of median fluorescent intensity levels for THP-1 wild 
type and THP-1 mCherry cell lines 
Unstimulated and PMA stimulated (80, 120 and 160ng/mL) THP-1 and THP-1-
mCherry cells lines were fixed analysed using flow cytometry. The mCherry median 
fluorescent intensity was measured from the live cell population and plotted in 
arbitrary units. 
 
Another qPCR experiment was performed to determine whether PMA differentiation 
of THP-1 cells increases gene expression for the transduced THP-1 cell lines. The cell 
lines with the highest dilution ratio for each gene of interest was harvested for RNA 
extraction. RNA was extracted from THP-1 WT, THP-1 mCherry and transduced 
THP-1 cell lines. The isolated RNA was converted into cDNA and subsequent qPCR 
and data analysis was carried out in the same manner as the previous qPCR 
experiment. Significant gene expression was only observed in the CCT6 transduced 
THP-1 cells lines, compared to THP-1 mCherry gene expression (Figure 5.3). For the 
CCT6 transduced cell line, a significant increase of 2.1 fold (Figure 5.3(A); CCT6 
1:32; 211.2%; (p≤0.0001; n=3)) was observed when compared to THP-1 mCherry. 
No significant difference in PARK7 and SH3BGRL3 gene expression was observed 
when compared to THP-1 mCherry levels (Figure 5.3(B) PARK7 1:64; 86.3%; p=ns; 
n=3. (C); SH3BGRL3 1:32; 108.2%; p=ns; n=3).  
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Figure 5.3: Expression confirmation of CCT6, PARK7 and SH3BGRL3 in 
differentiated THP-1 cells 
RNA from THP-1 cell lines, stimulated with 160 ng/mL of PMA, was extracted and 
cDNA generated. qPCR was performed for the following genes; CCT6 (A), PARK7 
(B) and SH3BGRL3 (C). Data was normalised to GAPDH transcript levels (n=3). 
Values were represented as % of THP-1 mCherry expression. SD were plotted based 
on triplicate values. One way ANOVA’s were performed for statistical analyses * p≤ 
0.05 and  **** p≤ 0.0001. 
 
5.3.2. THP-1 Expression Cell Lines Significantly Restrict HIV-1 
Infection 
The PMA differentiated qPCR data revealed the CCT6 (dilution ratio 1:64) had 
significantly higher levels of gene expression compared to the THP-1 mCherry levels. 
However, the overall increase for all the genes was not substantial. Nonetheless, HIV-
1 challenge experiments were performed to investigate whether these gene changes 
could independently enhance HIV-1 infection. All three transduced THP-1 cell lines 
were included despite PARK7 not displaying an increase in expression post PMA 
differentiation. Briefly, THP-1 cells were differentiated with varying concentrations 
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of PMA (80, 120, 160 ng/mL). Typical concentrations used to differentiate THP-1 
cells are 120 ng/mL (434, 435). Therefore, including a titration of PMA could reveal 
differing profiles based on the extent of differentiation. After 24 hrs of differentiation, 
the culture medium was replaced with fresh RF-10 and then infected with replication 
defective HIV-1 GFP. At 3 dpi, the nuclei of live cells were stained with NucBlue and 
then imaged on the Cytell. The number of GFP positive cells and nuclei were 
enumerated for each condition using IN Cell Investigator software. Surprisingly, 
CCT6, PARK7 and SH3BGRL3 transduced cell lines displayed extensive inhibition 
of HIV-1 infection compared to THP-1 WT and THP-1-mCherry cell lines (Figure 
5.4). Across all PMA concentrations, the CCT6 transduced THP-1 cells showed a 
significant reduction in HIV-1 infection compared to THP-1-mCherry cells. This 
represented a 14.5, 12.3 and 13.3 fold decrease for 80 ng/mL, 120 ng/mL and 160 
ng/mL, respectively (Figure 5.4(A) p≤0.05; n=6 (B) p≤0.05; n=6 (C) p≤0.05; n=6). 
The PARK7 transduced THP-1 cell line showed an inhibition of HIV-1 infection 
across all PMA concentrations compared to THP-1 WT, with 7.1, 6.7 and 7.8 fold 
decreases observed for 80 ng/mL, 120 ng/mL and 160 ng/mL, respectively. The 
SH3BGRL3 transduced THP-1 cell lines also displayed restriction in HIV-1 infection 
across all PMA concentrations compared to THP-1 WT, with 11.5, 10.5 and 9.6 fold 
decreases observed for 80 ng/mL, 120 ng/mL and 160 ng/mL, respectively. 
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Figure 5.4: HIV-1 infection experiments for expression THP-1 cells lines 
THP-1 cells lines were differentiated with either 80 ng/mL, 120 ng/mL or 160 ng/mL 
of PMA and infected with HIV-1 GFP. At 3 dpi, the nuclei were live-stained with 
NucBlue before being imaged with the Cytell. Infected cells for each condition was 
normalised to the nuclei sum and represented as a percentage value. SD were plotted 
based on six replicates (n=6). Non-parametric Kruskal-Wallis test * p≤ 0.05. 
 
5.3.3. Verification of Knockdown THP-1 Cell Lines 
To verify the knockdown for each transduced THP-1 cell line, qPCR was performed 
to measure the transcript levels for each gene of interest. The pre-optimised primer-
probe sets used for the qPCR are listed in Table 2.5. RNA was extracted from THP-1 
WT, THP-1 cells transduced with scrambled shRNA (termed THP-1 scrambled) and 
each transduced THP-1 cell line. Isolated RNA was converted into cDNA prior to 
qPCR to measure the gene expression levels of ACSL3, ATP13A1, CALR, CD63, 
CYP27A, ERO1L, FKBP5 and SAMHD1. Data was analysed using the ΔΔCt method 
(424), with each sample being standardised to GAPDH. Initially gene of interest 
expression was compared to THP-1 WT levels, since the THP-1 scrambled cell line 
had not been generated. For each gene of interest knockdown, at least one of the 
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transduced cell lines showed a significant decrease in gene expression compared to 
wild type THP-1 cells (Figure 5.5).  
Each transduced cell line that displayed the greatest decrease for their gene of interest 
was analysed again and compared to the THP-1 scrambled cell line. This was to 
account for any potential differential expression due to the puromycin expression. 
When compared to THP-1 scrambled levels, the gene knockdowns were as follows: 
ACSL3 1:512 (Figure 5.6 (A); 70.7% decrease; p≤0.001; n=3); ATP13A1 1:256 
(Figure 5.6 (B); 83.8% decrease; p≤0.0001; n=3); CALR 1:32 (Figure 5.6 (C); 91.4% 
decrease; p≤0.01; n=3); CD63 1:64 (Figure 5.6(D); 49.9% decrease; p≤0.0001; n=3); 
CYP27A 1:64 (Figure 5.6 (E); 54.7% decrease; p≤0.01; n=3); ERO1L 1:64 (Figure 
5.6(F); 88.2% decrease; p≤0.0001; n=3); FKBP5 1:512 (Figure 5.6 (G); 68.8% 
decrease; p≤0.0001; n=3) and SAMHD1 1:128 (Figure 5.6 (H); 89.6% decrease; 
p≤0.01; n=3). The qPCR data revealed each cell line achieved at least 50% gene 
knockdown. Subsequent downstream experiments utilised the above cell line dilution 
ratios. A table outlining each knockdown cell lines used for down stream experiments 
is listed in highlighted bold in Table 5.4. 
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Figure 5.5: Confirmation of all THP-1 knockdown cell lines 
RNA from THP-1 cell lines were extracted and cDNA generated. qPCR was 
performed on knockdown THP-1 cells lines for the following genes; ACSL3 (A), 
ATP13A1 (B), CALR (C), CD63 (D), CYP27A (E), ERO1L (F), FKBP5 (G) and 
SAMHD1 (H). Data was normalised to GAPDH transcript levels (n=3). Values were 
represented as % of THP-1 wildtype expression (n=3). SD were plotted based on 
triplicate values. ** p≤ 0.01  **** p≤ 0.0001. One way ANOVA was used for 
statistical analyses. 
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Figure 5.6: Confirmation of finalised THP-1 knockdown cell lines 
RNA from THP-1 cell lines were extracted and cDNA generated. qPCR was 
performed on knockdown THP-1 cells lines for the following genes; ACSL3 (A), 
ATP13A1 (B), CALR (C), CD63 (D), CYP27A (E), ERO1L (F), FKBP5 (G) and 
SAMHD1 (H). Data was normalised to GAPDH transcript levels (n=3). Values were 
represented as % of THP-1 scrambled expression (n=3). SD were plotted based on 
triplicate values. ** p≤ 0.01 *** p≤ 0.001   **** p≤ 0.0001. One way ANOVA was 
used for statistical analyses. 
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5.3.4. THP-1 Knockdown Cell Lines did not Significantly enhance HIV-1 
in their Undifferentiated Form 
Undifferentiated knockdown THP-1 cell lines were investigated whether 
enhancement of HIV-1 infection could occur in the absence of Vpx exposure. Briefly, 
each gene of interest knockdown and wild type THP-1 cells were infected with 
replication defective HIV-1 GFP. At 3 dpi, the cells were fixed and the percentage of 
GFP positive cells was analysed using flow cytometry. HIV-1 infection levels did not 
significantly change for any knockdown THP-1 cell line (Figure 5.7). The SAMHD1 
knockdown THP-1 cell line showed the largest increase in infection of 2-fold. The 
second largest increase in HIV-1 infection was seen in the CALR knockdown, 
representing a 1.6 fold increase. Undifferentiated THP-1 cells exposed to Vpx 
marginally increased infection by 1.26-fold. This correlates with previous data that 
undifferentiated THP-1 cells are not sensitive to Vpx exposure (304). 
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Figure 5.7: HIV-1 challenge experiment for undifferentiated knockdown THP-1 
cells lines 
Unstimulated THP-1 cells lines were challenged with HIV-1 GFP. At 3 dpi, cells 
were fixed and analysed using flow cytometry. From the live population, the 
percentage of GFP positive cells were calculated. SD was plotted based of three 
replicates (n=3). The horizontal line was set at the mean value of THP-1 wild type 
infection. 
 
 
5.3.5. Differentiated CALR and FKBP5 Knockdown THP-1 Cell Lines 
Enhance HIV-1 Infection Similar to the SAMHD1 THP-1 
Knockdown 
Differentiated THP-1 knockdown cell lines were investigated whether enhancement 
of HIV-1 infection could occur in the absence of Vpx exposure. Varying 
concentrations of PMA were used for this experiment to investigate whether a 
differing macrophage like phenotype could alter the profile of gene knockdowns that 
potentially increase HIV-1 infection. Briefly, THP-1 knockdown cell lines and THP-1 
wild type cells were differentiated for 24 hrs with 80 ng/mL, 120 ng/mL or 160 
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ng/mL of PMA. Medium was replaced with fresh RF-10 and then infected with MOI 
0.1 HIV-1-GFP. At 3 dpi, the nuclei of live cells were stained with NucBlue and 
imaged on the Cytell. The number of GFP positive cells and nuclei were counted for 
each condition using the Cell Investigator software. As expected, across all PMA 
concentrations a significant increase in HIV-1 infection was observed for the Vpx 
stimulated wild type THP-1 cells and SAMHD1 THP-1 knockdown cell line (304, 
306). Upon Vpx stimulation, HIV-1 infection increased by 2.9 fold  (Figure 5.8(A); 
p≤0.0001; n=9), 3.3 fold (Figure 5.8(B); p≤0.0001; n=9) and 2.8 fold (Figure 5.8(C); 
p≤0.0001; n=9) for the PMA concentrations 80 ng/mL, 120 ng/mL or 160 ng/mL, 
respectively. The SAMHD1 THP-1 knockdown cell line increased HIV-1 infection by 
2.1 fold (Figure 5.8(A); p≤0.01; n=9), 2.2 fold (Figure 5.8(B); p≤0.01; n=9) and 2.1 
fold (Figure 5.8(C); p≤0.01; n=9) for the PMA concentrations 80 ng/mL, 120 ng/mL 
or 160 ng/mL, respectively. The CALR THP-1 knockdown cell line significantly 
increased HIV-1 infection across all PMA concentrations, with a 2.2 fold (Figure 
5.8(A); p≤0.01; n=9), 2.1 fold (Figure 5.8(B); p≤0.01; n=9) and 1.8 fold (Figure 
5.8(C); p≤0.05; n=9). Further, the FKBP5 THP-1 knockdown cell line significantly 
increased HIV-1 infection at the highest concentration of PMA, with 1.9 fold (Figure 
5.8(C); p≤0.05; n=9) observed at 160 ng/mL PMA. 
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Figure 5.8: HIV-1 infection experiments for PMA stimulated knockdown THP-1 
cells lines 
THP-1 cells lines were differentiated with either 80 ng/mL, 120 ng/mL or 160 ng/mL 
of PMA and infected with HIV-1 GFP. At 3 dpi, the nuclei were live-stained with 
NucBlue before being imaged with the Cytell. Infected cells for each condition was 
normalised to the nuclei sum and represented as a percentage value. SD were plotted 
based on nine replicates (n=9). The Kruskal-Wallis test was used for statistical 
analysis * p≤ 0.05 **p≤ 0.01  **** p≤ 0.0001. Values were compared to THP-1 
scrambled. For each PMA concentration, the horizontal line is set the mean value of 
THP-1 scrambled infection. 
 
5.3.6. Examining Protein Levels of SAMHD1, Calreticulin and FKBP51 
Post-Vpx Exposure; Short and Long Term 
The gene knockdowns that significantly increased HIV-1 infection, CALR, FKBP5 
and SAMHD1, were selected for further investigation. In Chapter 4, the proteomic 
experiments were conducted on macrophages and dendritic cells, which were exposed 
to Vpx for 24 hrs. The original protein target list was generated from only primary 
macrophages, as the cell line used to generate the panel of stable knockdown or over 
expressions was the macrophage like THP-1 cell line. As the phenotypes from the 
knockdowns were observed in the THP-1 cell line, primary macrophages and 
 148 
dendritic cells were used to further investigate CALR, FKBP5 and SAMHD1. The 
genes CALR, FKBP5 and SAMHD1 encode for the following proteins; calreticulin 
(CRT), FKBP51 and SAMHD1, respectively. All three proteins were down-regulated 
at 24 hrs post Vpx exposure. However, the long term abundances for CRT and 
FKBP51 have not been determined. Therefore, western blots for all three proteins 
were conducted on primary macrophages (MDMs) and dendritic cells (MDDCs). The 
SAMHD1 protein acting as a known control, since the abundance of SAMHD1 short 
and long term post Vpx exposure has been established in Chapter 3 (section 3.3.2 and 
section 3.3.3). The time points 1, 7 and 14 dps were used to determine the protein 
abundances for the three proteins.  
As expected, for both macrophages and dendritic cells significant reduction in 
SAMHD1 levels was observed. The greatest reduction was 98% (Figure 5.9(A); 
p≤0.001; n=3) and 99.9% (Figure 5.9(B); p≤0.05; n=3) for macrophages and dendritic 
cells, respectively. CRT showed no significant change in abundance post Vpx 
exposure. When compared to their relevant negative control for macrophages and 
dendritic cells, the greatest reduction observed was 5.8% (Figure 5.9(C) 7 dps; p=ns; 
n=3), 15.5% (Figure 5.9(D) 7 dps; p=ns; n=3), respectively. Present in the western 
blots of all macrophage samples, a separate 75 kDa band was noticed, which was 
substantially decreased in the Vpx stimulated samples, reflecting the change observed 
in the proteomic study (Figure 5.10). The separate 75 kDa band has also been 
detected in membrane anchored CRT samples in a study conducted by Wada and 
colleagues (436). 
FKBP51 showed no significant change in abundance post Vpx exposure. When 
compared to their relevant negative controls for macrophages and dendritic cells the 
greatest reduction in protein abundance was 41.1% (Figure 5.9(E) 7 dps; p=ns; n=3) 
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and 72.8% (Figure 5.9(F) 7 dps; p=ns; n=3). Interestingly, in the macrophage 
samples, the protein abundance of FKBP51 increased over time in the negative 
control, while in the dendritic cell culture, FKBP51 decreased over time, indicating a 
cell-type specific response. 
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Figure 5.9: Western blot analysis of Calreticulin, FKBP51 and SAMHD1 in 
Vpx stimulated macrophages, and dendritic cells 
Macrophages and dendritic cells were stimulated with VLPs in the presence or 
absence of Vpx. At 1, 7, and 14 dps cells were harvested for western blot analysis and 
probed for SAMHD1 (A, B), Calreticulin (C, D) and FKBP51 (E, F). Three biological 
replicates were performed for each cell type. Data was represented as arbitrary units 
normalised to GAPDH. SD were plotted based on the three replicates with one 
representative western blot is shown for each condition. 
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Figure 5.10: Densitometry analysis of 75 kD band present in Calreticulin 
probed western blots 
Macrophages were stimulated with VLPs in the presence or absence of Vpx. At 1, 7, 
and 14 dps cells were harvested for western blot analysis and probed for Calreticulin. 
Data was represented as arbitrary units normalised to GAPDH. Two donors are 
represented. 
 
5.4. Discussion 
To investigate whether any of the protein targets identified in Chapter 4 were capable 
of enhancing HIV-1 infection, a panel of knockdown/over expression THP1 cells 
lines were generated. The transduced THP-1 cells lines expressing genes for CCT6, 
PARK7 and SH3BGRL3 did not successfully increase target gene expression. 
Furthermore, compared to THP-1 cells transduced with the parent plasmid LVX-
mCherry-N1, significant inhibition of HIV-1 infection was observed for each cell line. 
This was perplexing for two reasons. Firstly, the proteomics data showed at 24 hrs 
post Vpx exposure, macrophages increased the abundance of CCT6, PARK7 and 
SH3BGRL3 proteins. Therefore, we hypothesised increased expression of the target 
protein would either increase or have no effect on HIV-1 infection. Secondly, the 
PARK7 transduced THP-1 cell line, which showed no over expression of the PARK7 
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transcript, restricted HIV-1 the least. Therefore, no valid conclusions could be 
determined from the over expression in THP-1 cells lines. We hypothesise the 
generation of all three transduced cell lines mediated an antiviral response against the 
expressed gene. This firstly caused the transcript to be degraded and secondly 
rendered the cells refractory to HIV-1 infection. Interferon (IFN) modulation of 
microRNAs (miRNAs) have been documented in response to lentiviral infection 
(437). Furthermore, post IFN-α treatment, both undifferentiated and differentiated 
THP-1 cells become refractory to HIV-1 infection (438). It could be possible that the 
miRNA pathway degraded the CCT6, PARK7 and SH3BGRL3 transcripts and not the 
mCherry mRNA, as it is foreign to the THP-1 cells. However, if IFN-α and other 
ISGs were being expressed in undifferentiated THP-1 cells, the antiviral response 
would carry over during PMA differentiation. So why do transduced THP-1 mCherry 
cells show almost equivalent HIV-1 infection levels to THP-1 WT cells? Further 
examination is required to elucidate the mechanism of why inefficient expression and 
subsequent inhibition of HIV-1 infection is occurring within the cell lines. These 
studies would include measuring type I interferon in the THP-1 transduced cell lines 
or investigating known interferon stimulated genes (ISGs), such as interferon 
regulatory factor I (IRFI) (439). Alternatively, generation of stable cell lines utilising 
the single cell cloning method could be employed. This would generate a monoclonal 
population of THP-1 cells, which could potentially be more definitive in the 
expression of the target genes. Indeed, a previous study by Bonifati and colleagues 
has successfully overexpressed SAMHD1 in THP-1 cells, using the LVX plasmid and 
clonally sorting them (440). 
The generation of knockdown THP-1 cells lines efficiently reduced the expression of 
their respective gene targets. The smallest reduction of 49.9% was observed for the 
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transduced CD63 knockdown THP-1 cell line. In their undifferentiated state, the panel 
of THP-1 knockdown cell lines did not significantly enhance or restrict HIV-1 
infection compared to THP-1 WT. The greatest increase in HIV-1 infection was 
observed in the SAMHD1 and CALR knockdown cell lines. Previous studies have 
demonstrated that in the absence of SAMHD1, THP-1 cells have an increased 
susceptibility to HIV-1 infection (306). The gene CALR that encodes the protein CRT 
has not been documented to increase HIV-1 infection.  
Differentiated THP-1 cell lines were also investigated to determine whether one of the 
gene knockdowns could independently enhance HIV-1 infection. The panel of 
knockdown THP-1 cell lines were differentiated with varying concentrations of PMA 
to reflect different stages of macrophage differentiation. As expected, across all PMA 
concentrations Vpx stimulated WT and SAMHD1 knockdown THP-1 cells showed 
the greatest increase in HIV-1 infection. The knockdown THP-1 cell line for CALR 
also showed an increase in HIV-1 infection across all PMA concentrations. 
Additionally, the FKBP5 knockdown cell line showed a significant increase in HIV-1 
infection, however only at the highest concentration of PMA. Multiple studies have 
been conducted to investigate host cell genes linked to HIV-1 replication (441-444). 
Interestingly, none of these studies identified CALR or FKBP5 genes to enhance 
HIV-1 infection. 
The three gene targets CALR, FKBP5 and SAMHD1, that significantly increased 
HIV-1 infection, were selected for further investigation. Follow up protein 
experiments were conducted in primary macrophages and dendritic cells to 
investigate the protein abundances over short and long term exposures to Vpx. As 
expected the protein abundance of SAMHD1 in both macrophages and dendritic cells 
was substantially reduced at all time points.  
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The protein FKBP51 showed no significant change in abundance post-Vpx exposure. 
In dendritic cells, the FKBP51 protein decreased during the culturing of the cells. 
Large scatter was also present across all time points, indicating varied levels of 
protein across biological donors. There are a few reasons as to why the proteomic data 
did not correspond to the western blot data. Firstly, different biological replicates 
were used. As demonstrated in the western blot data, the abundances of FKBP51 are 
quite varied. Secondly, proteomic methods are more sensitive compared to western 
blots. Thirdly, different cell lysis methods were used for each method, with 
proteomics utilising a sonicator which would lyse cells more efficiently compared to 
the detergent used in the western blot method. The main function of FKBP51 is to act 
as a chaperone to Hsp90, regulating steroid hormone receptor (SHR) activity through 
its peptidyl prolyl isomerase (PPIase) domain (445). The majority of studies 
investigating FKBP51 are connected with oncology. Cancer cells with depleted 
FKBP51 have increased chemoresistance, hypothesised to occur through the Akt 
pathway (446). FKBP51 has also been shown to associate with mTORC2 
(mechanistic target of rapamycin complex 2), which is one of the two complexes that 
the therapeutic agent rapamycin inhibits. Rapamcyin has both immunosuppressant 
and anti-tumour properties (447) and has recently been established to enhance 
lentiviral transduction in human and mouse hematopoietic stem cells (448). The 
depletion of FKBP51 could render the cells more susceptible to HIV-1 infection in a 
similar manner to rapamycin treatment. 
In macrophages and dendritic cells, CRT protein abundance also did not significantly 
change post-Vpx exposure, short or long term. Large scatter was present across all 
time points, for macrophages and dendritic cells indicating that between biological 
replicates, a vast change in CRT abundance occurred. However, present in the 
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macrophage western blots, a separate 75 kDa band was noticed, which was 
substantially decreased in the Vpx stimulated samples, reflecting the change observed 
in the proteomic study. A study by Zhu and colleagues had demonstrated the presence 
of different CRT isoforms, one of which was a 75 kDa protein, associated with focal 
contacts and plasma membrane (449). Nonetheless, the gene CALR (CRT), once 
depleted in THP-1 cells, significantly enhanced HIV-1 infection.  
CRT is a multifaceted protein and is highly conserved across specifies, from protozoa 
to mammals (450). CRT contains an ER-retention signal, KDEL and mainly resides in 
the lumenal endoplasmic reticulum (ER) (451, 452). Studies have also shown CRT to 
be present at the plasma membrane (453, 454) as well as extracellularly (455). In the 
ER, CRT acts as a chaperone (456-458) and is involved in Ca2+ signalling (459, 
460). Extracellularly, CRT has been shown to bind to C1q, which is involved in the 
classical complement pathway to clear immune complexes. Upon binding, CRT 
prevents the activation of the complement pathway (455). At the plasma membrane, 
CRT (ecto-CRT) initiates the clearance of apoptotic cells (461). A loss of any of these 
functions could affect the cells HIV-1 susceptibility. In particular, ecto-CRT has been 
shown to facilitate immunogenic cell death (ICD) and is currently considered a 
common danger associated molecule (DAMP) for presented on cancer cells (462-
465). In the context of SIV/HIV-1 infection, the down regulation of ecto-CRT could 
be another Vpx mediated early host evasion, whereby Vpx exposed cells avoid ICD. 
To further investigate the 75 kDa CRT band observed in the western blot, the mass 
spectrometry based multiple reaction monitoring (MRM) could be utilised. This 
method allows targeted quantitation of peptide abundances in complex biological 
samples. The same CRT peptide sequences quantified in the proteomic experiment, 
can be specifically isolated and quantitated in the mass spectrometer. This approach 
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will allow for greater sensitivity and quantitation of the peptide of interest (466). 
Samples harvested from 1, 7 and 14 dps can be analysed to determine the short and 
long term abundance of CRT. SAMHD1 can also be analysed, which can serve as a 
control, since the short and long term abundances have already been established. 
Further experiments are required to evaluate the importance of FKBP5 and CALR in 
HIV-1 biology. To elucidate which part of the HIV-1 replication cycle FKBP5 and 
CALR effects, ToA assays can be conducted using antiretrovirals that inhibit entry, 
RTn and integration. The FKBP5 and CALR THP-1 KD cells lines would be 
compared to THP-1 scrambled and THP-1 SAMHD1 KD. Over expression cell lines 
of FKBP5 and CALR could also be produced to determine whether an increase in the 
protein could inhibit HIV-1 infection. Fluorescent microscopy experiments could be 
performed on CALR THP-1 KD cell lines to determine the cellular location/s of CRT 
that is contributing to enhancing HIV-1 infection. 
In summary, a panel of knockdown/over expression THP-1 cells lines were generated 
from a list of cellular proteins, which were modulated in macrophages 24 hrs post 
Vpx exposure. For the first time, two genes, FKBP5 and CALR were discovered to 
significantly increase HIV-1 infection, in the absence of Vpx.  
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5.5. Supplementary Figures 
 
(A) 
CCT6 
AAAATTGCGTGGAGCGGCACCGGATCCATGGCGGCGGTCAAAACACTCA
ACCCTAAAGCTGAGGTCGCACGCGCTCAAGCAGCTCTCGCGGTGAATATA
AGCGCAGCTAGGGGGCTCCAGGATGTGTTGCGCACAAATTTGGGGCCAAA
AGGGACAATGAAGATGCTGGTCTCCGGAGCCGGTGACATTAAGCTGACAA
AGGACGGAAACGTGTTGCTGCACGAGATGCAAATCCAGCATCCGACCGCC
TCCCTGATCGCAAAAGTCGCCACCGCGCAAGACGACATCACTGGGGATGG
CACCACCAGTAATGTCTTGATCATCGGTGAGCTGTTGAAGCAAGCCGATC
TGTACATTTCAGAGGGACTGCACCCCCGAATCATCACAGAAGGATTCGAG
GCTGCCAAAGAGAAGGCTCTTCAGTTTCTGGAAGAAGTGAAAGTATCTCG
GGAGATGGACAGAGAGACCCTGATTGATGTGGCACGGACCAGCTTGCGG
ACCAAAGTGCACGCTGAGCTGGCCGATGTGCTGACCGAAGCCGTGGTTGA
TAGCATCCTCGCGATAAAGAAGCAAGATGAACCGATTGATTTGTTTATGA
TCGAGATCATGGAAATGAAGCATAAAAGCGAAACCGACACTTCCCTTATT
AGGGGACTGGTGCTTGATCATGGAGCACGGCACCCTGATATGAAGAAGCG
CGTAGAAGATGCCTACATTCTCACATGCAATGTGTCCCTGGAATATGAGA
AGACAGAAGTAAATAGTGGCTTCTTTTACAAATCCGCGGAAGAACGCGAG
AAATTGGTGAAAGCAGAGAGGAAGTTTATAGAGGACCGGGTGAAGAAGA
TCATCGAACTGAAAAGAAAGGTGTGCGGAGATAGCGATAAAGGATTTGTC
GTGATTAATCAGAAGGGCATAGATCCCTTTTCCTTGGATGCACTTAGCAA
GAAGGCATCGTAGCTTTGCGCCGGGCAAAGAGAAGAAATATGGAGCGCC
TTACACTGGCTTGCGGTGGAGTGGCACTCAACAGCTTCGATGACCTGAGT
CCAGATTGTCTGGGCCATGCCGGTCTGGTGTATGAGTATACCCTGGGTGA
AGAGAAGTTTACTTTCATCGAGAAGTGTAATAATCCCCGGTCCGTAACCC
TCCTGATTAAAGGCCCCAATAAACATACACTGACACAGATCAAGGATGCC
GTGCGCGATGGACTGCGCGCTGTCAAAAATGCTATCGACGACGGGTGCGT
CGTGCCAGGCGCCGGGGCAGTAGAGGTGGCTATGGCTGAGGCGCTGATCA
AGCACAAGCCCTCAGTGAAAGGCCGGGCGCAACTGGGGGTACAGGCTTTC
GCGGATGCTCTGCTGATTATACCCAAAGTGCTCGCCCAGAATAGCGGATT
TGACTTGCAGGAGACCCTGGTCAAGATCCAAGCGGAGCACAGTGAATCAG
GACAGCTCGTTGGCGTGGATCTGAACACTGGTGAGCCAATGGTGGCCGCA
GAAGTGGGAGTGTGGGATAATTACTGCGTAAAGAAGCAGCTGCTTCATTC
TTGCACAGTGATTGCTACCAATATTCTGCTTGTAGACGAAATCATGAGGG
CCGGTATGTCTTCTTTGAAAGGTTAATCTAGAGTTGCGCTGGCAAATGTTC
AC1649 
 
(B) 
GLOD4 
AAAATTGCGTGGAGCGGCACCGGATCCATGGCAGCGCGCCGGGCTCTTCA
CTTCGTCTTTAAAGTTGGTAACCGATTTCAGACTGCAAGATTCTACCGCGA
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CGTTCTGGGAATGAAAGTGCTGCGACACGAAGAATTCGAGGAAGGATGC
AAGGCTGCATGCAATGGCCCCTACGACGGCAAATGGTCAAAGACTATGGT
GGGATTTGGCCCTGAGGACGATCACTTTGTGGCAGAGCTGACCTATAATT
ATGGCGTCGGCGATTACAAGCTTGGGAATGACTTTATGGGAATCACACTG
GCCAGTTCTCAAGCCGTAAGTAACGCTCGGAAACTCGAATGGCCACTGAC
GGAGGTCGCCGAAGGGGTGTTCGAGACCGAAGCACCGGGCGGCTACAAG
TTCTATCTTCAGAATCGGAGCCTGCCGCAGAGCGACCCAGTGCTCAAAGT
GACTCTGGCAGTCTCTGACCTTCAGAAGAGTCTTAACTACTGGTGCAACTT
GCTCGGCATGAAAATCTATGAAAAAGACGAAGAAAAGCAGAGAGCCCTT
CTGGGATACGCTGATAATCAATGCAAACTGGAGCTCCAAGGAGTGAAGG
GGGGCGTCGATCACGCCGCCGCCTTCGGCAGGATCGCCTTCAGCTGTCCA
CAGAAAGAACTTCCGGACTTGGAGGACCTCATGAAAAGGGAGAACCAGA
AAATCCTTACTCCTCTCGTGTCCCTCGACACACCGGGAAAAGCAACCGTC
CAGGTAGTGATCTTGGCCGATCCAGATGGCCATGAGATATGCTTCGTCGG
CGATGAGGCCTTCAGGGAGTTGTCCAAAATGGACCCCGAAGGCTCTAAGC
TGCTCGATGATGCAATGGCTGCAGACAAATCTGACGAATGGTTCGCCAAA
CACAACAAACCAAAAGCGTCCGGTTGATCTAGAGTTGCGCTGGCAAATGT
TCAC951 
 
(C) 
PARK7 
AAAATTGCGTGGAGCGGCACCGGATCCATGGCAAGCAAACGCGCACTGG
TTATTTTGGCCAAGGGAGCAGAAGAAATGGAGACGGTGATCCCAGTGGAC
GTTATGCGCCGGGCTGGAATCAAGGTAACAGTAGCCGGCCTCGCCGGTAA
GGACCCCGTTCAGTGTTCTCGAGACGTAGTGATTTGCCCTGACGCTAGCCT
CGAGGATGCAAAAAAAGAGGGCCCTTACGACGTAGTGGTGCTGCCAGGT
GGGAATTTGGGCGCCCAGAATCTGAGTGAAAGCGCCGCAGTCAAGGAGA
TTCTTAAGGAACAAGAGAATAGAAAAGGTCTGATAGCTGCCATTTGTGCA
GGTCCTACAGCTCTCCTCGCCCATGAAATTGGATTCGGCAGTAAGGTGAC
CACGCACCCTTTGGCAAAGGACAAGATGATGAATGGGGGCCATTACACCT
ATAGTGAGAACCGGGTCGAAAAGGACGGTCTGATCCTGACTAGCAGAGG
TCCCGGAACGTCTTTTGAGTTTGCCCTGGCAATTGTGGAGGCCTTGAATGG
TAAGGAAGTTGCTGCGCAGGTTAAAGCCCCACTGGTGCTTAAAGACTAGT
CTAGAGTTGCGCTGGCAAATGTTCAC624 
 
(D) 
SH3BGRL3 
AAAATTGCGTGGAGCGGCACCGGATCCATGTCTGGGCTCAGAGTGTATTC
CACGAGCGTCACCGGTTCGAGGGAGATCAAATCTCAGCAGTCCGAAGTGA
CGAGAATCTTGGACGGAAAAAGGATTCAGTATCAACTGGTTGACATTTCT
CAGGACAACGCATTGCGGGACGAGATGCGCGCGCTGGCTGGTAATCCAA
AAGCCACGCCCCCCCAGATTGTCAATGGAGATCAATACTGCGGCGATTAC
GAGCTCTTCGTCGAAGCCGTGGAACAGAACACACTCCAGGAATTTCTGAA
ACTTGCCTAGTCTAGAGTTGCGCTGGCAAATGTTCAC336 
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Supplementary Figure 5.1: Nucleotide sequences for gBlock gene fragments 
(Integrated DNA Technologies, Coralville, IA, United States). The CDS region 
for each gene of interest is flanked by common 5’ and 3’ adapters. Presented in 5’ – 
3’ format. Total length is indicated following the final base 
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CHAPTER SIX: GENERAL DISCUSSION 
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6. General Discussion 
The current treatment strategy for HIV-1 has successfully depleted plasma viral load 
to almost undetectable levels (<50 copies/mL) (320-322). However, if treatment is 
interrupted HIV-1 rebounds rapidly (323, 324). Consequently, patients are required to 
continue ART for the rest of their lives. The presence of viral reservoirs throughout 
the body harbour latent replication-competent virus and support low levels of 
replication. Resting CD4+ T cells, macrophages and dendritic cells contribute to the 
persistence of HIV-1 and are present in multiple anatomical sites (165, 170, 376, 
377). The latent HIV-1 reservoir represents a major hurdle towards eradication of 
HIV-1. Antiretroviral therapy is unable to impact upon this reservoir and thus a more 
targeted approach is required. One method of achieving this is through LV gene 
therapy.  
However, efficient delivery with current LV vectors is limited, primarily due to 
inefficient RTn of genetic constructs, resulting in poor integration and gene 
expression (387). A cellular protein, SAMHD1, has been established as the HIV-1 
restriction factor responsible for inefficient gene delivery in resting cells, such as the 
latent HIV-1 reservoir (305, 306). A viral protein called Vpx, encoded by the Sooty 
Mangabey SIV (SIVSM) and HIV-2 lineages has been shown to alleviate SAMHD1 
mediated HIV-1 restriction (305, 306). Experiments revealed Vpx degrades SAMHD1 
through proteasomal dependent degradation (298, 300, 388). This phenotype supports 
the future use of Vpx in the context of LV gene therapy vectors and DC-based 
vaccines (306, 366-369). Whilst this has immense potential in gene therapy strategies 
for an HIV-1 cure, the effects of introducing Vpx into an HIV-1 positive individual in 
vivo/ex vivo are not known. This needs to be carefully considered since the positive 
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effect Vpx has on RTn for lentiviral gene therapy vectors would also affect existing 
HIV-1 infected cells. Previous studies have examined the effect Vpx has on LV gene 
transduction (366-368, 467). However, none have investigated the effectiveness of 
Vpx to restrict HIV-1 infection when incorporated into anti-HIV gene therapy LV 
vectors. The main focus of this thesis was to examine the feasibility of incorporating 
Vpx into LV vectors to target the latent HIV-1 reservoir. We sought to characterise 
the following unknown questions: 
1. What short and long term effects does Vpx have on: 
o Its ability to enhance gene transduction/HIV-1 infection? 
o The efficacy of antiretroviral drugs inhibiting RTn (NRTI or NNRTI) 
and integration? 
 
2. Would there be differences in HIV-1 protection if Vpx were incorporated with anti- 
HIV genes that inhibited HIV-1 infection pre- or post-RT? 
 
3. Are hidden phenotypes occurring post-Vpx exposure, which could affect the usage 
of Vpx in clinical protocols? 
 
4. Do any significant protein changes that occur post-Vpx exposure have the 
capability to enhance HIV-1 infection, to a similar extent of SAMHD1 depletion? 
 
The first two questions were addressed in Chapter 3. Our results showed Vpx 
exposure increased lentiviral RTn and integration kinetics. Furthermore, increased 
permissiveness of cells to HIV-1 infection was observed over a period that exceeded 
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two weeks. Consequently, significant lowered potency of HIV-1 antiretrovirals 
inhibiting RTn and integration were detected. The Vpx-mediated decreased efficacy 
of the antiretroviral drugs has been documented in other studies for short term Vpx 
exposure (395, 396, 468, 469). This chapter has built upon these findings and 
established that Vpx affected antiretrovirals, both in the short and long term post-Vpx 
exposure. When Vpx was incorporated with anti-HIV genes inhibiting either pre-RTn 
(Cal-1) or post-RTn (shPromA) stages of the viral life-cycle, transduction levels 
significantly increased. However, a stronger antiviral effect was only observed with 
constructs that inhibit pre-RTn stages of the viral life cycle. This result is of great 
importance, as Cal-1 is currently undergoing Phase I/II trials in the United States of 
America and has been used in a humanised mouse model and non-human primate 
studies (348, 397, 398).  
The long term enhancement after Vpx stimulation observed in resting cells may 
restrict the use of this accessory protein to only pre-RTn gene therapy approaches.  
Decreasing the window of opportunity to enhance lentiviral RTn and integration 
kinetics would expand the use of Vpx in gene therapy protocols. One study observed 
Vpx is rapidly degraded in the cell through the proteasomal pathway (392). Therefore, 
it could be hypothesised that the long term phenotype is due to an interaction with a 
host protein. This interaction may not necessarily be SAMHD1, as a study by 
Hollenbaugh and colleagues have shown that post-Vpx treatment, the rate of 
SAMHD1 recovery and dNTP depletion does not correlate (408). Further 
investigation into how Vpx modulates a cell for enhanced gene transduction in 
required. Currently, immunoprecipitation of Vpx in THP-1 cells constitutively 
expressing tagged-Vpx is the only analysis of host cell interactions (306). This was an 
important study, as SAMHD1 was identified as a HIV-1 restriction factor, however 
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immunoprecipitation is a targeted approach and cannot reveal any hidden phenotypes. 
A hidden phenotype (off target effects) could have detrimental or beneficial effects 
for Vpx incorporation into clinical protocols. 
This notion drove the aims of Chapter 4, which addressed question three. Proteomics 
was used to analyse the protein expression patterns post Vpx exposure. This powerful 
tool elucidated functional protein networks, which did not highlight any detrimental 
pathways such as the stress-activated nuclear factor-κβ (NFκβ), mitochondrial 
controlled apoptosis or mitogen-activated protein kinases (MAPK) (426). Further to 
this, selection criteria were applied to generate a list of protein targets, which 
significantly changed post Vpx exposure. The protein targets were used to generate a 
panel of stable cells lines to investigate whether the individual protein targets could 
enhance HIV-1 infection in the absence of Vpx. Chapter 5 described these 
experiments which covered question four. The panel of knockdown/over expression 
THP-1 cells lines revealed two genes, FKBP5 and CALR that significantly increased 
in HIV-1 infection, in the absence of Vpx. Both genes have not been previously 
documented to enhance HIV-1 infection, despite multiple studies investigating host 
cell genes linked to HIV-1 replication (441-444). The discovery of two novel intrinsic 
HIV-1 restriction factors highlights the possibility that Vpx may be overcoming 
multiple restriction factors to enhance HIV-1 infection. Further characterisation of 
these host-encoded restriction factors are required to elucidate the mechanism of how 
these proteins, FKBP51 and CRT, can enhance HIV-1 infection.  Insight into the 
latter protein CRT, may indeed be related to its role as a “danger” signaling molecule 
with depletion of surface CRT representing a novel Vpx driven viral evasion strategy 
shortly after infection. Indeed, there is a wealth of evidence that supports surface 
expression of CRT to represent an “eat me” signal for phagocytes to attack cells, 
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especially in the context of leukemias and other cancers. Whilst this would be another 
mechanistic means that would aid SIV and/or HIV 2 pathogenesis, the use of Vpx in 
lentiviral vectors may be crucial in avoiding virally induced apoptosis in cells that 
would have otherwised been genetically modified for HIV protection.  
The HIV-1 latent reservoir predominantly consists of resting memory CD4+ T cells 
(167-169). Therefore it is crucial to successfully transduce these cells for an effective 
gene therapy strategy. However, resting CD4+ T cells are notoriously difficult to 
efficiently transduce with LV constructs. This is the main reason why this thesis 
utilised primary macrophages (MDMs) and dendritic cells (MDDCs) as a resting cell 
model for experiments. The envelope of choice for most gene therapy vectors is 
Vesicular Stomatitis Virus glycoprotein (VSVg) because they can infect most cells 
and are particularly stable, allowing concentration of lentivirus (470, 471). Resting 
CD4+ T cells do not express the LDL receptor VSVg uses for entry, therefore VSVg 
pseudotyped LV vectors have limited fusionogenic activity (472, 473). To bypass this 
restriction, our laboratory has been working on a novel targeted approach, utilising 
HIV-1 envelope to selectively transduce CD4 expressing cells. A dual tropic HIV-1 
envelope from the Spln7 isolate (474), has been demonstrated to efficiently enter 
resting CD4+ T cells (Andrew Wong, unpublished data). We hypothesise, 
pseudotyping Vpx containing LV vectors with the Spln7 envelope would overcome 
both the entry and RTn restriction present in resting CD4+ T cells. Indeed, a previous 
study by Geng and colleagues has shown increased transduction of resting CD4+ T 
cells in the presence of Vpx (368). Experiments incorporating Vpx into Spln7 
pseudotyped anti-HIV gene therapy vectors are currently underway and are 
importantly confirming many of the results pioneered in our macrophage and 
dendritic cells experiments. 
 166 
For additional safety, clinical protocols require a third-generation lentiviral system. 
All the experiments carried out in this thesis involved a second-generation lentiviral 
system. For production of Vpx containing lentivirus, four plasmids were used. Firstly, 
a packaging plasmid, which contains the Vpx packaging motif and encodes Gag, Pol, 
Rev and Tat genes. Secondly, an expression plasmid, which encodes viral LTRs and 
the psi packaging signal. Thirdly, an envelope plasmid encoding a specific 
glycoprotein eg. VSVg. Lastly, the Vpx encoding plasmid. The third generation 
system improved the biosafety of the previous system by placing the Gag/Pol genes 
and Rev gene on separate plasmids (475). Employing the third generation lentiviral 
system requires optimisation of lentivirus transfection protocols to accommodate 
another plasmid. This is quite achievable as Vpx has previously been successful 
incorporated into a third generation LV system (369). 
A dual gene therapy approach would have the greatest effect on HIV-1 infected 
patients. For example, dual utilisation of Cal-1 (pre-RT) would protect against HIV-1 
infection, and shPromA (post-RT) would to stabilize the latent reservoir. Furthermore, 
incorporating Vpx into LV vectors would also successfully transduce the latent 
reservoir. For uninfected cells, prevention of HIV-1 entry would be driven through 
the expression of Cal-1. For infected cells, expression of shPromA would restrict 
HIV-1 reactivation and additionally, Cal-1 would prevent any potential superinfection 
and subsequent enhancement of HIV-1 replication because of the presence of Vpx. 
Multiple expression of anti-HIV genes can be efficiently expressed in the same LV 
plasmid, if different promoters were used to drive each anti-HIV gene (476). 
Currently, a plasmid containing both Cal-1 and PromA has been generated in our 
laboratory and plans for humanised mouse models investigations are currently in 
progress. 
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The incorporation of Vpx protein into gene therapy vectors would also be beneficial 
in facilitating gene therapy protocols targeting resting cells, as Vpx mediates an 
increase in both RTn and integration kinetics alongside a significant increase in 
overall gene delivery. These effects could help in two key ways. Firstly, scaling up to 
generate Good Manufacturing Practice (GMP)-compliant lentivirus batches for 
clinical trials would be economically more feasible. Since substantially less lentivirus 
would be required to achieve equivalent transduction rates a reduced number of 
batches for high-titer vector preparations would be required. Typically, an MOI of at 
least 1 is used in clinical protocols, which is at least 5 times more compared to our 
protocols (348, 398, 405). As a result, the total number of time-consuming, rigorous 
batch tests can be reduced, as less overall lentivirus will be required for protocols. 
Additionally, using less lentivirus to achieve equivalent transduction rates would 
decrease the likelihood of toxicity, inflammation or immune responses observed in 
vivo (406, 407). Secondly, the time required to generate transduced cells for re-
infusion could be decreased, as significantly less time is needed for successful gene 
expression due to the increase in RTn and integration kinetics. Finally, the majority of 
gene therapy protocols using CD4+ and CD8+ T cells routinely require extensive 
cytokine stimulation and/or broad activation to ensure VSVg receptors are expressed 
on the surface of T cells, to enhance endocytosis and to eliminate major restrictions to 
RTn (SAMHD1 and very low dNTP levels).  What this thesis outlines is a method 
that can readily overcome the latter restrictions to RTn in resting cells. If this method 
is coupled with envelopes beyond VSVg (eg. HIV-1 or measles glycoproteins), the 
need to stimulate cells to enable transduction becomes effectively redundant, as the 
viral vector overcomes these obstacles. In the context of HIV-1 cure efforts, cells may 
indeed be isolated and immediately genetically modified ex vivo. We envisage this 
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approach, would benefit cure efforts at several levels. Firstly, the time and cost to 
genetically modify CD4+ T cells would be significantly less when cells are not 
stimulated with clinical grade cytokines or activation reagents. Secondly, we predict 
the activation status and composition of our immune system would be conserved in 
comparison to methods that uniformly activate all T cells. Indeed, recent gene therapy 
methods using CAR T cells, adverse effects have been observed in patients based on 
immunological overstimulation (477). Whilst this maybe related to the CAR T cell in 
vivo reaction, it also may relate to the same CAR T cells being continuously activated 
and expanded ex vivo prior to redelivery. Finally approaches that transcriptionally 
silence HIV-1 and lock it down at the genomic level would significantly benefit from 
approaches that keep the virus silent during the genetic manipulation stage. Whilst all 
of these advantages would be greatly beneficial for HIV-1 cure efforts using gene 
therapy, the observations within this thesis have the potential to impact gene therapy 
strategies that target other diseases. This may indeed be vaccine related, where 
antigen presenting cells are engineered ex vivo to augment immune responses in vivo. 
Or as briefly mentioned above, our approaches may indeed provide powerful 
solutions for immunotherapy protocols, substantially reducing the time required ex 
vivo for the generation of CAR T cells. 
In summary, this thesis demonstrated a way to overcome the major delivery obstacle 
presented when delivering anti-HIV genes into cells of the HIV-1 latent reservoir. 
Vpx significantly increased lentiviral delivery of anti-HIV genes, with the greatest 
anti-viral effect observed with the pre-RTn construct. The proteomic study 
investigating Vpx mediated protein expression in macrophages and dendritic cells 
furthered our understanding of how Vpx modulates the cells to enhance lentiviral 
transduction. Furthermore, it did not highlight any detrimental effects Vpx could have 
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on a cell, supporting its potential use in clinical protocols. A panel of stable cell lines 
generated from proteins targets identified in Chapter 4 discovered two novel intrinsic 
HIV-1 restriction factors. Further characterisation is required to evaluate the 
importance of these proteins in HIV-1 biology. Overall, this thesis supports the 
feasibility of utilising Vpx with gene therapy vectors. It is in a broad sense taking 
what we have observed from virology and applying it to real methods that can be 
available for the clinic. Indeed this journey has taught us that many of the obstacles in 
gene therapy can be overcome by the simple process of bio-prospecting viral 
genes/proteins to build more powerful vectors. Whilst in the present gene therapy 
protocols, we make cells work harder to be genetically manipulated, our technology 
can potentially remove this costly and potentially redundant process by placing the 
responsibility on the viral particle to do the work in the first place. As such, an 
Australian provisional patent has been filed (Application No. 2016901535) and 
ongoing work is being pursued to successfully transduce all cell types of the HIV-1 
latent reservoir. 
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Appendix 5: List of all significantly changed proteins to Vpx stimulation of Dendritic Cells at 1 dps. First biological replicate (iTRAQ1). 
Log2 ratio (+Vpx/-Vpx) and Z score are listed below 
UniProt 
Accession 
Number 
Protein Name 
Gene 
Symbol 
# peptides Log2 Ratio Z score 
P63104 14-3-3 protein zeta/delta 1433Z 3 -0.293 -2.124 
Q9Y6K5 2'-5'-oligoadenylate synthase 3 OAS3 2 0.185 1.675 
O00231 26S proteasome non-ATPase regulatory subunit 11 PSD11 2 -0.302 -2.168 
P62847 40S ribosomal protein S24 RS24 3 0.205 1.773 
P23526 Adenosylhomocysteinase SAHH 3 0.247 1.978 
Q10567 AP-1 complex subunit beta-1 AP1B1 4 -0.199 -1.591 
Q96CW1 AP-2 complex subunit mu AP2M1 2 -0.229 -1.841 
O14497 AT-rich interactive domain-containing protein 1A ARI1A 2 0.274 2.083 
 172 
P48047 ATP synthase subunit O, mitochondrial ATPO 3 -0.262 -1.978 
P30622 CAP-Gly domain-containing linker protein 1 CLIP1 2 0.174 1.531 
P16152 Carbonyl reductase [NADPH] 1 CBR1 4 -0.226 -1.817 
P07339 Cathepsin D CATD 3 -0.251 -1.892 
P08311 Cathepsin G CATG 2 0.278 2.217 
P20645 Cation-dependent mannose-6-phosphate receptor MPRD 2 0.274 2.168 
Q7LBR1 Charged multivesicular body protein 1b CHM1B 2 -0.421 -2.617 
O43633 Charged multivesicular body protein 2a CHM2A 2 -0.212 -1.657 
O00299 Chloride intracellular channel protein 1 CLIC1 4 -0.219 -1.693 
Q00610 Clathrin heavy chain 1 CLH1 5 -0.469 -2.787 
Q16630 
Cleavage and polyadenylation specificity factor 
subunit 6 
CPSF6 2 0.274 2.124 
 173 
P09669 Cytochrome c oxidase subunit 6C COX6C 3 0.204 1.752 
Q13561 Dynactin subunit 2 DCTN2 3 0.169 1.502 
P24534 Elongation factor 1-beta EF1B 4 0.175 1.545 
P29692 Elongation factor 1-delta EF1D 3 0.177 1.560 
P61916 Epididymal secretory protein E1 NPC2 2 -0.327 -2.336 
Q04637 Eukaryotic translation initiation factor 4 gamma 1 IF4G1 2 0.181 1.623 
P07954 Fumarate hydratase, mitochondrial FUMH 2 0.246 1.948 
P09211 Glutathione S-transferase P GSTP1 4 -0.258 -1.919 
P34932 Heat shock 70 kDa protein 4 HSP74 2 -0.192 -1.560 
P07900 Heat shock protein HSP 90-alpha HS90A 5 -0.238 -1.866 
P22626 Heterogeneous nuclear ribonucleoproteins A2/B1 ROA2 2 0.252 2.011 
 174 
P19367 Hexokinase-1 HXK1 3 -0.220 -1.732 
P52790 Hexokinase-3 HXK3 2 0.283 2.273 
Q92522 Histone H1x H1X 3 0.171 1.516 
P13760 
HLA class II histocompatibility antigen, DRB1-4 beta 
chain 
2B14 4 0.179 1.607 
Q13568 Interferon regulatory factor 5 IRF5 2 0.286 2.336 
P00338 L-lactate dehydrogenase A chain LDHA 3 -0.223 -1.752 
P10253 Lysosomal alpha-glucosidase LYAG 2 -0.318 -2.273 
P15586 N-acetylglucosamine-6-sulfatase GNS 2 -0.185 -1.502 
P28331 
NADH-ubiquinone oxidoreductase 75 kDa subunit, 
mitochondrial 
NDUS1 2 -0.317 -2.217 
Q9UKX7 Nuclear pore complex protein Nup50 NUP50 2 0.208 1.795 
 175 
Q8TEM1 Nuclear pore membrane glycoprotein 210 PO210 2 0.183 1.640 
Q9Y618 Nuclear receptor corepressor 2 NCOR2 5 0.232 1.866 
Q8WX93 Palladin PALLD 2 0.313 2.410 
P23284 Peptidyl-prolyl cis-trans isomerase B PPIB 3 -0.219 -1.712 
Q9H2H8 Peptidyl-prolyl cis-trans isomerase-like 3 PPIL3 2 -0.191 -1.545 
P32119 Peroxiredoxin-2 PRDX2 2 -0.213 -1.675 
Q6Y7W6 
PERQ amino acid-rich with GYF domain-containing 
protein 2 
PERQ2 3 0.195 1.712 
P13796 Plastin-2 PLSL 8 -0.208 -1.623 
Q14005 Pro-interleukin-16 IL16 2 0.256 2.046 
P35232 Prohibitin PHB 2 -0.292 -2.083 
Q92733 Proline-rich protein PRCC PRCC 2 0.198 1.732 
 176 
Q96C01 Protein FAM136A F136A 2 -0.225 -1.795 
Q9UNF0 
Protein kinase C and casein kinase substrate in 
neurons protein 2 
PACN2 3 0.225 1.817 
Q96M27 Protein PRRC1 PRRC1 2 0.178 1.575 
P06702 Protein S100-A9 S10A9 5 0.243 1.919 
Q8ND24 RING finger protein 214 RN214 3 0.235 1.892 
Q9Y3Z3 SAM domain and HD domain-containing protein 1 SAMHD1 2 -0.561 -3.126 
Q8WVM8 Sec1 family domain-containing protein 1 SCFD1 2 -0.351 -2.410 
Q9Y3F4 Serine-threonine kinase receptor-associated protein STRAP 2 -0.209 -1.640 
Q9H299 SH3 domain-binding glutamic acid-rich-like protein 3 SH3L3 3 0.185 1.657 
Q9P270 SLAIN motif-containing protein 2 SLAI2 2 0.179 1.591 
O43765 
Small glutamine-rich tetratricopeptide repeat-
SGTA 2 0.525 3.126 
 177 
containing protein alpha 
Q13596 Sorting nexin-1 SNX1 3 -0.224 -1.773 
O60493 Sorting nexin-3 SNX3 2 0.419 2.787 
Q14247 Src substrate cortactin SRC8 2 0.328 2.500 
P31040 
Succinate dehydrogenase [ubiquinone] flavoprotein 
subunit, mitochondrial 
DHSA 3 0.188 1.693 
O00560 Syntenin-1 SDCB1 2 -0.260 -1.948 
Q99832 T-complex protein 1 subunit eta TCPH 3 0.228 1.841 
P49368 T-complex protein 1 subunit gamma TCPG 5 -0.189 -1.531 
P40227 T-complex protein 1 subunit zeta TCPZ 4 -0.195 -1.575 
P37837 Transaldolase TALDO 5 -0.265 -2.046 
Q13428 Treacle protein TCOF 2 0.339 2.617 
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Q05209 Tyrosine-protein phosphatase non-receptor type 12 PTN12 2 -0.265 -2.011 
O43395 U4/U6 small nuclear ribonucleoprotein Prp3 PRPF3 3 -0.398 -2.500 
Q00341 Vigilin VIGLN 2 -0.206 -1.607 
P21796 Voltage-dependent anion-selective channel protein 1 VDAC1 2 -0.188 -1.516 
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Appendix 6: List of all significantly changed proteins to Vpx stimulation of Dendritic Cells at 4 dps. First biological replicate (iTRAQ1). 
Log2 ratio (+Vpx/-Vpx) and Z score are listed below 
  
UniProt 
Accession 
Number 
Protein Name 
Gene 
Symbol 
# peptides Log2 Ratio Z score 
P62847 40S ribosomal protein S24 RS24 3 -1.502 -0.253 
P10809 60 kDa heat shock protein, mitochondrial CH60 9 -2.617 -0.507 
P62913 60S ribosomal protein L11 RL11 2 -1.712 -0.307 
Q9UNX3 60S ribosomal protein L26-like 1 RL26L 2 -2.168 -0.403 
Q02878 60S ribosomal protein L6 RL6 3 -2.336 -0.446 
P11021 78 kDa glucose-regulated protein GRP78 13 -1.560 -0.273 
 180 
P24752 Acetyl-CoA acetyltransferase, mitochondrial THIL 2 1.795 0.375 
O15145 Actin-related protein 2/3 complex subunit 3 ARPC3 2 -1.516 -0.256 
Q9H4A4 Aminopeptidase B AMPB 2 1.675 0.356 
P14868 Aspartate--tRNA ligase, cytoplasmic SYDC 2 1.841 0.386 
O75947 ATP synthase subunit d, mitochondrial ATP5H 3 -1.752 -0.310 
Q9NNX6 CD209 antigen CD209 2 2.500 0.528 
Q00610 Clathrin heavy chain 1 CLH1 5 -1.575 -0.281 
Q14019 Coactosin-like protein COTL1 4 -2.273 -0.433 
P09669 Cytochrome c oxidase subunit 6C COX6C 3 1.948 0.394 
Q14204 Cytoplasmic dynein 1 heavy chain 1 DYHC1 3 2.410 0.510 
Q8N163 DBIRD complex subunit KIAA1967 K1967 3 2.124 0.447 
 181 
P53634 Dipeptidyl peptidase 1 CATC 5 -1.657 -0.292 
P04843 
Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit 1 
RPN1 3 -1.693 -0.302 
P49792 E3 SUMO-protein ligase RanBP2 RBP2 2 1.623 0.349 
P24534 Elongation factor 1-beta EF1B 4 -2.410 -0.466 
P17813 Endoglin EGLN 2 1.817 0.376 
P61916 Epididymal secretory protein E1 NPC2 2 2.336 0.505 
P60842 Eukaryotic initiation factor 4A-I IF4A1 3 2.046 0.426 
P60228 Eukaryotic translation initiation factor 3 subunit E EIF3E 2 1.531 0.335 
P47756 F-actin-capping protein subunit beta CAPZB 5 -1.531 -0.257 
Q01469 Fatty acid-binding protein, epidermal FABP5 2 -1.732 -0.310 
P02792 Ferritin light chain FRIL 3 -1.545 -0.259 
 182 
P14314 Glucosidase 2 subunit beta GLU2B 2 -1.640 -0.292 
P07203 Glutathione peroxidase 1 GPX1 3 -2.011 -0.384 
P62826 GTP-binding nuclear protein Ran RAN 3 -1.948 -0.377 
Q9H910 
Hematological and neurological expressed 1-like 
protein 
HN1L 2 1.560 0.339 
P26583 High mobility group protein B2 HMGB2 2 1.919 0.392 
P16401 Histone H1.5 H15 5 -1.607 -0.289 
P57053 Histone H2B type F-S H2BFS 4 -2.083 -0.393 
P62805 Histone H4 H4 3 1.502 0.324 
P50502 Hsc70-interacting protein F10A1 2 2.617 0.530 
P50213 
Isocitrate dehydrogenase [NAD] subunit alpha, 
mitochondrial 
IDH3A 2 1.545 0.338 
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Q07666 
KH domain-containing, RNA-binding, signal 
transduction-associated protein 1 
KHDR1 3 1.892 0.391 
P33241 Lymphocyte-specific protein 1 LSP1 8 -1.623 -0.289 
O94776 Metastasis-associated protein MTA2 MTA2 3 1.978 0.402 
P56192 Methionine--tRNA ligase, cytoplasmic SYMC 2 2.168 0.448 
P00387 NADH-cytochrome b5 reductase 3 NB5R3 2 1.693 0.357 
P22307 Non-specific lipid-transfer protein NLTP 4 -2.500 -0.493 
P49790 Nuclear pore complex protein Nup153 NU153 2 1.516 0.328 
Q8TEM1 Nuclear pore membrane glycoprotein 210 PO210 2 2.273 0.488 
P22392 Nucleoside diphosphate kinase B NDKB 4 -1.773 -0.315 
P50897 Palmitoyl-protein thioesterase 1 PPT1 2 -2.046 -0.385 
P62937 Peptidyl-prolyl cis-trans isomerase A PPIA 10 -1.919 -0.364 
 184 
P51659 Peroxisomal multifunctional enzyme type 2 DHB4 2 -1.866 -0.348 
P13796 Plastin-2 PLSL 8 -1.841 -0.331 
Q9UHX1 Poly(U)-binding-splicing factor PUF60 PUF60 2 -1.978 -0.380 
P02545 Prelamin-A/C LMNA 7 1.607 0.342 
P09668 Pro-cathepsin H CATH 2 3.126 0.589 
Q07954 Prolow-density lipoprotein receptor-related protein 1 LRP1 2 2.787 0.569 
P28066 Proteasome subunit alpha type-5 PSA5 2 -1.795 -0.315 
P21980 Protein-glutamine gamma-glutamyltransferase 2 TGM2 2 -1.892 -0.349 
P63000 Ras-related C3 botulinum toxin substrate 1 RAC1 2 2.083 0.432 
P51148 Ras-related protein Rab-5C RAB5C 4 1.575 0.340 
Q92900 Regulator of nonsense transcripts 1 RENT1 2 2.011 0.413 
 185 
P38159 RNA-binding motif protein, X chromosome RBMX 2 2.217 0.481 
Q9Y3Z3 SAM domain and HD domain-containing protein 1 SAMHD1 2 -3.126 -1.086 
O15127 Secretory carrier-associated membrane protein 2 SCAM2 0 -2.217 -0.418 
Q9H299 SH3 domain-binding glutamic acid-rich-like protein 3 SH3L3 3 -2.787 -0.657 
P42224 
Signal transducer and activator of transcription 1-
alpha/beta 
STAT1 2 1.773 0.374 
Q9Y5X3 Sorting nexin-5 SNX5 2 1.712 0.361 
Q99832 T-complex protein 1 subunit eta TCPH 3 1.640 0.350 
P40227 T-complex protein 1 subunit zeta TCPZ 4 -1.675 -0.292 
Q13263 Transcription intermediary factor 1-beta TIF1B 4 1.866 0.388 
P55084 Trifunctional enzyme subunit beta, mitochondrial ECHB 4 -2.124 -0.399 
P29144 Tripeptidyl-peptidase 2 TPP2 3 1.657 0.352 
 186 
O43399 Tumor protein D54 TPD54 2 -1.817 -0.323 
Q05209 Tyrosine-protein phosphatase non-receptor type 12 PTN12 2 1.732 0.367 
Q00341 Vigilin VIGLN 2 1.752 0.374 
P21796 Voltage-dependent anion-selective channel protein 1 VDAC1 2 -1.591 -0.285 
O75083 WD repeat-containing protein 1 WDR1 3 1.591 0.341 
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Appendix 7: List of all significantly changed proteins to Vpx stimulation of Dendritic Cells at 1 dps. Second biological replicate 
(iTRAQ2). Log2 ratio (+Vpx/-Vpx) and Z score are listed below 
  
 
UniProt 
Accession 
Number 
Protein Name 
Gene 
Symbol 
# peptides Log2 Ratio Z score 
Q15029 
116 kDa U5 small nuclear ribonucleoprotein 
component 
U5S1 3 0.471 2.056 
P0CW22 40S ribosomal protein S17-like RS17L 3 0.379 1.726 
P62269 40S ribosomal protein S18 RS18 2 0.651 2.654 
P39019 40S ribosomal protein S19 RS19 3 -0.383 -2.090 
P62861 40S ribosomal protein S30 RS30 3 -0.399 -2.167 
 188 
P46781 40S ribosomal protein S9 RS9 2 0.643 2.538 
P17858 6-phosphofructokinase, liver type K6PL 2 -0.255 -1.599 
P62906 60S ribosomal protein L10a RL10A 2 0.504 2.167 
P26373 60S ribosomal protein L13 RL13 3 0.774 2.822 
P46779 60S ribosomal protein L28 RL28 2 0.851 3.157 
P39023 60S ribosomal protein L3 RL3 2 0.349 1.557 
P62899 60S ribosomal protein L31 RL31 2 0.362 1.628 
P18124 60S ribosomal protein L7 RL7 2 0.597 2.449 
Q9UKK9 ADP-sugar pyrophosphatase NUDT5 2 -0.282 -1.628 
P15144 Aminopeptidase N AMPN 2 0.357 1.599 
P08758 Annexin A5 ANXA5 8 0.402 1.801 
 189 
O95782 AP-2 complex subunit alpha-1 AP2A1 3 0.376 1.675 
Q0VD83 Apolipoprotein B receptor APOBR 4 -0.298 -1.691 
Q99856 AT-rich interactive domain-containing protein 3A ARI3A 2 -0.336 -1.913 
P56385 ATP synthase subunit e, mitochondrial ATP5I 3 -0.350 -1.994 
P13995 
Bifunctional methylenetetrahydrofolate 
dehydrogenase/cyclohydrolase, mitochondrial 
MTDC 2 -0.304 -1.726 
Q96T60 Bifunctional polynucleotide phosphatase/kinase PNKP 2 0.419 1.866 
Q13557 
Calcium/calmodulin-dependent protein kinase type II 
subunit delta 
KCC2D 2 0.346 1.544 
P04040 Catalase CATA 2 -0.242 -1.506 
P09496 Clathrin light chain A CLCA 2 -0.297 -1.675 
Q9H0L4 Cleavage stimulation factor subunit 2 tau variant CSTFT 3 -0.487 -2.376 
 190 
P31146 Coronin-1A COR1A 5 0.450 1.965 
P20674 Cytochrome c oxidase subunit 5A, mitochondrial COX5A 4 -0.417 -2.211 
O75923 Dysferlin DYSF 2 0.334 1.506 
P24534 Elongation factor 1-beta EF1B 3 -0.560 -2.654 
P29692 Elongation factor 1-delta EF1D 5 -0.347 -1.965 
Q99961 Endophilin-A2 SH3G1 3 0.337 1.531 
Q14152 Eukaryotic translation initiation factor 3 subunit A EIF3A 5 0.434 1.913 
P23588 Eukaryotic translation initiation factor 4B IF4B 2 -0.254 -1.585 
Q92945 Far upstream element-binding protein 2 FUBP2 4 -0.328 -1.866 
P09382 Galectin-1 LEG1 3 0.395 1.781 
P17931 Galectin-3 LEG3 7 -0.392 -2.127 
 191 
P09104 Gamma-enolase ENOG 2 0.353 1.585 
P13284 Gamma-interferon-inducible lysosomal thiol reductase GILT 2 -0.253 -1.544 
O95479 GDH/6PGL endoplasmic bifunctional protein G6PE 3 0.376 1.691 
P11413 Glucose-6-phosphate 1-dehydrogenase G6PD 8 0.336 1.518 
P00367 Glutamate dehydrogenase 1, mitochondrial DHE3 2 0.486 2.127 
P78417 Glutathione S-transferase omega-1 GSTO1 2 0.483 2.090 
P52272 Heterogeneous nuclear ribonucleoprotein M HNRPM 16 -0.329 -1.889 
P16401 Histone H1.5 H15 6 -0.254 -1.571 
Q09028 Histone-binding protein RBBP4 RBBP4 2 0.404 1.843 
P50502 Hsc70-interacting protein F10A1 4 -0.309 -1.744 
P04264 Keratin, type II cytoskeletal 1 K2C1 2 -0.771 -3.157 
 192 
Q07666 
KH domain-containing, RNA-binding, signal 
transduction-associated protein 1 
KHDR1 2 -0.312 -1.762 
Q86UP2 Kinectin KTN1 2 -0.268 -1.613 
P36776 Lon protease homolog, mitochondrial LONM 2 0.529 2.259 
P33121 Long-chain-fatty-acid--CoA ligase 1 ACSL1 2 0.350 1.571 
P55145 Mesencephalic astrocyte-derived neurotrophic factor MANF 2 0.373 1.659 
P22307 Non-specific lipid-transfer protein NLTP 3 -0.531 -2.449 
P23284 Peptidyl-prolyl cis-trans isomerase B PPIB 4 -0.446 -2.259 
P30044 Peroxiredoxin-5, mitochondrial PRDX5 5 -0.327 -1.843 
Q6ZUJ8 Phosphoinositide 3-kinase adapter protein 1 BCAP 2 0.467 2.024 
P20020 Plasma membrane calcium-transporting ATPase 1 AT2B1 2 0.584 2.376 
Q9UKK3 Poly [ADP-ribose] polymerase 4 PARP4 2 0.390 1.744 
 193 
Q9UHV9 Prefoldin subunit 2 PFD2 3 -0.650 -2.822 
P07602 Proactivator polypeptide SAP 3 0.453 1.994 
Q99623 Prohibitin-2 PHB2 2 0.363 1.643 
Q9UQ80 Proliferation-associated protein 2G4 PA2G4 4 -0.300 -1.708 
Q5VYK3 Proteasome-associated protein ECM29 homolog ECM29 3 -0.294 -1.659 
P48634 Protein PRRC2A PRC2A 2 -0.249 -1.531 
P31949 Protein S100-A11 S10AB 2 0.521 2.211 
P46087 Putative ribosomal RNA methyltransferase N NOP2 2 0.358 1.613 
P50395 Rab GDP dissociation inhibitor beta GDIB 7 0.427 1.889 
P15153 Ras-related C3 botulinum toxin substrate 2 RAC2 2 0.449 1.939 
P61006 Ras-related protein Rab-8A RAB8A 2 0.394 1.762 
 194 
P08575 Receptor-type tyrosine-protein phosphatase C PTPRC 2 0.377 1.708 
Q96PK6 RNA-binding protein 14 RBM14 2 -0.287 -1.643 
Q15424 Scaffold attachment factor B1 SAFB1 2 -0.547 -2.538 
O94804 Serine/threonine-protein kinase 10 STK10 2 0.402 1.822 
Q9H299 SH3 domain-binding glutamic acid-rich-like protein 3 SH3L3 3 -0.363 -2.056 
P26368 Splicing factor U2AF 65 kDa subunit U2AF2 3 -0.254 -1.557 
O00560 Syntenin-1 SDCB1 2 -0.324 -1.822 
P13686 Tartrate-resistant acid phosphatase type 5 PPA5 2 -0.338 -1.939 
P19971 Thymidine phosphorylase TYPH 15 -0.315 -1.781 
O75896 Tumor suppressor candidate 2 TUSC2 2 -0.461 -2.313 
P45974 Ubiquitin carboxyl-terminal hydrolase 5 UBP5 2 0.554 2.313 
 195 
P50552 Vasodilator-stimulated phosphoprotein VASP 4 -0.246 -1.518 
O43516 WAS/WASL-interacting protein family member 1 WIPF1 4 -0.318 -1.801 
Q15942 Zyxin ZYX 6 -0.357 -2.024 
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UniProt 
Accession 
Number 
Protein Name 
Gene 
Symbol 
# peptides Log2 Ratio Z score 
P09110 3-ketoacyl-CoA thiolase, peroxisomal THIK 3 1.066 2.822 
P0CW22 40S ribosomal protein S17-like RS17L 3 -0.663 -1.913 
P15880 40S ribosomal protein S2 RS2 3 -0.604 -1.744 
P62861 40S ribosomal protein S30 RS30 3 -0.894 -2.376 
P10809 60 kDa heat shock protein, mitochondrial CH60 12 -0.599 -1.708 
P26373 60S ribosomal protein L13 RL13 3 -0.714 -1.994 
 197 
O75608 Acyl-protein thioesterase 1 LYPA1 2 0.794 2.313 
Q14444 Caprin-1 CAPR1 3 0.629 1.965 
P07339 Cathepsin D CATD 11 -0.615 -1.781 
P16070 CD44 antigen CD44 3 -1.099 -2.654 
P48960 CD97 antigen CD97 2 0.497 1.585 
P60953 Cell division control protein 42 homolog CDC42 3 0.755 2.211 
O75390 Citrate synthase, mitochondrial CISY 3 0.516 1.659 
P09496 Clathrin light chain A CLCA 2 -2.087 -3.157 
O95319 CUGBP Elav-like family member 2 CELF2 3 -0.578 -1.643 
P99999 Cytochrome c CYC 2 -0.791 -2.167 
P10606 Cytochrome c oxidase subunit 5B, mitochondrial COX5B 3 -0.531 -1.518 
 198 
Q14204 Cytoplasmic dynein 1 heavy chain 1 DYHC1 4 0.652 2.056 
Q9UJU6 Drebrin-like protein DBNL 3 0.503 1.599 
O75923 Dysferlin DYSF 2 0.490 1.557 
P11161 E3 SUMO-protein ligase EGR2 EGR2 2 0.571 1.801 
P38117 Electron transfer flavoprotein subunit beta ETFB 4 -0.565 -1.599 
P24534 Elongation factor 1-beta EF1B 3 -1.107 -2.822 
P29692 Elongation factor 1-delta EF1D 5 -0.624 -1.822 
P41091 Eukaryotic translation initiation factor 2 subunit 3 IF2G 2 0.651 2.024 
Q14152 Eukaryotic translation initiation factor 3 subunit A EIF3A 5 0.613 1.913 
O00303 Eukaryotic translation initiation factor 3 subunit F EIF3F 3 0.894 2.376 
Q9GZV4 Eukaryotic translation initiation factor 5A-2 IF5A2 2 -0.887 -2.313 
 199 
P09382 Galectin-1 LEG1 3 -0.611 -1.762 
P06744 Glucose-6-phosphate isomerase G6PI 2 -0.622 -1.801 
Q92598 Heat shock protein 105 kDa HS105 3 0.613 1.889 
P50502 Hsc70-interacting protein F10A1 4 -0.861 -2.259 
P04264 Keratin, type II cytoskeletal 1 K2C1 2 -0.577 -1.628 
Q8N1G4 Leucine-rich repeat-containing protein 47 LRC47 2 0.492 1.571 
P23141 Liver carboxylesterase 1 EST1 2 0.525 1.691 
P40121 Macrophage-capping protein CAPG 4 -0.531 -1.506 
P55145 Mesencephalic astrocyte-derived neurotrophic factor MANF 2 0.569 1.781 
Q9UPN3 
Microtubule-actin cross-linking factor 1, isoforms 
1/2/3/5 
MACF1 4 0.598 1.843 
Q15691 
Microtubule-associated protein RP/EB family member 
MARE1 2 -0.662 -1.889 
 200 
1 
P08571 Monocyte differentiation antigen CD14 CD14 2 0.474 1.544 
P60660 Myosin light polypeptide 6 MYL6 5 -0.588 -1.675 
Q09666 Neuroblast differentiation-associated protein AHNAK AHNK 45 -0.585 -1.659 
P35658 Nuclear pore complex protein Nup214 NU214 2 0.629 1.994 
O75376 Nuclear receptor corepressor 1 NCOR1 2 0.718 2.167 
P06748 Nucleophosmin NPM 4 -0.551 -1.544 
Q8NFH3 Nucleoporin Nup43 NUP43 2 0.617 1.939 
P23284 Peptidyl-prolyl cis-trans isomerase B PPIB 4 -0.644 -1.866 
Q16822 
Phosphoenolpyruvate carboxykinase [GTP], 
mitochondrial 
PCKGM 2 0.594 1.822 
Q6ZUJ8 Phosphoinositide 3-kinase adapter protein 1 BCAP 2 0.914 2.449 
 201 
O75934 Pre-mRNA-splicing factor SPF27 SPF27 2 0.550 1.762 
Q9NQ88 Probable fructose-2,6-bisphosphatase TIGAR TIGAR 3 0.780 2.259 
Q07954 Prolow-density lipoprotein receptor-related protein 1 LRP1 2 0.926 2.538 
P25787 Proteasome subunit alpha type-2 PSA2 3 0.527 1.726 
Q5VYK3 Proteasome-associated protein ECM29 homolog ECM29 3 1.086 3.157 
P07237 Protein disulfide-isomerase PDIA1 9 -0.594 -1.691 
P13667 Protein disulfide-isomerase A4 PDIA4 7 -0.723 -2.024 
Q9C005 Protein dpy-30 homolog DPY30 2 0.677 2.090 
Q92520 Protein FAM3C FAM3C 2 0.446 1.506 
P26447 Protein S100-A4 S10A4 3 -0.696 -1.965 
P06702 Protein S100-A9 S10A9 7 -0.557 -1.571 
 202 
P21980 Protein-glutamine gamma-glutamyltransferase 2 TGM2 10 -0.896 -2.449 
P46087 Putative ribosomal RNA methyltransferase NOP2 NOP2 2 0.548 1.744 
P15153 Ras-related C3 botulinum toxin substrate 2 RAC2 2 -0.604 -1.726 
P61020 Ras-related protein Rab-5B RAB5B 2 0.519 1.675 
P52566 Rho GDP-dissociation inhibitor 2 GDIR2 4 -0.680 -1.939 
Q9UKM9 RNA-binding protein Raly RALY 3 -0.732 -2.056 
Q9Y3Z3 SAM domain and HD domain-containing protein 1 SAMHD1 4 -0.736 -2.090 
O94804 Serine/threonine-protein kinase 10 STK10 2 1.005 2.654 
P50453 Serpin B9 SPB9 2 0.452 1.518 
Q9Y6M7 Sodium bicarbonate cotransporter 3 S4A7 2 0.508 1.613 
Q96JI7 Spatacsin SPTCS 2 0.717 2.127 
 203 
Q7KZF4 Staphylococcal nuclease domain-containing protein 1 SND1 2 -0.576 -1.613 
Q96I99 
Succinyl-CoA ligase [GDP-forming] subunit beta, 
mitochondrial 
SUCB2 2 0.526 1.708 
P10599 Thioredoxin THIO 2 -0.564 -1.585 
Q9BRA2 Thioredoxin domain-containing protein 17 TXD17 3 -0.544 -1.531 
P37837 Transaldolase TALDO 4 -0.832 -2.211 
Q9UM00 
Transmembrane and coiled-coil domain-containing 
protein 1 
TMCO1 2 0.459 1.531 
P62312 U6 snRNA-associated Sm-like protein LSm6 LSM6 2 0.508 1.628 
Q969H8 UPF0556 protein C19orf10 CS010 2 -0.931 -2.538 
Q709C8 Vacuolar protein sorting-associated protein 13C VP13C 2 0.509 1.643 
P45880 Voltage-dependent anion-selective channel protein 2 VDAC2 2 -0.763 -2.127 
 204 
Q6ZS81 WD repeat- and FYVE domain-containing protein 4 WDFY4 2 0.599 1.866 
P12956 X-ray repair cross-complementing protein 6 XRCC6 3 -0.638 -1.843 
Q15942 Zyxin ZYX 6 -0.554 -1.557 
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Appendix 9: List of all significantly changed proteins to Vpx stimulation of Macrophages at 1dps. First biological replicate (iTRAQ3). 
Log2 ratio (+Vpx/-Vpx) and Z score are listed below 
UniProt 
Accession 
Number 
Protein Name 
Gene 
Symbol 
# peptides Log2 Ratio Z score 
P61604 10 kDa heat shock protein, mitochondrial CH10 8 -0.209 -1.613 
P31946 14-3-3 protein beta/alpha 1433B 6 0.213 1.540 
P62195 26S protease regulatory subunit 8 PRS8 4 0.254 1.781 
Q13442 28 kDa heat- and acid-stable phosphoprotein HAP28 2 0.238 1.719 
P62280 40S ribosomal protein S11 RS11 2 0.355 2.287 
P46781 40S ribosomal protein S9 RS9 5 0.224 1.623 
P62906 60S ribosomal protein L10a RL10A 3 -0.222 -1.654 
 206 
P26373 60S ribosomal protein L13 RL13 5 -0.198 -1.549 
M0R3D6 60S ribosomal protein L18a (Fragment) RPL18A 2 -0.302 -2.063 
P49588 Alanine--tRNA ligase, cytoplasmic SYAC 4 0.269 1.895 
K7EJT8 AP-2 complex subunit beta AP2B1 2 -0.230 -1.731 
P25705 ATP synthase subunit alpha, mitochondrial ATPA 24 -0.217 -1.633 
P06576 ATP synthase subunit beta, mitochondrial ATPB 20 -0.249 -1.807 
O75947 ATP synthase subunit d, mitochondrial ATP5H 5 -0.225 -1.675 
P48047 ATP synthase subunit O, mitochondrial ATPO 8 -0.320 -2.162 
E9PHY5 Band 4.1-like protein 2 EPB41L2 2 0.279 1.982 
Q3LXA3 
Bifunctional ATP-dependent dihydroxyacetone 
kinase/FAD-AMP lyase (cyclizing) 
DHAK 2 -0.446 -2.464 
P80723 Brain acid soluble protein 1 BASP1 4 0.366 2.367 
 207 
P07384 Calpain-1 catalytic subunit CAN1 5 0.218 1.576 
P27797 Calreticulin CALR 27 -0.228 -1.697 
Q14444 Caprin-1 CAPR1 2 -0.615 -3.275 
P50416 Carnitine O-palmitoyltransferase 1, liver isoform CPT1A 3 0.219 1.585 
P23786 Carnitine O-palmitoyltransferase 2, mitochondrial CPT2 3 -0.246 -1.794 
E7EU96 Casein kinase II subunit alpha CSNK2A1 3 0.220 1.594 
P07858 Cathepsin B CATB 3 -0.204 -1.585 
P25774 Cathepsin S CATS 5 -0.217 -1.643 
F8W022 CD63 antigen (Fragment) CD63 2 -0.269 -1.895 
P36222 Chitinase-3-like protein 1 CH3L1 6 -0.239 -1.768 
Q10570 
Cleavage and polyadenylation specificity factor 
subunit 1 
CPSF1 2 0.261 1.835 
 208 
F8VVA7 Coatomer subunit zeta-1 COPZ1 2 -0.284 -1.963 
Q9NZB2 
Constitutive coactivator of PPAR-gamma-like protein 
1 
F120A 2 0.486 2.951 
Q9BR76 Coronin-1B COR1B 3 -0.195 -1.515 
P10606 Cytochrome c oxidase subunit 5B, mitochondrial COX5B 3 0.243 1.743 
Q7L576 Cytoplasmic FMR1-interacting protein 1 CYFP1 2 -0.349 -2.287 
Q9Y3Z3 
Deoxynucleoside triphosphate triphosphohydrolase 
SAMHD1 
SAMHD1 14 -0.323 -2.190 
G3V1D3 Dipeptidyl peptidase 3 G3V1D3 5 0.224 1.613 
Q02880 DNA topoisomerase 2-beta TOP2B 2 -0.263 -1.849 
Q9BS26 Endoplasmic reticulum resident protein 44 ERP44 2 -0.200 -1.567 
P42126 Enoyl-CoA delta isomerase 1, mitochondrial ECI1 2 -0.305 -2.086 
 209 
Q96HE7 ERO1-like protein alpha ERO1A 4 -0.508 -2.524 
F8WAE5 Eukaryotic translation initiation factor 2 subunit 1 EIF2A 2 0.236 1.708 
P55884 Eukaryotic translation initiation factor 3 subunit B EIF3B 7 0.212 1.515 
H3BRV0 Eukaryotic translation initiation factor 3 subunit C EIF3C 3 -0.271 -1.911 
B4DEW9 Eukaryotic translation initiation factor 3 subunit F EIF3F 2 0.410 2.679 
I3L397 
Eukaryotic translation initiation factor 5A-1 
(Fragment) 
I3L397 3 0.232 1.675 
O14980 Exportin-1 XPO1 2 0.391 2.464 
P09382 Galectin-1 LEG1 10 -0.264 -1.864 
O75223 Gamma-glutamylcyclotransferase GGCT 3 -0.578 -2.679 
Q03013 Glutathione S-transferase Mu 4 GSTM4 2 0.285 2.042 
Q53EU6 Glycerol-3-phosphate acyltransferase 3 GPAT3 2 0.317 2.162 
 210 
Q9HC38 Glyoxalase domain-containing protein 4 GLOD4 3 0.264 1.879 
Q9H4A6 Golgi phosphoprotein 3 GOLP3 2 0.250 1.768 
P01116 GTPase KRas RASK 2 0.227 1.643 
O60832 H/ACA ribonucleoprotein complex subunit 4 DKC1 3 -0.271 -1.928 
Q12931 Heat shock protein 75 kDa, mitochondrial TRAP1 2 -0.277 -1.945 
P26583 High mobility group protein B2 HMGB2 4 0.283 2.001 
P17096 High mobility group protein HMG-I/HMG-Y HMGA1 2 0.272 1.928 
Q5Y7A7 
HLA class II histocompatibility antigen, DRB1-13 
beta chain 
2B1D 2 0.404 2.593 
P01857 Ig gamma-1 chain C region IGHG1 4 0.320 2.190 
Q00722-2 
Isoform 2 of 1-phosphatidylinositol 4,5-bisphosphate 
phosphodiesterase beta-2 
PLCB2 2 0.271 1.911 
 211 
Q96CW1-2 Isoform 2 of AP-2 complex subunit mu AP2M1 2 -0.257 -1.821 
P06737-2 Isoform 2 of Glycogen phosphorylase, liver form PYGL 7 0.216 1.558 
P04233-2 
Isoform 2 of HLA class II histocompatibility antigen 
gamma chain 
HG2A 2 0.212 1.531 
Q9UNF0-2 
Isoform 2 of Protein kinase C and casein kinase 
substrate in neurons protein 2 
PACN2 2 -0.318 -2.135 
Q9UIB8-5 Isoform 5 of SLAM family member 5 SLAF5 2 -0.289 -2.021 
Q9HD20-2 
Isoform B of Probable cation-transporting ATPase 
13A1 
AT131 2 -0.233 -1.743 
P13645 Keratin, type I cytoskeletal 10 K1C10 4 0.292 2.063 
P35527 Keratin, type I cytoskeletal 9 K1C9 14 0.261 1.849 
P04264 Keratin, type II cytoskeletal 1 K2C1 23 0.343 2.220 
 212 
P36776 Lon protease homolog, mitochondrial LONM 2 -0.239 -1.781 
Q5K4L6 Long-chain fatty acid transport protein 3 S27A3 4 -0.228 -1.708 
O95573 Long-chain-fatty-acid--CoA ligase 3 ACSL3 4 -0.224 -1.664 
O60488 Long-chain-fatty-acid--CoA ligase 4 ACSL4 2 -0.444 -2.413 
P61626 Lysozyme C LYSC 4 0.249 1.755 
O94776 Metastasis-associated protein MTA2 MTA2 2 0.273 1.945 
O75439 Mitochondrial-processing peptidase subunit beta MPPB 2 0.215 1.549 
P28482 Mitogen-activated protein kinase 1 MK01 2 0.212 1.523 
O14745 Na(+)/H(+) exchange regulatory cofactor NHE-RF1 NHRF1 2 -0.538 -2.593 
P23368 NAD-dependent malic enzyme, mitochondrial MAOM 5 -0.225 -1.686 
P55160 Nck-associated protein 1-like NCKPL 2 -0.196 -1.531 
 213 
P05204 Non-histone chromosomal protein HMG-17 HMGN2 2 0.293 2.086 
J3QK90 NSFL1 cofactor p47 NSF1C 2 0.259 1.821 
P50897 Palmitoyl-protein thioesterase 1 PPT1 3 -0.206 -1.594 
Q13451 Peptidyl-prolyl cis-trans isomerase FKBP5 FKBP5 2 -0.238 -1.755 
P36871 Phosphoglucomutase-1 PGM1 2 0.236 1.697 
Q6NYC8 Phostensin PPR18 4 0.313 2.135 
E7EU05 Platelet glycoprotein 4 (Fragment) CD36 5 0.241 1.731 
Q6UX71 Plexin domain-containing protein 2 PXDC2 2 -0.397 -2.367 
P09874 Poly [ADP-ribose] polymerase 1 PARP1 2 -0.287 -1.982 
C9IZG4 Protein CutA CUTA 2 0.262 1.864 
Q99497 Protein DJ-1 PARK7 4 0.216 1.567 
 214 
E9PDL6 Protein NDRG1 NDRG1 2 0.586 3.275 
P55786 Puromycin-sensitive aminopeptidase PSA 5 0.258 1.794 
P11498 Pyruvate carboxylase, mitochondrial PYC 5 -0.268 -1.879 
B4DJA5 Ras-related protein Rab-5A RAB5A 2 -0.332 -2.220 
Q12913 Receptor-type tyrosine-protein phosphatase eta PTPRJ 3 0.221 1.604 
M0QZR4 Rho guanine nucleotide exchange factor 1 ARHGEF1 2 -0.578 -2.789 
Q8NBX0 Saccharopine dehydrogenase-like oxidoreductase SCPDL 2 0.357 2.325 
D6RGI3 Septin 11, isoform CRA_b SEPT11 2 0.378 2.413 
Q5T5C7 Serine--tRNA ligase, cytoplasmic Q5T5C7 3 0.274 1.963 
B4DNJ6 Serine-threonine kinase receptor-associated protein STRAP 2 -0.301 -2.042 
P62714 
Serine/threonine-protein phosphatase 2A catalytic 
subunit beta isoform 
PP2AB 2 -0.202 -1.576 
 215 
Q5T123 SH3 domain-binding glutamic acid-rich-like protein 3 SH3BGRL3 4 0.396 2.524 
A0MZ66 Shootin-1 SHOT1 2 -0.206 -1.604 
Q9UHB9 Signal recognition particle subunit SRP68 SRP68 2 -0.287 -2.001 
K7ENL3 Signal transducer and activator of transcription 3 STAT3 2 -0.340 -2.253 
P42226 Signal transducer and activator of transcription 6 STAT6 3 0.284 2.021 
Q9UNH7 Sorting nexin-6 SNX6 2 0.346 2.253 
Q02318 Sterol 26-hydroxylase, mitochondrial CYP27A 4 -0.195 -1.523 
J3KQE0 SUN domain-containing protein 2 SUN2 4 -0.194 -1.506 
Q92797 Symplekin SYMPK 2 0.307 2.110 
P40227 T-complex protein 1 subunit zeta TCPZ 6 0.212 1.506 
O95881 Thioredoxin domain-containing protein 12 TXD12 2 -0.216 -1.623 
 216 
Q8NBS9 Thioredoxin domain-containing protein 5 TXND5 2 -0.600 -2.951 
Q92616 Translational activator GCN1 GCN1L 3 0.418 2.789 
C9IZQ1 Translocon-associated protein subunit alpha C9IZQ1 2 -0.261 -1.835 
P51571 Translocon-associated protein subunit delta SSRD 3 -0.197 -1.540 
Q92544 Transmembrane 9 superfamily member 4 TM9S4 2 -0.380 -2.325 
H0Y8N0 Transmembrane protein 33 (Fragment) TMEM33 2 0.235 1.686 
Q5VZU9 Tripeptidyl-peptidase 2 TPP2 2 0.228 1.654 
Q9UMX0 Ubiquilin-1 UBQL1 2 0.224 1.633 
B0I1T2 Unconventional myosin-Ig MYO1G 4 -0.309 -2.110 
R4GN72 V-type proton ATPase subunit d 1 ATP6V0D1 4 -0.200 -1.558 
O75396 Vesicle-trafficking protein SEC22b SC22B 4 0.258 1.807 
 217 
 
 
 
 
 
 
 
 
 
 
 
P08670 Vimentin VIME 65 -0.230 -1.719 
Q15942 Zyxin ZYX 2 0.229 1.664 
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Appendix 10: List of all significantly changed proteins to Vpx stimulation of Dendritic Cells at 1dps. First biological replicate (iTRAQ3). 
Log2 ratio (+Vpx/-Vpx) and Z score are listed below 
  
UniProt 
Accession 
Number 
Protein Name 
Gene 
Symbol 
# peptides Log2 Ratio Z score 
K7EJ81 
116 kDa U5 small nuclear ribonucleoprotein 
component 
EFTUD2 3 0.256 1.623 
P31946 14-3-3 protein beta/alpha 1433B 6 -0.277 -1.755 
P62258 14-3-3 protein epsilon 1433E 6 0.305 1.963 
Q02218 2-oxoglutarate dehydrogenase, mitochondrial ODO1 4 0.267 1.664 
B7Z6B8 2,4-dienoyl-CoA reductase, mitochondrial DECR1 9 0.271 1.686 
R4GNH3 26S protease regulatory subunit 6A PSMC3 5 -0.344 -2.086 
 219 
P35998 26S protease regulatory subunit 7 PRS7 4 0.347 2.190 
Q99714 3-hydroxyacyl-CoA dehydrogenase type-2 HCD2 5 -0.471 -2.679 
K7ELC2 40S ribosomal protein S15 K7ELC2 2 -0.228 -1.531 
P0CW22 40S ribosomal protein S17-like RS17L 5 -0.328 -2.021 
P39019 40S ribosomal protein S19 RS19 6 -0.400 -2.367 
P50914 60S ribosomal protein L14 RL14 3 0.273 1.708 
P62829 60S ribosomal protein L23 RL23 5 0.319 2.063 
P62899 60S ribosomal protein L31 RL31 2 -0.260 -1.664 
E5RGR0 Acyl-protein thioesterase 1 (Fragment) LYPLA1 3 -0.276 -1.743 
P49588 Alanine--tRNA ligase, cytoplasmic SYAC 4 -0.381 -2.190 
P17050 Alpha-N-acetylgalactosaminidase NAGAB 4 0.231 1.506 
 220 
Q10567 AP-1 complex subunit beta-1 AP1B1 3 -0.236 -1.585 
P02649 Apolipoprotein E APOE 5 0.296 1.895 
Q12797 Aspartyl/asparaginyl beta-hydroxylase ASPH 4 -0.316 -1.928 
P30049 ATP synthase subunit delta, mitochondrial ATPD 3 0.315 2.021 
Q92499 ATP-dependent RNA helicase DDX1 DDX1 2 -0.219 -1.523 
P14384 Carboxypeptidase M CBPM 3 -0.272 -1.719 
P50416 Carnitine O-palmitoyltransferase 1, liver isoform CPT1A 3 0.771 3.275 
B4DVD8 Caspase-1 subunit p20 CASP1 2 -0.410 -2.413 
P25774 Cathepsin S CTSS 5 -0.440 -2.593 
Q9NNX6 CD209 antigen CD209 6 -0.299 -1.864 
P48960 CD97 antigen CD97 4 0.325 2.086 
 221 
P35606 Coatomer subunit beta' COPB2 2 0.315 2.001 
Q9Y678 Coatomer subunit gamma-1 COPG1 4 0.361 2.220 
P04080 Cystatin-B CYTB 5 -0.267 -1.697 
P01034 Cystatin-C CYTC 3 0.270 1.675 
P10606 Cytochrome c oxidase subunit 5B, mitochondrial COX5B 3 -0.399 -2.325 
Q9Y6G9 Cytoplasmic dynein 1 light intermediate chain 1 DC1L1 2 0.328 2.110 
Q13011 
Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, 
mitochondrial 
ECH1 9 0.283 1.755 
Q9Y3Z3 
Deoxynucleoside triphosphate triphosphohydrolase 
SAMHD1 
SAMHD1 14 -0.900 -3.275 
P36957 
Dihydrolipoyllysine-residue succinyltransferase 
component of 2-oxoglutarate dehydrogenase complex, 
ODO2 3 0.292 1.849 
 222 
mitochondrial 
Q13217 DnaJ homolog subfamily C member 3 DNJC3 3 -0.580 -2.789 
O60496 Docking protein 2 DOK2 3 0.476 2.524 
P46977 
Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit STT3A 
STT3A 2 0.336 2.135 
Q15075 Early endosome antigen 1 EEA1 2 -0.265 -1.686 
B4DVB8 ELAV-like protein 1 ELAV1 3 -0.237 -1.594 
Q53GQ0 Estradiol 17-beta-dehydrogenase 12 DHB12 4 0.302 1.945 
F8WAE5 Eukaryotic translation initiation factor 2 subunit 1 EIF2A 2 0.274 1.719 
O75821 Eukaryotic translation initiation factor 3 subunit G EIF3G 2 -0.384 -2.220 
P23588 Eukaryotic translation initiation factor 4B EIF4B 3 0.285 1.781 
I3L397 
Eukaryotic translation initiation factor 5A-1 
EIF5A 3 -0.428 -2.524 
 223 
(Fragment) 
Q01469 Fatty acid-binding protein, epidermal FABP5 3 -0.290 -1.807 
P02792 Ferritin light chain FRIL 9 -0.317 -1.945 
P17900 Ganglioside GM2 activator SAP3 3 0.283 1.768 
O60763 General vesicular transport factor p115 USO1 7 -0.258 -1.643 
P07203 Glutathione peroxidase 1 GPX1 5 0.255 1.604 
P00390 Glutathione reductase, mitochondrial GSHR 5 -0.319 -1.982 
P09211 Glutathione S-transferase P GSTP1 8 -0.297 -1.849 
Q53EU6 Glycerol-3-phosphate acyltransferase 3 GPAT3 2 0.367 2.253 
P51991 Heterogeneous nuclear ribonucleoprotein A3 ROA3 4 0.318 2.042 
Q9BUJ2 
Heterogeneous nuclear ribonucleoprotein U-like 
protein 1 
HNRL1 3 0.257 1.633 
 224 
P09429 High mobility group protein B1 HMGB1 6 -0.343 -2.063 
Q92522 Histone H1x H1X 2 -0.318 -1.963 
Q99878 Histone H2A type 1-J H2A1J 2 -0.315 -1.911 
Q8N257 Histone H2B type 3-B H2B3B 2 -0.231 -1.549 
P62805 Histone H4 H4 12 -0.328 -2.001 
P13760 
HLA class II histocompatibility antigen, DRB1-4 beta 
chain 
HLA-DRB1 9 -0.232 -1.558 
H0Y4R1 
Inosine-5'-monophosphate dehydrogenase 2 
(Fragment) 
IMPDH2 3 -0.236 -1.576 
P05107 Integrin beta-2 ITB2 11 -0.336 -2.042 
P51572-2 Isoform 2 of B-cell receptor-associated protein 31 BAP31 3 0.300 1.911 
Q9BSJ8-2 Isoform 2 of Extended synaptotagmin-1 ESYT1 6 0.290 1.835 
 225 
P28331-2 
Isoform 2 of NADH-ubiquinone oxidoreductase 75 
kDa subunit, mitochondrial 
NDUS1 5 0.256 1.613 
P12931-2 
Isoform 2 of Proto-oncogene tyrosine-protein kinase 
Src 
SRC 2 0.245 1.567 
Q99729-3 
Isoform 3 of Heterogeneous nuclear ribonucleoprotein 
A/B 
ROAA 5 0.237 1.540 
Q15424-3 Isoform 3 of Scaffold attachment factor B1 SAFB1 2 -0.214 -1.506 
P09651-2 
Isoform A1-A of Heterogeneous nuclear 
ribonucleoprotein A1 
ROA1 8 -0.281 -1.781 
P63000-2 
Isoform B of Ras-related C3 botulinum toxin substrate 
1 
RAC1 2 -0.295 -1.835 
P35527 Keratin, type I cytoskeletal 9 K1C9 14 0.288 1.821 
P04264 Keratin, type II cytoskeletal 1 K2C1 23 0.241 1.549 
 226 
P61626 Lysozyme C LYSC 4 -0.359 -2.110 
Q14165 Malectin MLEC 2 0.261 1.643 
O94776 Metastasis-associated protein MTA2 MTA2 2 0.247 1.585 
P28482 Mitogen-activated protein kinase 1 MK01 2 0.384 2.325 
P58546 Myotrophin MTPN 2 -0.293 -1.821 
O14745 Na(+)/H(+) exchange regulatory cofactor NHE-RF1 NHRF1 2 -0.278 -1.768 
P62937 Peptidyl-prolyl cis-trans isomerase A PPIA 7 -0.418 -2.464 
Q13162 Peroxiredoxin-4 PRDX4 4 0.308 1.982 
P30086 Phosphatidylethanolamine-binding protein 1 PEBP1 4 -0.286 -1.794 
Q6P4A8 Phospholipase B-like 1 PLBL1 4 -0.230 -1.540 
Q8NC51 
Plasminogen activator inhibitor 1 RNA-binding 
protein 
PAIRB 3 -0.262 -1.675 
 227 
P09874 Poly [ADP-ribose] polymerase 1 PARP1 2 -0.233 -1.567 
F5H7K6 Polyubiquitin-C UBC 6 -0.245 -1.613 
Q9UMS4 Pre-mRNA-processing factor 19 PRP19 3 -0.398 -2.287 
Q6P2Q9 Pre-mRNA-processing-splicing factor 8 PRP8 5 -0.259 -1.654 
P26196 Probable ATP-dependent RNA helicase DDX6 DDX6 2 0.499 2.789 
O60568 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 3 PLOD3 4 0.300 1.928 
Q9UQ80 Proliferation-associated protein 2G4 PA2G4 4 -0.267 -1.708 
Q9UL46 Proteasome activator complex subunit 2 PSME2 6 0.280 1.743 
P28066 Proteasome subunit alpha type-5 PSA5 3 0.417 2.413 
P28070 Proteasome subunit beta type-4 PSB4 4 -0.376 -2.162 
B5MCQ5 Protein disulfide-isomerase A6 PDIA6 12 -0.219 -1.515 
 228 
E9PS38 Protein NEDD8-MDP1 
NEDD-
MDP1 
2 -0.655 -2.951 
P31949 Protein S100-A11 S10AB 3 0.481 2.679 
P06703 Protein S100-A6 S10A6 4 -0.362 -2.135 
P05109 Protein S100-A8 S10A8 8 0.553 2.951 
Q01105 Protein SET SET 5 0.375 2.287 
Q13283 Ras GTPase-activating protein-binding protein 1 G3BP1 3 0.342 2.162 
P51153 Ras-related protein Rab-13 RAB13 2 0.294 1.864 
F5H157 Ras-related protein Rab-35 (Fragment) RAB35 2 0.433 2.464 
P61020 Ras-related protein Rab-5B RAB5B 2 0.287 1.807 
P20340 Ras-related protein Rab-6A RAB6A 4 0.254 1.594 
Q9HB40 Retinoid-inducible serine carboxypeptidase RISC 2 0.404 2.367 
 229 
P52566 Rho GDP-dissociation inhibitor 2 GDIR2 11 -0.314 -1.879 
J3KTE4 Ribosomal protein L19 RPL19 2 -0.314 -1.895 
Q8NBX0 Saccharopine dehydrogenase-like oxidoreductase SCPDL 2 0.272 1.697 
Q13177 Serine/threonine-protein kinase PAK 2 PAK2 5 -0.388 -2.253 
P02787 Serotransferrin TRFE 3 0.243 1.558 
O76094 Signal recognition particle subunit SRP72 SRP72 2 0.296 1.879 
Q04837 Single-stranded DNA-binding protein, mitochondrial SSBP 3 0.286 1.794 
Q02318 Sterol 26-hydroxylase, mitochondrial CYP27A 4 0.279 1.731 
E9PBJ5 
Succinate dehydrogenase [ubiquinone] flavoprotein 
subunit, mitochondrial 
SDHA 3 0.480 2.593 
Q9Y6N5 Sulfide:quinone oxidoreductase, mitochondrial SQRD 15 0.237 1.531 
P30048 
Thioredoxin-dependent peroxide reductase, 
PRDX3 6 0.235 1.515 
 230 
 
 
 
 
 
mitochondrial 
P37802 Transgelin-2 TAGL2 5 -0.247 -1.633 
P61088 Ubiquitin-conjugating enzyme E2 N UBE2N 4 0.246 1.576 
Q969H8 UPF0556 protein C19orf10 CS010 3 0.237 1.523 
P36543 V-type proton ATPase subunit E 1 VATE1 4 -0.246 -1.623 
Q96QK1 Vacuolar protein sorting-associated protein 35 VPS35 5 -0.276 -1.731 
Q00341 Vigilin VIGLN 2 0.263 1.654 
F5H740 Voltage-dependent anion-selective channel protein 3 VDAC1 5 -0.243 -1.604 
 231 
Appendix 11: List of all significantly changed proteins to Vpx stimulation of Macrophages at 1dps. Second biological replicate (iTRAQ4). 
Log2 ratio (+Vpx/-Vpx) and Z score are listed below 
  
UniProt 
Accession 
Number 
Protein Name 
Gene 
Symbol 
# peptides Log2 Ratio Z score 
O00231 26S proteasome non-ATPase regulatory subunit 11 PSD11 3 -0.264 -1.807 
O43242 26S proteasome non-ATPase regulatory subunit 3 PSMD3 3 -0.300 -1.932 
B1AK13 
3-hydroxymethyl-3-methylglutaryl-Coenzyme A lyase 
(Hydroxymethylglutaricaciduria), isoform CRA_b 
HMGCL 3 -0.228 -1.589 
P49189 4-trimethylaminobutyraldehyde dehydrogenase AL9A1 2 -0.237 -1.639 
P46781 40S ribosomal protein S9 RS9 3 -0.247 -1.729 
P17858 6-phosphofructokinase, liver type K6PL 7 0.228 1.660 
 232 
B4DQJ8 6-phosphogluconate dehydrogenase, decarboxylating PGD 15 0.252 1.807 
Q92688 
Acidic leucine-rich nuclear phosphoprotein 32 family 
member B 
AN32B 2 0.216 1.542 
P61160 Actin-related protein 2 ARP2 9 0.214 1.534 
O15143 Actin-related protein 2/3 complex subunit 1B ARC1B 8 0.238 1.729 
O15145 Actin-related protein 2/3 complex subunit 3 ARPC3 4 0.209 1.508 
Q9Y305 Acyl-coenzyme A thioesterase 9, mitochondrial ACOT9 4 -0.241 -1.650 
P23526 Adenosylhomocysteinase AHCY 2 0.353 2.209 
P61204 ADP-ribosylation factor 3 ARF3 7 0.237 1.717 
P05091 Aldehyde dehydrogenase, mitochondrial ALDH2 3 -0.304 -1.969 
O00116 
Alkyldihydroxyacetonephosphate synthase, 
peroxisomal 
ADAS 8 -0.305 -1.988 
 233 
P26572 
Alpha-1,3-mannosyl-glycoprotein 2-beta-N-
acetylglucosaminyltransferase 
MGAT1 2 -0.227 -1.579 
P21397 Amine oxidase [flavin-containing] A AOFA 5 0.250 1.793 
F5H0G8 Arachidonate 15-lipoxygenase LOX15 19 -0.422 -2.314 
P30049 ATP synthase subunit delta, mitochondrial ATPD 2 -0.291 -1.882 
O43491 Band 4.1-like protein 2 E41L2 3 0.322 2.098 
P80723 Brain acid soluble protein 1 BASP1 8 -0.247 -1.717 
Q96CX2 BTB/P KCD12 3 0.280 1.898 
Q99653 Calcineurin B homologous protein 1 CHP1 2 -0.213 -1.508 
Q6NUK1 
Calcium-binding mitochondrial carrier protein 
SCaMC-1 
SCMC1 3 -0.244 -1.660 
H0Y7A7 Calmodulin (Fragment) CALM2 5 0.389 2.454 
 234 
P27797 Calreticulin CALR 25 -0.230 -1.608 
P50416 Carnitine CPT1A 3 -0.324 -2.051 
F8W022 CD63 antigen (Fragment) CD63 2 -0.222 -1.542 
Q9Y3Z3 
Deoxynucleoside triphosphate triphosphohydrolase 
SAMHD1 
SAMHD1 11 -0.309 -2.008 
E7ESM9 DNA-directed RNA polymerase I subunit RPA34 CD3EAP 4 0.219 1.579 
E9PNQ1 
Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit STT3A 
STT3A 2 -0.366 -2.241 
P24534 Elongation factor 1-beta EF1B 3 0.357 2.276 
Q96RP9 Elongation factor G, mitochondrial EFGM 2 -0.422 -2.355 
P07099 Epoxide hydrolase 1 HYEP 2 0.242 1.767 
Q96HE7 ER ERO1A 4 -0.222 -1.551 
 235 
E9PGM1 Eukaryotic translation initiation factor 4 gamma 1 EIF4G1 3 0.265 1.866 
O60841 Eukaryotic translation initiation factor 5B IF2P 2 -0.558 -2.780 
Q01469 Fatty acid-binding protein, epidermal FABP5 5 0.346 2.178 
P51648 Fatty aldehyde dehydrogenase AL3A2 4 -0.229 -1.599 
J3QLD9 Flotillin-2 FLOT2 3 -0.226 -1.570 
P17096 High mobility group protein HMG-I/HMG-Y HMGA1 2 -0.245 -1.671 
P10412 Histone H1.4 H14 4 -0.868 -3.267 
P30455 
HLA class I histocompatibility antigen, A-36 alpha 
chain 
1A36 4 -0.235 -1.629 
P30460 
HLA class I histocompatibility antigen, B-8 alpha 
chain 
1B08 6 -0.226 -1.561 
Q9H2U2 Inorganic pyrophosphatase 2, mitochondrial IPYR2 2 -0.264 -1.821 
 236 
H0Y4R1 
Inosine-5'-monophosphate dehydrogenase 2 
(Fragment) 
IMPDH2 4 0.288 1.932 
Q9UNM6-2 
Isoform 2 of 26S proteasome non-ATPase regulatory 
subunit 13 
PSD13 3 0.428 2.583 
P51572-2 Isoform 2 of B-cell receptor-associated protein 31 BAP31 11 -0.217 -1.525 
Q9HC38-2 Isoform 2 of Glyoxalase domain-containing protein 4 GLOD4 3 0.228 1.639 
Q3ZCQ8-2 
Isoform 2 of Mitochondrial import inner membrane 
translocase subunit TIM50 
TIM50 2 -0.297 -1.898 
Q15019-2 Isoform 2 of Septin-2 SEPT2 4 0.224 1.608 
P08621-2 
Isoform 2 of U1 small nuclear ribonucleoprotein 70 
kDa 
RU17 2 -0.471 -2.583 
P18510-3 Isoform 3 of Interleukin-1 receptor antagonist protein IL1RA 4 0.214 1.525 
 237 
Q49A26-3 Isoform 3 of Putative oxidoreductase GLYR1 GLYR1 2 -0.267 -1.836 
P07108-5 Isoform 5 of Acyl-CoA-binding protein ACBP 3 0.356 2.241 
Q9HD20-2 
Isoform B of Probable cation-transporting ATPase 
13A1 
ATP13A1 4 -0.262 -1.793 
Q16719 Kynureninase KYNU 2 0.252 1.821 
Q96AG4 Leucine-rich repeat-containing protein 59 LRC59 3 -0.246 -1.705 
P09960 Leukotriene A-4 hydrolase LKHA4 13 0.228 1.650 
O60711 Leupaxin LPXN 2 0.409 2.513 
O95573 Long-chain-fatty-acid--CoA ligase 3 ACSL3 2 -0.215 -1.516 
O60488 Long-chain-fatty-acid--CoA ligase 4 ACSL4 5 0.224 1.619 
P40121 Macrophage-capping protein CAPG 13 0.232 1.682 
Q16891 Mitochondrial inner membrane protein IMMT 8 0.229 1.671 
 238 
P29966 Myristoylated alanine-rich C-kinase substrate MARCS 3 0.453 2.669 
P28331 
NADH-ubiquinone oxidoreductase 75 kDa subunit, 
mitochondrial 
NDUS1 4 -0.284 -1.866 
P05204 Non-histone chromosomal protein HMG-17 HMGN2 3 -0.234 -1.619 
H0Y449 
Nuclease-sensitive element-binding protein 1 
(Fragment) 
YBX1 4 0.383 2.402 
Q02818 Nucleobindin-1 NUCB1 4 0.220 1.589 
Q9Y2X3 Nucleolar protein 58 NOP58 2 -0.255 -1.780 
Q32Q12 Nucleoside diphosphate kinase NME1 5 0.303 1.988 
Q13451 Peptidyl-prolyl cis-trans isomerase FKBP5 FKBP5 3 -0.359 -2.209 
P30044 Peroxiredoxin-5, mitochondrial PRDX5 3 0.318 2.074 
Q8IV08 Phospholipase D3 PLD3 3 -0.310 -2.029 
 239 
Q8TD55 Pleckstrin homology domain-containing family PKHO2 2 0.274 1.882 
Q92841 Probable ATP-dependent RNA helicase DDX17 DDX17 5 0.241 1.754 
P17844 Probable ATP-dependent RNA helicase DDX5 DDX5 3 -0.392 -2.276 
Q9UL46 Proteasome activator complex subunit 2 PSME2 3 0.233 1.694 
P25786 Proteasome subunit alpha type-1 PSA1 2 0.254 1.836 
Q13438 Protein OS9 3 -0.428 -2.454 
Q99497 Protein DJ-1 PARK7 3 0.493 2.780 
E7EU23 Rab GDP dissociation inhibitor beta GDIB 7 0.227 1.629 
Q15404 Ras suppressor protein 1 RSU1 2 0.343 2.150 
P61026 Ras-related protein Rab-10 RAB10 3 -0.298 -1.915 
Q96TC7 Regulator of microtubule dynamics protein 3 RMD3 2 -0.328 -2.098 
 240 
P00352 Retinal dehydrogenase 1 AL1A1 2 0.255 1.851 
P52566 Rho GDP-dissociation inhibitor 2 GDIR2 8 0.220 1.599 
O76021 Ribosomal L1 domain-containing protein 1 RL1D1 2 0.217 1.570 
P22087 rRNA 2'- FBRL 3 -0.335 -2.150 
P10768 S-formylglutathione hydrolase ESTD 2 -0.300 -1.950 
Q8NBX0 Saccharopine dehydrogenase-like oxidoreductase SCPDL 3 -0.252 -1.767 
E7EPK1 Septin-7 SEPT7 3 0.563 2.942 
Q13501 Sequestosome-1 SQSTM 4 -0.278 -1.851 
P02787 Serotransferrin TRFE 7 -0.425 -2.402 
P35237 Serpin B6 SPB6 3 0.243 1.780 
O75368 SH3 domain-binding glutamic acid-rich-like protein SH3L1 5 0.240 1.741 
 241 
Q5T123 SH3 domain-binding glutamic acid-rich-like protein 3 SH3BGRL3 4 0.310 2.008 
O76094 Signal recognition particle subunit SRP72 SRP72 2 0.285 1.915 
Q9UIB8 SLAM family member 5 SLAF5 2 0.366 2.314 
P62314 Small nuclear ribonucleoprotein Sm D1 SMD1 2 0.310 2.029 
B7Z9S8 Sodium/potassium-transporting ATPase subunit beta-1 AT1B1 2 -0.350 -2.178 
Q12874 Splicing factor 3A subunit 3 SF3A3 2 -0.437 -2.513 
Q02318 Sterol 26-hydroxylase, mitochondrial CYP27A 8 -0.251 -1.754 
P38646 Stress-70 protein, mitochondrial GRP75 24 -0.221 -1.534 
Q9UQE7 Structural maintenance of chromosomes protein 3 SMC3 2 -0.491 -2.669 
P53597 
Succinyl-CoA ligase [ADP/GDP-forming] subunit 
alpha, mitochondrial 
SUCA 3 0.298 1.950 
O00560 Syntenin-1 SDCB1 3 0.299 1.969 
 242 
P50991 T-complex protein 1 subunit delta TCPD 2 0.334 2.123 
Q99832 T-complex protein 1 subunit eta TCPH 4 0.217 1.551 
P40227 T-complex protein 1 subunit zeta TCPZ 4 0.217 1.561 
P04066 Tissue alpha-L-fucosidase FUCO 3 0.691 3.267 
P20290 Transcription factor BTF3 BTF3 2 0.234 1.705 
Q14956 Transmembrane glycoprotein NMB GPNMB 3 -0.248 -1.741 
P09769 Tyrosine-protein kinase Fgr FGR 2 -0.331 -2.123 
Q9Y224 UPF0568 protein C14orf166 CN166 2 -0.246 -1.694 
E7EUC7 UTP--glucose-1-phosphate uridylyltransferase UGP2 5 0.313 2.051 
P21283 V-type proton ATPase subunit C 1 VATC1 2 -0.326 -2.074 
Q9P0L0 
Vesicle-associated membrane protein-associated 
protein A 
VAPA 5 -0.245 -1.682 
 243 
 
 
 
 
 
 
 
 
 
 
 
Q00341 Vigilin VIGLN 4 0.214 1.516 
Q96D96 Voltage-gated hydrogen channel 1 HVCN1 3 -0.577 -2.942 
Q13303 Voltage-gated potassium channel subunit beta-2 KCAB2 3 0.383 2.355 
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Appendix 12: List of all significantly changed proteins to Vpx stimulation of Dendritic Cells at 1dps. Second biological replicate 
(iTRAQ4). Log2 ratio (+Vpx/-Vpx) and Z score are listed below 
 
 
UniProt 
Accession 
Number 
Protein Name 
Gene 
Symbol 
# peptides Log2 Ratio Z score 
Q04446 1,4-alpha-glucan-branching enzyme GLGB 3 0.277 1.694 
P27348 14-3-3 protein theta 1433T 2 0.264 1.639 
P62333 26S protease regulatory subunit 10B PRS10 3 0.454 2.123 
R4GNH3 26S protease regulatory subunit 6A PSMC3 3 0.256 1.589 
J3KMX5 40S ribosomal protein S13 RPS13 4 -0.446 -2.178 
P62249 40S ribosomal protein S16 RS16 4 -0.303 -1.671 
O95336 6-phosphogluconolactonase 6PGL 3 0.224 1.516 
 245 
J3QQ67 60S ribosomal protein L18 (Fragment) RPL18 3 -0.320 -1.793 
P62917 60S ribosomal protein L8 RL8 2 -0.370 -2.008 
O15145 Actin-related protein 2/3 complex subunit 3 ARPC3 4 -0.270 -1.525 
O15511 Actin-related protein 2/3 complex subunit 5 ARPC5 4 0.299 1.807 
P68032 Actin, alpha cardiac muscle 1 ACTC 5 0.565 2.513 
P60709 Actin, cytoplasmic 1 ACTB 10 -0.298 -1.660 
P53999 
Activated RNA polymerase II transcriptional 
coactivator p15 
TCP4 3 0.254 1.579 
C9JIF9 Acylamino-acid-releasing enzyme APEH 3 -0.332 -1.851 
P17050 Alpha-N-acetylgalactosaminidase NAGAB 2 0.456 2.150 
Q9BXS5 AP-1 complex subunit mu-1 AP1M1 3 0.301 1.821 
Q9BRQ8 Apoptosis-inducing factor 2 AIFM2 2 -0.312 -1.717 
 246 
O75947 ATP synthase subunit d, mitochondrial ATP5H 4 0.309 1.851 
P30049 ATP synthase subunit delta, mitochondrial ATPD 2 0.260 1.619 
P08236 Beta-glucuronidase BGLR 2 -0.294 -1.639 
P11586 C-1-tetrahydrofolate synthase, cytoplasmic C1TC 2 -0.409 -2.123 
P07384 Calpain-1 catalytic subunit CAN1 2 0.292 1.780 
P27797 Calreticulin CALR 25 0.347 1.932 
P00918 Carbonic anhydrase 2 CAH2 3 -0.294 -1.650 
Q9NNX6 CD209 antigen CD209 5 0.375 1.969 
F8W022 CD63 antigen (Fragment) CD63 2 -0.455 -2.209 
P36222 Chitinase-3-like protein 1 CH3L1 6 -0.364 -1.988 
Q14019 Coactosin-like protein COTL1 7 0.254 1.570 
 247 
P10606 Cytochrome c oxidase subunit 5B, mitochondrial COX5B 4 -0.274 -1.561 
P08574 Cytochrome c1, heme protein, mitochondrial CY1 2 -0.288 -1.629 
Q9HBB2 Cytoplasmic aconitate hydratase IRP1 2 0.496 2.314 
Q8N163 DBIRD complex subunit KIAA1967 K1967 2 0.775 2.942 
Q9Y3Z3 
Deoxynucleoside triphosphate triphosphohydrolase 
SAMHD1 
SAMHD1 11 -1.027 -2.942 
G3V1D3 Dipeptidyl peptidase 3 DPP3 2 0.256 1.599 
F8W1I6 Dynactin subunit 2 DCTN2 2 0.271 1.660 
O75923 Dysferlin DYSF 3 -0.278 -1.589 
P24534 Elongation factor 1-beta EF1B 3 0.677 2.780 
Q96RP9 Elongation factor G, mitochondrial EFGM 2 -0.716 -2.669 
B3KSH1 Eukaryotic translation initiation factor 3 subunit F EIF3F 2 0.407 2.029 
 248 
B3KS98 Eukaryotic translation initiation factor 3 subunit H EIF3H 4 0.442 2.098 
K7ES31 Eukaryotic translation initiation factor 3 subunit K EIF3K 2 -0.274 -1.570 
P15090 Fatty acid-binding protein, adipocyte FABP4 8 0.262 1.629 
P05413 Fatty acid-binding protein, heart FABPH 2 -0.263 -1.508 
P02794 Ferritin heavy chain FRIH 6 -0.318 -1.767 
P02792 Ferritin light chain FRIL 6 -0.323 -1.836 
Q3V6T2 Girdin GRDN 2 -0.378 -2.029 
G8JLB6 Heterogeneous nuclear ribonucleoprotein H HNRNPH1 3 0.474 2.209 
P58876 Histone H2B type 1-D H2B1D 2 -0.359 -1.969 
Q8N257 Histone H2B type 3-B H2B3B 2 -0.320 -1.807 
Q71DI3 Histone H3.2 H32 5 -0.308 -1.694 
 249 
P62805 Histone H4 H4 10 -0.460 -2.276 
Q5SP06 
HLA class II histocompatibility antigen, DR alpha 
chain 
HLA-DRA 3 0.283 1.717 
Q27J81 Inverted formin-2 INF2 3 -0.308 -1.682 
P51572-2 Isoform 2 of B-cell receptor-associated protein 31 BAP31 11 -0.379 -2.051 
Q14839-2 
Isoform 2 of Chromodomain-helicase-DNA-binding 
protein 4 
CHD4 2 0.238 1.534 
Q8N766-2 Isoform 2 of ER membrane protein complex subunit 1 EMC1 4 -0.273 -1.551 
P49137-2 Isoform 2 of MAP kinase-activated protein kinase 2 MAPK2 2 -0.314 -1.741 
Q06323-2 Isoform 2 of Proteasome activator complex subunit 1 PSME1 3 0.271 1.671 
P51858-3 Isoform 3 of Hepatoma-derived growth factor HDGF 5 0.259 1.608 
Q49A26-3 Isoform 3 of Putative oxidoreductase GLYR1 GLYR1 2 -0.406 -2.098 
 250 
Q9HD20-2 
Isoform B of Probable cation-transporting ATPase 
13A1 
ATP13A1 4 -0.282 -1.599 
Q9NZB2-4 
Isoform D of Constitutive coactivator of PPAR-
gamma-like protein 1 
F120A 3 -0.564 -2.402 
P05164-3 Isoform H7 of Myeloperoxidase PERM 9 0.303 1.836 
J3KR24 Isoleucine--tRNA ligase, cytoplasmic IARS 3 -0.455 -2.241 
P35527 Keratin, type I cytoskeletal 9 K1C9 3 0.571 2.583 
P05455 Lupus La protein LA 6 0.434 2.074 
P42785 Lysosomal Pro-X carboxypeptidase PCP 2 0.269 1.650 
P11279 Lysosome-associated membrane glycoprotein 1 LAMP1 3 0.422 2.051 
F5H1S8 Malectin (Fragment) MLEC 2 -0.321 -1.821 
A8MXP9 Matrin-3 MATR3 2 0.491 2.241 
 251 
Q15691 
Microtubule-associated protein RP/EB family member 
1 
MARE1 3 0.224 1.508 
Q8TCT9 Minor histocompatibility antigen H13 HM13 3 -0.313 -1.729 
B4DLN1 Mitochondrial dicarboxylate carrier SLC25A10 2 0.286 1.741 
Q99685 Monoglyceride lipase MGLL 3 0.272 1.682 
G3V0I5 
NADH dehydrogenase (Ubiquinone) flavoprotein 1, 
51kDa, isoform CRA_c 
NDUFV1 2 -0.271 -1.534 
E9PAV3 Nascent polypeptide-associated complex subunit alpha NACA 2 0.406 2.008 
P55160 Nck-associated protein 1-like NCKPL 2 -0.332 -1.866 
P43490 Nicotinamide phosphoribosyltransferase NAMPT 2 0.296 1.793 
Q02790 Peptidyl-prolyl cis-trans isomerase FKBP4 FKBP4 2 0.402 1.988 
Q13162 Peroxiredoxin-4 PRDX4 3 -0.286 -1.619 
 252 
Q8TD55 Pleckstrin homology domain-containing family PKHO2 2 -0.491 -2.355 
Q9BUB1 PRKAR2A protein PRKAR2A 3 0.291 1.767 
Q9UQ80 Proliferation-associated protein 2G4 PA2G4 2 -0.334 -1.882 
Q9UL46 Proteasome activator complex subunit 2 PSME2 3 0.372 1.950 
G3V5Z7 Proteasome subunit alpha type PSMA6 2 -0.355 -1.950 
P25788 Proteasome subunit alpha type-3 PSA3 2 -0.309 -1.705 
P49720 Proteasome subunit beta type-3 PSB3 4 0.247 1.551 
Q13438 Protein OS9 3 0.327 1.882 
H9KV28 Protein diaphanous homolog 1 DIAPH1 2 0.458 2.178 
P31949 Protein S100-A11 S100A11 3 -0.272 -1.542 
P26447 Protein S100-A4 S100A4 4 -0.350 -1.915 
 253 
R4GN98 Protein S100-A6 (Fragment) S100A6 2 -0.890 -2.780 
P05109 Protein S100-A8 S100A8 5 -0.686 -2.583 
P06702 Protein S100-A9 S100A9 8 -0.577 -2.454 
P31150 Rab GDP dissociation inhibitor alpha GDIA 2 0.314 1.866 
Q5VY93 Rho guanine nucleotide exchange factor 2 ARHGEF2 2 -0.319 -1.780 
Q9HBH0 Rho-related GTP-binding protein RhoF RHOF 2 -0.276 -1.579 
F8W8N3 S-phase kinase-associated protein 1 (Fragment) SKP1 2 0.505 2.355 
O15127 Secretory carrier-associated membrane protein 2 SCAM2 3 -0.382 -2.074 
Q5T5C7 Serine--tRNA ligase, cytoplasmic SARS 2 0.337 1.898 
Q5T123 SH3 domain-binding glutamic acid-rich-like protein 3 SH3BGRL3 4 0.253 1.561 
Q9UIB8 SLAM family member 5 SLAF5 2 -0.642 -2.513 
 254 
Q13596 Sorting nexin-1 SNX1 3 -0.413 -2.150 
P53597 
Succinyl-CoA ligase [ADP/GDP-forming] subunit 
alpha, mitochondrial 
SUCA 3 -0.351 -1.932 
Q8TED4 Sugar phosphate exchanger 2 SPX2 2 -0.472 -2.314 
A8MXY0 Syntaxin 4A (Placental), isoform CRA_c STX4 2 0.537 2.402 
O00560 Syntenin-1 SDCB1 3 0.226 1.525 
Q9Y490 Talin-1 TLN1 48 0.242 1.542 
E7EPD0 Target of Myb protein 1 MYB 3 0.343 1.915 
B8ZZW7 Thymosin alpha-1 PTMA 2 0.950 3.267 
P62328 Thymosin beta-4 TYB4 2 -1.447 -3.267 
P61586 Transforming protein RhoA RHOA 2 0.286 1.729 
P37802 Transgelin-2 TAGL2 6 0.495 2.276 
 255 
 P51571 Translocon-associated protein subunit delta SSRD 2 -0.314 -1.754 
Q15363 Transmembrane emp24 domain-containing protein 2 TMED2 2 0.545 2.454 
Q08J23 tRNA (cytosine(34)-C(5))-methyltransferase NSUN2 2 0.277 1.705 
Q9BUF5 Tubulin beta-6 chain TBB6 4 0.289 1.754 
P45974 Ubiquitin carboxyl-terminal hydrolase 5 UBP5 4 -0.349 -1.898 
P54727 UV excision repair protein RAD23 homolog B RD23B 2 0.608 2.669 
O75348 V-type proton ATPase subunit G 1 VATG1 2 -0.284 -1.608 
Q96D96 Voltage-gated hydrogen channel 1 HVCN1 3 -0.265 -1.516 
 256 
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